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ABSTRACT 
PLASMODIUM INFECTIONS OF WILD APES AND HUMAN ZOONOTIC RISK 
Dorothy Elizabeth Loy 
Beatrice H. Hahn, MD 
 
Plasmodium falciparum and Plasmodium vivax cause over 95% of all human 
malaria infections. To control and potentially eliminate these pathogens, it is important to 
understand their origins and evolutionary history. The recent discovery of a multitude of 
Plasmodium species in apes revealed that P. vivax and P. falciparum evolved from 
parasites infecting African apes, but the zoonotic threat posed by ape parasites and the 
precise circumstances surrounding the emergence of Plasmodium in humans remain 
unknown. Thus, in this thesis, I asked two questions: Are humans exposed to ape 
parasites and what can be learned about the history of human P. vivax through analyses 
of related ape parasites. To address the first question, I asked whether humans living near 
Plasmodium-infected apes develop pre-erythrocytic infections in the absence of blood 
stage infections. Screening 504 Cameroonian fecal samples for ape Plasmodium species, 
I found no evidence of abortive liver infection. Next, to facilitate genome sequencing of 
ape P. vivax, I adapted selective whole genome amplification (SWGA) to P. vivax, 
achieving a dramatic increase in the proportion of P. vivax DNA in human samples without 
introducing systemic sequence errors. I then generated partial P. vivax genome 
sequences from six chimpanzees and one gorilla, which revealed that human strains of P. 
vivax exhibit ~10-fold less diversity and have a unique excess of nonsynonymous 
nucleotide polymorphisms. This suggests a recent bottleneck and greatly relaxed purifying 
selection in the human parasite lineage. Investigating potential host specificity 
determinants, I found that ape P. vivax parasites encode three reticulocyte binding protein 
v 
 
genes (rbp2d, rbp2e, and rbp3) whose orthologs are pseudogenes in human P. vivax 
strains. However, recombinant RBP2e and RBP3 proteins bound human, chimpanzee, 
and gorilla erythrocytes with similar efficiency. These results suggest that the P. vivax 
ancestor infected humans and apes in Africa, and that modern human P. vivax is derived 
from parasites that escaped Africa. Although many questions remain concerning the 
biology and zoonotic potential of ape malaria parasites, my studies show that comparative 
genomics, coupled with functional parasite studies, can yield new insights that are relevant 
to the prevention and eradication of human malaria. 
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CHAPTER 1 – Out of Africa: Origins and evolution of the human malaria parasites 
Plasmodium falciparum and Plasmodium vivax 
Dorothy E. Loya,b, Weimin Liua, Yingying Lia, Gerald H. Learna, Lindsey J. Plenderleithc, 
Sesh A. Sundararamana,b, Paul M. Sharpc, Beatrice H. Hahna,b 
Departments of Medicinea and Microbiologyb, Perelman School of Medicine, University 
of Pennsylvania, Philadelphia, Pennsylvania 19104, USA; cInstitute of Evolutionary 
Biology, and Centre for Immunity, Infection and Evolution, University of Edinburgh, 
Edinburgh EH9 3FL, UK; 
 
Adapted from a review published in 2017 in Int J Para 47(2-3):87-97.  
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1.1 Introduction 
Of the Plasmodium species known to commonly infect humans, P. falciparum and P. vivax 
cause the vast majority of malaria morbidity and mortality, and are the principal targets of 
malaria prevention and eradication efforts. P. falciparum is highly prevalent in sub-
Saharan Africa where it is responsible for an estimated 216 million clinical cases and over 
400,000 malaria-related deaths annually, predominantly in children under 5 years of age 
(World Health Organization, 2017).  P. vivax is rare in sub-Saharan Africa, but endemic in 
many parts of Asia, Oceania, as well as Central and South America where it causes an 
estimated 8.6 million cases of clinical malaria, which represent about half of all malaria 
cases outside Africa (World Health Organization, 2017). 
Given the devastating effects of malaria, the origins of the human Plasmodium 
parasites have long been a subject of interest. Descriptions of malaria-like illness can be 
found in ancient texts from China, India, the Middle East, Africa, and Europe, indicating 
that humans have been combatting Plasmodium infections through much of our recorded 
history (Carter and Mendis, 2002).  Indeed, variants in the human genome that are 
associated with resistance to Plasmodium infection and malaria-associated disease are 
estimated to be thousands of years old (Hedrick, 2011). One such variant is the sickle cell 
trait, which is common in African populations and protects against fatal P. falciparum 
malaria (Taylor et al., 2012). Similarly, a mutation that abolishes the expression of the 
Duffy antigen receptor of chemokines on the surface of red blood cells (the so-called “Duffy 
negative phenotype”) approaches fixation in west and central Africa and confers almost 
complete protection from P. vivax parasitemia (Miller et al., 1976; Howes et al., 2011). 
Together, these findings indicate that Plasmodium infections have impacted human health 
for millennia, but the prevailing view has been that this history goes back much further. 
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One long-standing hypothesis suggested that humans and chimpanzees each 
inherited P. falciparum-like infections from their common ancestor, and that these 
parasites co-evolved with their respective host species for millions of years (Escalante 
and Ayala, 1994). In contrast, P. vivax was believed to have arisen several hundred 
thousand years ago, following the cross-species transmission of a macaque parasite in 
Southeast Asia (Escalante et al., 2005; Jongwutiwes et al., 2005; Mu et al., 2005; Neafsey 
et al., 2012). However, both of these theories have recently been refuted following the 
characterization of a large number of additional Plasmodium parasites from African apes. 
Specifically, it is now clear that P. falciparum is a relatively new infection of humans, which 
arose after the acquisition of a gorilla parasite, likely within the past 10,000 years (Liu et 
al., 2010a; Sundararaman et al., 2016). Similarly, P. vivax did not emerge in Asia, but 
represents a bottlenecked lineage that escaped out of Africa before the spread of Duffy 
negativity rendered African humans resistant to P. vivax (Liu et al., 2014). In this chapter, 
I describe the findings that led to this new understanding and summarize what is known 
about the epidemiology, vector tropism, zoonotic potential, and pathogenicity of the ape 
precursors of the human parasites.  
 
1.2 Early studies of ape Plasmodium infections 
The first indication that African apes harbor Plasmodium infections was the finding of three 
morphologically distinct forms of parasites in the blood of wild-caught chimpanzees (Pan 
troglodytes) and western gorillas (Gorilla gorilla) in Cameroon (Reichenow, 1920).  
Microscopic characterization identified ape parasites that resembled human P. falciparum, 
P. malariae, and either P. ovale or (the similar) P. vivax, suggesting the existence of 
distinct Plasmodium species, which were classified as P. reichenowi, P. rhodaini, and P. 
schwetzi, respectively (Sluiter et al., 1922; Brumpt, 1939).  Moreover, P. falciparum and 
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P. reichenowi were found to differ substantially from the other Plasmodium species in both 
life cycle and gametocyte morphology, prompting their placement into a separate 
subgenus, termed Laverania (Bray, 1958; Coatney et al., 1971). The existence of two 
divergent clades of malaria parasites infecting primates was subsequently confirmed when 
the various Plasmodium species were first molecularly characterized (Figure 1-1). 
Comparing rRNA small subunit gene sequences, Escalante and Ayala (1994) showed that 
among the known species P. falciparum and P. reichenowi were each other’s closest 
relatives, and that both were only distantly related to other Plasmodium species. Assuming 
that rRNA gene sequences in Plasmodium species evolved at the same rate as had been 
estimated for some bacteria, it was inferred that P. falciparum and P. reichenowi had 
diverged ~10 million years ago, close to the time of the human-chimpanzee common 
ancestor. This led to the conclusion that human and chimpanzee parasites had co-
diverged with their respective hosts (Escalante and Ayala, 1994). Due to a lack of 
preserved material, gene sequences from P. schwetzi and P. rhodaini were never 
determined, and so their relationship to other malaria parasites remains unknown.  
Interest in ape Laverania infections was rekindled in 2009 when Ollomo and 
colleagues found parasites morphologically similar to P. reichenowi in the blood of two pet 
chimpanzees from Gabon (Ollomo et al., 2009). Analysis of mitochondrial DNA (mtDNA) 
sequences revealed that these parasites were related to, but divergent from, P. falciparum 
and P. reichenowi, suggesting the existence of a third Laverania species which they 
named P. gaboni (Ollomo et al., 2009). Follow-up studies of additional captive and wild 
apes confirmed a greater diversity of Laverania parasites, but interpretations differed as 
to the number of species and their host associations. Amplifying mtDNA and nuclear gene 
sequences of parasites from members of two chimpanzee subspecies, Rich and 
colleagues identified several distinct Laverania lineages, but chose to consider all of them 
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as “P. reichenowi”, even though one of these new lineages corresponded to P. gaboni 
(Rich et al., 2009). In contrast, Krief and colleagues classified a similar diversity of 
chimpanzee parasites into three species, termed P. reichenowi, P. billcollinsi, and P. 
billbrayi, where the latter corresponded to P. gaboni (Krief et al., 2010). These 
investigators also amplified P. falciparum mtDNA from the blood of captive bonobos (Pan 
paniscus), concluding that this ape species represents the likely source of the human 
infection (Krief et al., 2010). Finally, Prugnolle and colleagues developed non-invasive 
methods that permitted parasite detection in ape fecal samples, which identified diverse 
Laverania lineages not only in chimpanzees but also in western gorillas (Prugnolle et al., 
2010). However, these investigators classified all chimpanzee parasites as either P. 
reichenowi or P. gaboni, and concluded that P. falciparum-like sequences found in fecal 
samples of wild-living western gorillas indicated ongoing transmission from humans to 
gorillas (Prugnolle et al., 2010). The consensus of these studies was that wild-living apes 
harbor a much greater diversity of Laverania parasites than previously recognized. 
However, there was disagreement concerning the number of ape Laverania species as 
well as the origin of P. falciparum, with some investigators implicating chimpanzees (Rich 
et al., 2009; Duval et al., 2010; Prugnolle et al., 2010) and others bonobos (Krief et al., 
2010) as the likely original source of the parasites now infecting humans. 
 
1.3 Seven Laverania species in wild-living apes 
The seemingly discrepant results from these early studies were reconciled by 
comprehensive studies of Laverania infections in wild-living apes, which employed 
improved fecal-based detection methods and targeted different regions of both organelle 
and nuclear parasite genomes (Liu et al., 2010a). One technical advance was the use of 
limiting dilution PCR (termed single genome amplification or SGA), which in contrast to 
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standard (bulk) PCR precludes the generation of in vitro recombinants that confound 
phylogenetic analyses (Liu et al., 2010b). Using this approach to characterize the 
molecular epidemiology of ape malaria, Plasmodium infections were found to be 
widespread in both chimpanzees and western gorillas, including parasites that were 
closely related to human P. malariae, P. ovale and P. vivax (Liu et al., 2010a).  However, 
the great majority of parasite sequences grouped within one of three chimpanzee-specific 
or three gorilla-specific parasite lineages, with each clade being well supported and quite 
distinct from the others, pointing to the existence of six Laverania species in chimpanzees 
and gorillas (Figure 1-1).  Subsequent surveys of wild-living apes in Gabon (Boundenga 
et al., 2015) and Cote d’Ivoire (Kaiser et al., 2010) confirmed these findings, demonstrating 
that chimpanzees and western gorillas represent a substantial Laverania reservoir. 
Recently, a comprehensive survey of wild-living bonobos revealed the existence of a 
seventh Laverania species, termed P. lomaminensis (Figure 1-1; Liu et al., 2017). 
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Figure 1-1. Evolutionary relationships of Plasmodium species.  Colors highlight 
Plasmodium species that infect humans (red), chimpanzees (blue), bonobos (purple), and 
gorillas (green). Four groups of Plasmodium species are shown, with subgenus 
designations indicated for primate parasites.  The phylogeny was estimated by maximum 
likelihood analysis of 2.4 kb of the mitochondrial genome; the scale bar indicates 0.03 
substitutions per site. 
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Figure 1-2A summarizes current knowledge concerning the geographic distribution 
and host species association of ape Laverania infections at over 100 field sites across 
sub-Saharan Africa (Kaiser et al., 2010; Liu et al., 2010a; De Nys et al., 2013; Boundenga 
et al., 2015; Liu et al., 2016, Liu et al., 2017). All chimpanzee subspecies, including 
western (P. t. verus), Nigeria-Cameroon (P. t. ellioti), central (P. t. troglodytes) and eastern 
(P. t. schweinfurthii) chimpanzees, as well as western lowland gorillas (G. g. gorilla) are 
endemically infected with Laverania parasites, with fecal detection rates ranging from 24% 
to 40% (Table 1-1). The true prevalence rates are likely to be considerably higher, since 
the amount of Laverania DNA that is shed into fecal samples is substantially less than that 
from replicating parasites in the blood (Liu et al., 2010a; Sundararaman et al., 2016).  
Although Cross River gorillas (G. g. diehli) and eastern lowland gorillas (G. beringei 
graueri) have appeared to be free of Laverania infections, the numbers of individuals 
tested from these potential hosts are still too small to draw definitive conclusions (Liu et 
al., 2010a). Analyses of nearly 3,500 SGA-derived mitochondrial, apicoplast and nuclear 
DNA sequences from ape fecal and blood samples have confirmed the existence of seven 
Laverania species (Figures 1-1 and 1-3). Of these, P. reichenowi, P. gaboni, and P. 
billcollinsi are found in wild-living chimpanzees, while P. praefalciparum, P. blacklocki, and 
P. adleri are found in western gorillas and P. lomaminensis is found in bonobos. All seven 
Laverania species have been classified based on numerous SGA-derived organelle and 
nuclear gene sequences from many different field isolates (Liu et al., 2010a; Liu et al., 
2016, Liu et al., 2017).  Whole genome sequencing of P. reichenowi and P. gaboni 
parasites confirmed that they represent distinct species, with no evidence of interspecific 
hybridization (Otto et al.,2014; Sundararaman et al., 2016). While it has been argued that 
detection of parasite DNA in either feces or blood, in itself, is not proof of productive 
Plasmodium infection (Valkiunas et al., 2011), the high prevalence rates of Laverania 
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infections (Table 1-1) and their widespread distribution (Figure 1-2A) provide compelling 
evidence for significant ongoing transmission.  
Of note, five of the six Laverania parasites that infect chimpanzees and gorillas 
exhibit strict host specificity when infecting wild-living apes, including at field sites where 
Laverania species are co-circulating in sympatric chimpanzee and gorilla populations 
(octagons in Figure 1-2A). Single genome amplification, which yields a proportional 
representation of all parasites present in a sample, failed to detect even minor fractions of 
P. reichenowi, P. billcollinsi, P. adleri, P. praefalciparum, or P. blacklocki from the “wrong” 
host species in over a hundred Laverania infected chimpanzee and gorillas (Liu et al., 
2016).  In contrast, P. gaboni is able to infect multiple host species, as it has been amplified 
from numerous chimpanzee and bonobo fecal samples (Liu et al., 2017, see Figure 1-3A) 
though it has not been detected in gorilla fecal samples. In addition, the bonobo parasite 
P. lomaminesis has been amplified from a single chimpanzee sample, suggesting that its 
restriction to bonobos is not absolute (Liu et al., 2017, see Figure 1-3A). However, our 
failure to amplify P. lomaminesis from additional chimpanzee samples despite extensive 
screening of chimpanzees living near bonobos suggests that P. lomaminesis is not 
endemic in chimpanzees. Interestingly, this host species specificity can be broken when 
chimpanzees and gorillas are kept together in captivity (Duval et al., 2010; Pacheco et al., 
2013), and so it will be of great interest to decipher the aspects of host and/or vector 
biology that contribute to host species restriction in the wild.  
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Figure 1-2. Geographic distribution of (A) Laverania and (B) P. vivax infections in 
wild-living apes. Field sites are shown in relation to the ranges of the four subspecies of 
the common chimpanzee (P. t. verus, black, upper left inset, P. t. ellioti, purple; P. t. 
troglodytes, magenta; P. t. schweinfurthii, blue), the Cross River (G. g. diehli, yellow 
stripe), western lowland (G. g. gorilla, red stripe), and eastern lowland (G. b. graueri, cyan 
stripe) gorilla, as well as the bonobo (P. paniscus, orange) in sub-Saharan Africa 
(Caldecott and Miles, 2005). Field sites are labeled by a two-letter code (Liu et al., 2010a; 
Liu et al., 2014, Liu et al., 2017) or numbers (Boundenga et al., 2015), and those where 
ape malaria was detected are highlighted in yellow. Because chimpanzee and gorilla 
ranges overlap, we have colored the two letter code to indicate whether chimpanzees 
(black), gorillas (green), or both (red) were infected at a given field site. Triangles denote 
ape rescue centers and asterisks mosquito collection sites. Circles, squares, and 
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hexagons identify locations where fecal samples were collected from chimpanzees, 
gorillas, or both species, respectively. Ovals indicate bonobo sites. At the TA and KB sites, 
blood and tissue samples were obtained from injured or deceased habituated 
chimpanzees (Kaiser et al., 2010; Krief et al., 2010; De Nys et al., 2013). Diamonds in 
panel B indicate the capture sites of ape P. vivax infected sanctuary chimpanzees (black 
border) and gorillas (green border), respectively, and a star denotes the location where a 
European forester became infected with ape P. vivax (Prugnolle et al., 2013). Data were 
compiled from published (Kaiser et al., 2010; Liu et al., 2010a; De Nys et al., 2013; Paupy 
et al., 2013; Prugnolle et al., 2013; Liu et al., 2014; Boundenga et al., 2015; Liu et al., 
2017) and unpublished studies (Table 1-1). 
12 
 
   
13 
 
Figure 1-3. Evolutionary relationships of ape and human Laverania parasites. The 
phylogenetic relationships of (A) mitochondrial cytochrome B (cytB; 956 bp) and (B) 
nuclear lactate dehydrogenase (ldh; 772 bp) gene sequences, as well as (C) concatenated 
mitochondrial protein (CoxI/CoxIII/CytB; 981 amino acids) sequences are shown. Ape 
parasite sequences are colored according to their host species (Pan troglodytes verus, 
light blue; Pan troglodytes troglodytes, red; Pan troglodytes schweinfurthii, dark blue; Pan 
troglodytes ellioti, orange; Gorilla gorilla gorilla, green; Pan paniscus, purple), and human 
parasite reference sequences are shown in black. A black circle denotes the Plasmodium 
reichenowi PrCDC reference sequence (Otto et al., 2014) derived from a chimpanzee 
captured in the Belgian Congo (now the Democratic Republic of the Congo) (Pan 
troglodytes schweinfurthii) (Coatney et al., 1971). (C) Four Plasmodium falciparum 
sequences from captive bonobos (Krief et al., 2010) and one Plasmodium praefalciparum 
sequence from a captive greater spot-nosed monkey (Prugnolle et al., 2011) are shown 
in purple and grey, respectively. Parentheses indicate Laverania spp. Phylogenies were 
generated using maximum likelihood methods. Asterisks at major nodes indicate 
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bootstrap values ≥ 65%, and the scale bars represent (A, B) 0.01 nucleotide substitutions 
per site, or (C) 0.001 amino acid replacements per site, respectively. Sequences were 
combined from multiple studies (Kaiser et al., 2010; Krief et al., 2010; Liu et al., 2010a, 
2016, 2017; Prugnolle et al., 2011). 
 
1.4 Origin of P. falciparum in western gorillas and emergence in humans 
Characterization of the various ape Laverania species identified one lineage in western 
gorillas that was comprised of parasites that were nearly identical to P. falciparum (Liu et 
al., 2010a; Prugnolle et al., 2010). This was initially interpreted as indicating that human 
parasites can infect gorillas (Prugnolle et al., 2010). However, with the characterization of 
mtDNA sequences from large numbers of additional wild-living gorillas, it became 
apparent that all extant P. falciparum strains from humans fall within the radiation of these 
gorilla parasites (Liu et al., 2010a).  Analyses of both mitochondrial (Figure 1-3A) and 
nuclear (Figure 1-3B) sequences confirmed these relationships, indicating that human P. 
falciparum resulted from the cross-species transmission of a parasite that had previously 
diversified in gorillas. This gorilla parasite lineage has been named P. praefalciparum to 
indicate its role in the origin of P. falciparum. To investigate how often P. praefalciparum 
crossed the species barrier to humans, we constructed a phylogenetic tree from 
concatenated mitochondrial protein sequences of these and closely related P. reichenowi 
parasites, which yielded evidence for only a single transmission event (Figure 1-3C). 
These findings are consistent with results from epidemiological surveys in Cameroon and 
Gabon, which demonstrated that humans living in the immediate vicinity of wild-living 
chimpanzees and gorillas do not harbor ape Laverania parasites (Sundararaman et al., 
2013; Delicat-Loembet et al., 2015). Thus, P. praefalciparum parasites appear incapable 
of infecting humans, suggesting that the particular gorilla parasite strain that was able to 
cross the host species barrier must have carried one or more highly unusual mutations 
that conferred an ability to colonize humans.  
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Although alternative hypotheses concerning the origin of P. falciparum have been 
proposed, none has stood the test of time. For example, the finding of a P. praefalciparum 
infection in a greater spot-nosed monkey (Cercopithecus nictitans) (Figure 1-3C) was 
taken to indicate that P. falciparum could have originated in monkeys (Prugnolle et al., 
2011). However, this theory ignored the fact that P. praefalciparum sequences had been 
amplified from numerous wild-living gorillas at 11 different field sites up to 750 km apart, 
whereas only a single captive infected monkey was reported (Sharp et al., 2011). Indeed, 
subsequent testing of nearly 300 wild-caught greater spot-nosed monkeys failed to identify 
a single P. praefalciparum infection, indicating that this monkey species is not a natural 
reservoir for this parasite (Ayouba et al., 2012). Similarly, amplification of P. falciparum 
sequences from captive bonobos was taken to indicate that the human malaria parasite 
originated in this ape species (Krief et al., 2010). However, phylogenetic analysis of these 
sequences revealed that they were completely interspersed with human P. falciparum 
(Figure 1-3C), which together with the finding of drug resistance mutations in the bonobo 
parasites (Krief et al., 2010), indicated that these apes had acquired parasites from the 
local human population. This is not without precedent, since human P. falciparum has on 
occasion been found to infect chimpanzees in captivity (Duval et al., 2010; Pacheco et al., 
2013).  
P. falciparum has long been suspected to exhibit unusually low levels of genetic 
diversity (Rich et al., 1998), but the underlying causes have remained unclear. Recent 
genome-wide comparisons of the chimpanzee parasites P. gaboni and P. reichenowi have 
shown that their within-species genetic diversity is about 10-fold higher than that seen in 
P. falciparum (Sundararaman et al., 2016). Thus, the extremely low diversity among extant 
P. falciparum strains is not a general characteristic of Laverania parasites. Recent 
selective sweeps of drug resistance mutations have reduced levels of polymorphism in 
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P. falciparum, but because resistant and sensitive strains continue to recombine in 
mosquitoes, diversity has only been reduced in the immediate vicinity of the selected loci 
(Nair et al., 2003; Volkman et al., 2007). Instead, the greatly reduced level of diversity 
across the entire P. falciparum genome most likely resulted from a recent severe 
population bottleneck, which is most plausibly explained by the gorilla-to-human cross-
species transmission event though subsequent bottlenecks secondary to human and 
mosquito adaptation may also have contributed to the observed genetic diversity. 
 
1.5 A sylvatic reservoir of P. vivax and African origin of P. vivax 
Although early studies indicated that chimpanzees and gorillas harbor P. vivax-like 
parasites, the number of sequences recovered was too limited to draw definitive 
conclusions (Kaiser et al., 2010; Krief et al., 2010; Liu et al., 2010a).  As for the Laverania 
species, elucidation of the molecular epidemiology of P. vivax in apes required a 
comprehensive analysis of wild-living populations across central Africa (Liu et al., 2014). 
Table 1-1 and Figure 1-2B summarize available data from published studies, showing that 
P. vivax is relatively common among central and eastern chimpanzees as well as western 
lowland gorillas, which together represent a considerable sylvatic P. vivax reservoir 
(Kaiser et al., 2010; Liu et al., 2010a; De Nys et al., 2013; Liu et al., 2014). In addition, P. 
vivax sequences have also been amplified from wild-living bonobos (Liu et al., 2017). 
However, amplification of P. vivax DNA sequences from fecal samples was considerably 
less efficient than from blood samples, most likely reflecting much lower parasite loads in 
fecal samples compared to blood (Liu et al., 2014). Thus, the observed fecal-based 
infection rates, which ranged from 2% to 8% for the various ape species and subspecies 
(Table 1-1), are expected to greatly underestimate the actual prevalence rates, perhaps 
by as much as an order of magnitude. The low sensitivity of fecal parasite detection may 
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also explain why P. vivax has not yet been detected in wild-living Nigeria-Cameroon 
chimpanzees or in Cross River gorillas. Indeed, P. vivax-like sequences were readily 
amplified from the blood of captive Nigeria-Cameroon chimpanzees, indicating that this 
subspecies is susceptible to P. vivax infection (Figure 1-4).  
Phylogenetic analyses of SGA-derived sequences showed that ape and human P. 
vivax were very closely related. In phylogenetic trees of mitochondrial (Figure 1-4A), 
nuclear (Figure 1-4B), and apicoplast (Figure 1-4C) sequences, human P. vivax 
sequences formed a single lineage within the radiation of the ape parasites. In contrast, 
parasite sequences derived from ape samples were interspersed, suggesting that P. vivax 
strains circulate freely between ape species. Of note, analysis of nearly 1,000 bushmeat 
samples failed to identify related sequences in samples from any of 16 different monkey 
species, strongly suggesting that P. vivax is restricted to apes (Liu et al., 2014).  
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Figure 1-4: Evolutionary relationships of ape and human P. vivax parasites. 
Phylogenies were derived from (A) mtDNA fragment D (2,539 bp), (B) nuclear DNA (ldh 
gene; 711 bp), and (C) apicoplast DNA (clpM gene; 574 bp). Parasite sequences are 
colored according to their host species (P. t. troglodytes, red; P. t. schweinfurthii, dark 
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blue; P. t. ellioti, orange; G. g. gorilla, green; Pan paniscus, purple; human, black); the red 
star denotes a parasite from a European who worked in an African forest. Mosquito (A. 
moucheti) derived sequences are shown in cyan. Reference sequences for P. cynomolgi, 
P. inui, P. fragile, and P. knowlesi are indicated.  A lineage of parasite sequences from 
wild chimpanzees, which is related to ape and human P. vivax, likely represents a new 
Plasmodium species, which has been designated P. carteri (black arrows). Phylogenies 
were generated using maximum likelihood methods.  Asterisks at major nodes indicate 
bootstrap values ≥ 65%, and the scale bars represent 0.01 nucleotide substitutions per 
site. Sequences were combined from multiple studies (Krief et al., 2010; Paupy et al., 
2013; Prugnolle et al., 2013; Liu et al., 2014, 2017). 
 
Until recently, the closest known relative of P. vivax was a parasite, P. cynomolgi, 
which infects macaques in Asia (Tachibana et al., 2012).  In phylogenetic trees, P. vivax 
and P. cynomolgi fall within a clade of parasites that includes at least eight other 
Plasmodium species infecting Asian macaques (Figure 1-1). The consensus view has thus 
been that P. vivax emerged in Southeast Asia following the cross-species transmission of 
a macaque parasite (Escalante et al., 2005; Jongwutiwes et al., 2005; Mu et al., 2005; 
Neafsey et al., 2012).  However, this hypothesis has always been at odds with two other 
observations. First, the high prevalence of the Duffy negative phenotype in sub-Saharan 
Africans, which suggested that this mutation arose in response to prolonged selection 
pressure from P. vivax (Carter, 2003) rather than another unidentified pathogen 
(Livingstone, 1984). Second, modern humans did not arrive in Asia until about 60,000 
years ago (Mellars, 2006); yet, P. vivax has likely diverged from macaque parasites much 
earlier than this (Escalante et al., 2005; Jongwutiwes et al., 2005; Mu et al., 2005; Neafsey 
et al., 2012). Thus, P. vivax would have had a rather convoluted history, requiring 
transmission from macaques to an early hominin, such as Homo erectus, followed by its 
diversification in that host before numerous lineages were transmitted to modern humans 
after they emerged from Africa. The discovery of P. vivax in large numbers of African great 
apes now resolves these inconsistencies, providing compelling evidence for an African, 
rather than an Asian, origin of human P. vivax.  
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The phylogenetic relationships of P. vivax strains suggest that all extant human P. 
vivax strains form a monophyletic clade within the radiation of ape parasites (Figure 1-4). 
This could be interpreted to mean that P. vivax originated in humans following a single 
transmission event.  However, the lack of host specificity of ape P. vivax in natural settings 
(Liu et al., 2014, Liu el al., 2017), along with the finding of a zoonotic ape P. vivax infection 
(Prugnolle et al., 2013), argues against this theory. Instead, it seems more likely, based 
on these short sequences, that extant human P. vivax represents a lineage that survived 
after spreading out of Africa. Human P. vivax strains that are currently found in 
Madagascar and parts of Africa are likely the result of a reintroduction of this parasite from 
Asia (Culleton and Carter, 2012).  
 While it could be argued that the ape P. vivax was brought to Africa by humans 
who migrated from Asia (Prugnolle et al., 2013), this hypothesis has been refuted by 
sequences indicating the existence of a related, but distinct, Plasmodium species that also 
infects African apes. This Plasmodium species, which is apparent in trees of 
mitochondrial, nuclear and apicoplast sequences (Figure 1-4), has been found in 
chimpanzees from two different locations in Cameroon (the BQ and DG field sites in Figure 
1-2) and represents the closest known relative of P. vivax. The most parsimonious 
interpretation of this finding is that the common ancestor of these two species was in 
Africa, indicating that the lineage existed there for a long time before P. vivax arose as a 
distinct species (Figure 1-4). We propose to designate this newly described species 
Plasmodium carteri, in honor of Richard Carter, who has long championed the hypothesis 
that P. vivax originated in Africa (Carter, 2003; Culleton and Carter, 2012). 
1.6 Zoonotic potential of ape parasites  
Despite the identification of suitable bridge vectors (Paupy et al., 2013; Makanga et al., 
2016), both experimental transmission and molecular epidemiological studies indicate that 
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ape Laverania parasites do not normally cause blood stage infections in humans. Attempts 
to inoculate humans with a parasite identified as “P. reichenowi” over 100 years ago did 
not result in parasitemia (Blacklock and Adler, 1922). More importantly, two recent field 
studies conducted in rural Cameroon and Gabon failed to identify ape Laverania infections 
in humans living in close proximity to infected chimpanzees and gorillas (Sundararaman 
et al., 2013; Delicat-Loembet et al., 2015). In contrast, experimental inoculation with P. 
schwetzi did result in patent parasitemia and clinical malaria in Duffy positive, but not Duffy 
negative, humans suggesting that the inoculum was likely ape P. vivax (Contacos 1970).  
Furthermore, natural infections of Duffy positive individuals can occur, as exemplified by 
the case of a Caucasian male who acquired this infection after working for 18 days in a 
forest in the Central African Republic (Figure 1-2B).  Parasite sequences amplified from 
this individual’s blood did not fall within the human P. vivax lineage, but instead clustered 
with parasites obtained from wild-living apes (Figure 1-4A), confirming acquisition by 
cross-species transmission from an ape (Prugnolle et al., 2013). These data indicate that 
ape Laverania parasites do not switch between host species, except under highly unusual 
circumstances, while ape P. vivax is much less host-specific and has the potential to infect 
Duffy positive humans, suggesting that human and ape P. vivax parasites represent a 
single species.  
 Importantly, however, none of these studies address the possibility that humans 
are exposed to ape parasites, which may cause a liver stage infection in the absence of a 
blood stage infection. Thus, it is currently unclear whether absence of blood stage 
infections in humans is a result of lack of exposure to mosquitoes carrying ape 
Plasmodium sporozoites, parasite-host incompatibility at the liver stage of infection, and/or 
parasite-host incompatibility at the blood stage of infection. In Chapter 2 of this 
dissertation, I use a fecal screen to search for ape Plasmodium infections in humans living 
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near infected apes, including hunter-gatherers who spend extensive time in or near ape 
habitat. Although studies in mice show that pre-erythrocytic Plasmodium DNA can be 
detected in stool, I did not detect evidence of abortive ape Plasmodium liver infections in 
the 504 Cameroonian humans screened. Instead, I identified a link between parasitemia 
and fecal Plasmodium DNA detection, suggesting that parasite DNA in fecal samples is 
derived from blood stage infections.  
 
1.7 Emergence of P. vivax in human populations 
While available organellar and nuclear sequences suggest an African origin of human P. 
vivax (Liu et al., 2014), nothing is known about the circumstances and mechanistic 
processes that led to the parasite’s emergence in humans. Yet, such information is critical 
to understand how ape parasites crossed the species barrier and whether such events 
are likely to occur again. The lack of in vitro culture systems poses a significant challenge 
to the functional analysis of ape Plasmodium parasites, but whole genome sequencing 
represents a critical first step towards understanding their biology (Otto et al., 2014; 
Sundararaman et al., 2016). In this dissertation, I present the results of comparative 
genomic analysis of ape and human P. vivax. In Chapter 3 I describe the adaptation of 
selective whole genome amplification (SWGA) to P. vivax-infected samples, and 
subsequently use this method in Chapter 4 to generate P. vivax genome sequences from 
six chimpanzees and one gorilla. Differences in the magnitude and pattern of 
polymorphism observed in ape and human P. vivax indicate that the human P. vivax 
lineage has undergone a recent bottleneck followed by rapid population expansion. 
Furthermore, both genome-wide analysis and functional protein studies suggest that the 
human P. vivax lineage has acquired remarkably few human-specific adaptations. Thus, 
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these studies provide insight into the zoonotic ape reservoir of malaria parasites and 
reveal the evolutionary history of P. vivax in humans. 
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2.1 Abstract 
African apes are endemically infected with numerous Plasmodium spp. including close 
relatives of human Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, and 
Plasmodium malariae. Although these ape parasites are not believed to pose a zoonotic 
threat, their ability to colonize humans has not been fully explored. In particular, it remains 
unknown whether ape parasites are able to initiate exo-erythrocytic replication in human 
hepatocytes following the bite of an infective mosquito. Since animal studies have shown 
that liver stage infection can result in the excretion of parasite nucleic acids into the bile, 
we screened fecal samples from 504 rural Cameroonians for Plasmodium DNA. Using 
pan-Laverania as well as P. malariae- and P. vivax-specific primer sets, we amplified 
human P. falciparum (n=14), P. malariae (n=1), and P. ovale wallikeri (n=1) mitochondrial 
sequences from fecal DNA of 15 individuals. However, despite using an intensified PCR 
screening approach we failed to detect ape Laverania, ape P. vivax or ape P. malariae 
parasites in these same subjects. One fecal sample from a hunter-gatherer contained a 
sequence closely related to the porcupine parasite Plasmodium atheruri. Since this same 
fecal sample also contained porcupine mitochondrial DNA, but a matching blood sample 
was Plasmodium-negative, it is likely that this hunter-gatherer consumed Plasmodium-
infected bushmeat. Fecal Plasmodium detection was not secondary to intestinal bleeding 
and/or infection with gastrointestinal parasites, but indicative of blood parasitemia. 
Quantitative PCR identified 26-fold more parasite DNA in the blood of fecal Plasmodium-
positive than fecal Plasmodium-negative individuals (P=0.01). However, among blood-
positive individuals only 10% - 20% had detectable Plasmodium sequences in their stool. 
Thus, fecal screening of rural Cameroonians failed to uncover abortive ape Plasmodium 
infections, but detected infection with human parasites, albeit with reduced sensitivity 
compared with blood analysis. 
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2.2 Introduction 
Wild-living African apes are naturally infected with a wide variety of Plasmodium spp., 
including seven members of the Laverania subgenus as well as close relatives of human 
Plasmodium vivax, Plasmodium malariae and Plasmodium ovale (Ollomo et al., 2009; 
Rich et al., 2009; Krief et al., 2010; Liu et al., 2010a, 2014, 2016, 2017; Prugnolle et al., 
2010). While the impact of these infections on wild ape populations remains to be 
explored, their genetic characterization has provided important new insight into the origins 
and evolution of human malaria. For example, Plasmodium praefalciparum, a parasite that 
naturally infects gorillas, was found to have crossed the species barrier to humans several 
thousand years ago, giving rise to Plasmodium falciparum (Liu et al., 2010a). In contrast, 
human P. vivax emerged from an ancestral stock of parasites that infected chimpanzees, 
gorillas and humans in Africa, until the spread of the protective Duffy-negative mutation 
eliminated P. vivax in humans there (Liu et al., 2014). African apes also harbor parasites 
that are closely related to human P. malariae, Plasmodium ovale wallikeri and 
Plasmodium ovale curtisi as well as Plasmodium spp. that do not have a known human 
counterpart (Duval et al., 2009, 2010; Hayakawa et al., 2009; Kaiser et al., 2010; Liu et 
al., 2010a, 2014). However, the precise relationships between these ape and human 
parasites, including their host species association and prevalence, have yet to be 
determined. Given the magnitude of the sylvatic Plasmodium reservoir and the fact that 
ape parasite-transmitting Anopheles vectors also feed on humans (Paupy et al., 2013; 
Makanga et al., 2016), the possibility of spillovers into the human population has to be 
considered. 
Laverania infections are common and widespread in chimpanzees (Pan 
troglodytes) and western gorillas (Gorilla gorilla), with estimated prevalence rates ranging 
from 29% to 40% (Loy et al., 2017). Similarly, ape P. vivax infections are widely distributed, 
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although fecal detection rates are generally lower than for Laverania parasites, likely 
reflecting lower blood titers (Loy et al., 2017). Several studies have addressed whether 
Plasmodium-infected apes serve as a recurrent source of human infection. PCR screening 
of more than 5,000 blood samples from individuals in rural Cameroon and Gabon failed to 
identify human infection with ape Laverania parasites (Sundararaman et al., 2013; Delicat-
Loembet et al., 2015; Ngoubangoye et al., 2016). However, one case of a zoonotic ape P. 
vivax infection was documented in a (Duffy-positive) European forest worker (Prugnolle et 
al., 2013). Consistent with experimental transmission studies conducted nearly 100 years 
ago (Blacklock and Adler, 1922), these results indicate substantial barriers to the cross-
species transmission of ape Laverania spp., while non-Laverania parasites such as ape 
P. vivax appear to exhibit a more promiscuous host tropism (Prugnolle et al., 2010, 2013; 
Rayner et al., 2011; Loy et al., 2017; Liu et al., 2017).  
Laverania host specificity is determined, at least in part, by interactions of parasite 
ligands with receptors on the surface of host red blood cells (Martin et al., 2005; Wanaguru 
et al., 2013). However, barriers to erythrocyte invasion do not necessarily preclude 
infection of host hepatocytes. Among non-Laverania spp., an African monkey parasite, 
Plasmodium gonderi, can invade and replicate in hepatocytes of several New World 
monkey species, but fails to establish a productive blood stage infection in these same 
hosts (Sullivan et al., 2002). Similarly, the macaque parasite Plasmodium fieldi and human 
P. ovale can progress through the exo-erythrocytic stage of their life cycle without resulting 
in subsequent parasitemia in owl monkeys (Aotus vociferans) and squirrel monkeys 
(Saimiri boliviensi), respectively (Millet et al., 1994; Sullivan et al., 1998). Although these 
examples represent experimental infections of non-natural host species, they raise the 
possibility that similar non-blood stage initiating (abortive) liver infections could also occur 
under natural conditions. For example, it has been reported that exo-erythrocytic 
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replication of P. vivax may occur in Duffy-negative humans who are protected from blood 
stage infection, since some individuals were found to have antibodies to the P. vivax MSP1 
protein (Herrera et al., 2005; Culleton et al., 2009), which is expressed on liver schizonts 
(Szarfman et al., 1988; Suhrbier et al., 1989) and merozoites (Holder and Freeman, 1984). 
Thus, in addition to blood analyses, studies of zoonotic Plasmodium infections should 
include approaches that can detect exo-erythrocytic stages of parasite development. 
Following the bite of an infective mosquito, sporozoites of mammalian Plasmodium 
parasites migrate to the liver where they initiate asexual replication in hepatocytes that 
mature into schizonts, which then release merozoites into the blood stream (Prudencio et 
al., 2006; Vaughan and Kappe, 2017). Since direct analysis of liver stage infection requires 
invasive methods, we wondered whether there was a non-invasive alternative. Previous 
studies of Plasmodium yoelli-infected mice demonstrated the presence of parasite DNA 
in the liver, gall bladder and stool of sporozoite-inoculated animals several days before 
the onset of parasitemia, indicating that pre-erythrocytic parasite forms are excreted from 
the infected liver into the bile (Abkallo et al., 2014). In addition, Plasmodium knowlesi DNA 
was found in the stool of a macaque, which was inoculated with infected erythrocytes, 12 
days after parasite DNA was last detected in the blood, indicating protracted clearance 
possibly through accumulation of parasite nucleic acids in the gall bladder (Kawai et al., 
2014). We thus reasoned that fecal analyses might reveal human Plasmodium infections 
even if they did not progress to a productive blood stage and/or caused only transient 
parasitemia.  
Here, we used a sensitive PCR screening approach to test fecal samples from 504 
rural Cameroonians for ape Plasmodium parasites, including subsistence agriculturalists 
and hunter-gatherers at risk of exposure to transmitting forest mosquito vectors. Targeting 
both Laverania and non-Laverania spp., we amplified P. falciparum, P. malariae and P. 
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ovale wallikeri sequences from a subset of individuals. However, none of the fecal 
samples contained ape Plasmodium parasites. Moreover, all were negative for P. vivax, 
which has recently been reported to infect both Duffy-positive and negative individuals in 
Cameroon (Fru-Cho et al., 2014; Mbenda and Das, 2014; Russo et al., 2017; Zimmerman, 
2017). Thus, fecal analyses of humans living in close proximity to wild chimpanzees and 
gorillas failed to yield evidence of abortive ape Plasmodium infections. 
 
2.3 Materials and methods 
Study sites and sample collection. Study participants were recruited from nine villages 
in the Northwest (Ntambang, NT; Sabga, SA), South (Bidou I, BI; Ndtoua, ND) and East 
(Nkolbikong, NK; Missoume, MI; Njibot, NJ; Aviation, AV; Bosquet, BO) Administrative 
Regions of Cameroon (Figure 2-1A), all of which represented rural communities. 
Moreover, the villages in the South and East Administrative Regions were located in 
densely forested areas in close proximity to the habitat of wild chimpanzees and gorillas 
previously shown to be Plasmodium-infected (Figure 2-1B). Fecal samples were obtained 
from a total of 504 individuals including 37 Fulani pastoralists (individuals who raise 
livestock), 142 rainforest hunter-gatherers (individuals who forage for meat and plant 
materials), and 325 Bantu-speaking agro-pastoralists (individuals who grow crops and 
raise livestock). For 80 of these individuals, matching blood samples collected on the 
same day as the fecal samples were also available. All samples were obtained from 
asymptomatic subjects with no signs of clinical illness. Fecal samples (~5 g) were placed 
in sterile plastic containers without preservatives, frozen at -80 °C, and shipped to the US 
on dry ice. Blood samples (collected in EDTA tubes) were obtained from adults (~10 ml) 
and juveniles (~6 ml), but not from children 10 years of age or younger. For long-term 
storage, whole blood from a subset of individuals was also blotted onto Whatman filter 
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cards (GE Healthcare, USA). All samples were coded with an alphanumerical identifier to 
protect participant confidentiality. The study was approved by the Institutional Review 
Board of the University of Pennsylvania, the Cameroonian National Ethics Committee and 
the Cameroonian Ministry of Public Health. All subjects provided written informed consent 
for the collection and analysis of samples.  
 
Extraction of fecal and blood DNA. Fecal DNA was extracted from ~220 mg aliquots 
using a modified “bead beating” method (Salonen et al., 2010) and the PSP Spin Stool 
DNA Plus Kit (Stratec Biomedical, Germany). Blood was processed in the field to isolate 
leukocytes (Miller et al., 1988), and DNA was extracted using the Puregene kit (Quigen, 
Germany). This was done to maximize DNA utilization for studies other than malaria. For 
quantitative PCR (qPCR) analysis of P. falciparum in blood samples, DNA from whole 
blood was extracted from three filter paper punches (3 mm in diameter) using the QIAamp 
DNA Mini Kit (Qiagen, Germany). DNA quality was determined using a Nanodrop, and the 
concentrations were determined using Qubit fluorometric quantitation.  
 
Intensified PCR for Plasmodium detection. Fecal DNA was screened using highly 
cross-reactive primers previously shown to amplify a 956 bp mitochondrial cytochrome B 
(cytB) fragment of both Laverania and non-Laverania parasites (Liu et al., 2010a, 2017). 
Studies of wild apes have shown that fecal samples contain only very limited quantities of 
parasite DNA (Liu et al., 2010a). To increase the likelihood of parasite detection, we 
intensified our PCR screening by testing multiple aliquots of the same fecal DNA using the 
same primers and cycling conditions (Liu et al., 2017). Depending on the amount of 
starting material, we performed between 10 and 20 independent PCRs per sample. This 
intensified approach was also used to screen fecal DNA for P. vivax and P. malariae 
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sequences, although in each case only four DNA aliquots were tested due to limited 
sample availability. For P. vivax, lineage-specific primers were used to amplify a 295 bp 
fragment of the cytochrome oxidase 1 (cox1) gene (Liu et al., 2014), while for P. malariae 
a 600 bp cytB fragment was targeted for amplification (Liu et al., 2017). DNA from 
matched, leukocyte-enriched blood samples, which were available for nine fecal 
Plasmodium-positive and 70 fecal Plasmodium-negative subjects from five villages (AV, 
BI, BO, MI, ND), were screened by regular PCR for Laverania, P. vivax and P. malariae 
infections. This was also done for a paired dried blood spot DNA from one additional fecal-
positive individual. All amplicons were sequenced using Sanger technologies, and 
amplicons with ambiguous bases were subsequently Illumina MiSeq sequenced using 
Nextera library preparation followed by read mapping to the appropriate Plasmodium 
reference sequence for base calling and variant identification. 
 
Differentiation of ape and human P. malariae. To increase the number of P. malariae 
reference sequences, we selected stored blood and fecal samples of infected apes (Liu 
et al., 2010a, 2014, 2016) and humans (Sundararaman et al., 2013) from our specimen 
bank previously shown to harbor this parasite. Using single template PCR and published 
primer sets, we amplified 3.4 kb (Liu et al., 2010a), 2.5 kb (Liu et al., 2014), or 956 bp (Liu 
et al., 2010a) fragments of the P. malariae mitochondrial genome. Two single nucleotide 
variants (SNVs) were used to assess whether P. malariae parasites identified in the blood 
(n=18) and fecal (n=1) samples of rural Cameroonians were of likely human or ape origin. 
SNV1 was amplified using P. malariae-specific cox1 primers, which generated a 104 bp 
fragment. Fecal DNA (2.5 μl) was amplified in a 25 μl reaction volume using 40 μM dNTPs, 
20 pmol of forward (ApePm_SNP1_oF 5’-ATTTTATCTACAGCTGCTGAATTT-3’) and 
reverse (ApePm_SNP1_oR 5’-TGTAATTAATAATGACCATGTTGATA-3’) primers, 1x 
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PCR buffer, and 0.25 μl of Taq from the Expand Long Template enzyme kit (Roche, USA). 
First round cycling conditions included an initial hot start of 2 min at 94 °C, followed by 15 
cycles of denaturation (94 °C, 10 s), annealing (45 °C, 30 s) and elongation (68 °C, 2 min), 
followed by 35 cycles of denaturation (94 °C, 10 s), annealing (48 °C, 30 s) and elongation 
(68 °C, 2 min, with 15 s increments for each successive cycle), followed by a final 
elongation step of 10 min at 68 °C. A 1 μl aliquot of the first round product was amplified 
using forward (ApePm_SNP1_iF 5’-TATCCACCATTAAGTACTTCTCTTAT-3’) and 
reverse (ApePm_SNP1_iR 5’-ACCTAATGTTAATCCTTTTGATCTTA-3’) primers in the 
second round PCR. Second round cycling conditions included an initial denaturation step 
of 2 min at 94 °C, followed by 60 cycles of denaturation (94 °C, 10 s), annealing (52 °C, 
30 s) and elongation (68 °C 1 min), followed by a final elongation step of 10 min at 68 °C. 
SNV2 was amplified using pan-Plasmodium or P. malariae-specific cytB primer pairs as 
previously described (Liu et al., 2010a; Liu et al., 2017), or by targeting a 110 bp cytB 
fragment using primers ApePm_SNP2_oF (5’-TTTTACCATTTTATGCAATGTTAAAA-3’) 
and ApePm_SNP2_oR (5’-AAATGAAAATTTCTTGTGGTAATTGA-3’) in the first round of 
PCR, and ApePm_SNP2_iF (5’-AATACCTAGTAAAACAGCAGGTT-3’) and 
ApePm_SNP2_iR (5’-AATGAACACATAAACCATATAATTGG-3’) in the second round. 
Amplification conditions were the same as for SNV1. 
 
Mammalian species determination A subset of human fecal samples (n=27) was 
subjected to mitochondrial DNA (D-loop) analysis to confirm their host species origin as 
previously described (Gao et al., 1999). To test for bushmeat consumption, the same 
samples were also screened for mitochondrial DNA from the African brush-tailed 
porcupine (Atherurus africanus), targeting a 219 bp cytB fragment using primers 
Aafricanuscytb_1F (5’-CTCCTYAAAATCATTAACCACTCATT-3’) and Aafricanuscytb_1R 
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(5’-GTTGCTATCACYGTAAGTAGTAATA-3’) in the first, and Aafricanuscytb_2F (5’-
AATATCTCAGRATGATGAAACTTC-3’) and Aafricanuscytb_2R (5’-
ATATTTCAAGTTTCYGTGAATGTGTA-3’) in the second round of PCR. Amplification 
conditions were the same as for P. malariae SNV1. 
 
Fecal testing for intestinal parasites and occult blood. Fecal samples were analyzed 
by wet-mount fecal microscopy with and without iodine staining in the field to identify 
visible gastrointestinal parasites or parasite ova, including human whipworm (Trichuris 
trichiura), hookworm (Ancylostoma duodenale), giant roundworm (Ascaris lumbricoides), 
and amebiasis (Entamoeba histolytica). A subset of stored, frozen fecal samples (n=84) 
were later thawed on ice and screened for occult blood using the Hemosure test 
(Hemosure, USA), a qualitative immunochemical test that detects human haemoglobin in 
stool samples, according to the manufacturer’s recommendations. Positive and negative 
control samples were processed in parallel.  
 
Quantitative PCR to determine P. falciparum DNA levels in blood samples. To 
quantify P. falciparum DNA in blood samples, we developed a quantitative Taqman-based 
PCR assay targeting a 141 bp fragment of the parasite mitochondrial cytB region. DNA 
from dried blood spots, which were available from eight fecal Plasmodium-positive and 20 
fecal Plasmodium-negative individuals, was incubated in a 25 µl reaction volume 
containing 1x Taqman Fast Universal MasterMix (Invitrogen), 0.4 µM of both forward 
(cytb_qpcr1_F 5’-GAGAATTATGGAGTGGATGGTGT-3’) and reverse (cytb_qpcr1_R 5’-
AGACATAACCAACGAAAGCAGT-3’) primers, and a FAM-labeled Taqman probe (6FAM-
ACATGCACGCAACAGGTGCT-TAMRA). PCR conditions included incubation for 2 min 
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at 50 °C, followed by a hot start of 10 min at 95 °C, followed by 45 cycles of 15 s at 95 °C 
and 45 s at 58 °C. A qPCR standard curve was generated by diluting known quantities of 
P. falciparum 3D7 DNA in human genomic DNA. All samples were run in triplicate 
alongside positive and negative controls. Plasmodium falciparum copies were averaged 
and normalized by the amount of input DNA (ng).   
 
Phylogenetic analyses. Parasite and host mitochondrial sequences were aligned using 
CLUSTAL W (Thompson et al., 1994) implemented in Geneious 9.1.2 (Kearse et al., 2012) 
with regions that could not be unambiguously aligned removed from subsequent analyses. 
Maximum likelihood phylogenetic trees were estimated using PhyML (Guindon et al., 
2010) with evolutionary models selected by jModelTest (Darriba et al., 2012). 
 
Statistical analyses. Differences in gastrointestinal parasite detection between fecal 
Plasmodium-positive and -negative individuals were assessed using a one-sided Fisher’s 
exact test after correcting for multiple tests using a Bonferroni correction. Differences in 
hemoglobin detection between fecal Plasmodium-positive and fecal Plasmodium-negative 
individuals were also assessed using a one-sided Fisher’s exact test. Differences in fecal 
Plasmodium detection between children and adults were assessed using a one-sided 
Fisher’s exact test. Blood parasite loads (determined by qPCR) of fecal Plasmodium-
positive and -negative individuals were compared using a one-sided Mann-Whitney test. 
 
Accession numbers. All newly derived Plasmodium and host mitochondrial sequences 
have been deposited in GenBank under accession numbers MF693406 - MF693457 (also 
see Tables S3-1). 
 
40 
 
2.4 Results 
Intensified PCR identifies P. falciparum, but not ape Laverania parasites, in fecal 
samples from rural Cameroonians Previous analyses of humans from rural Gabon and 
Cameroon failed to identify evidence of zoonotic ape Plasmodium infections 
(Sundararaman et al., 2013; Delicat-Loembet et al., 2015; Ngoubangoye et al., 2016). 
However, since only blood samples were tested, the possibility of abortive (non-blood 
stage initiating) liver infection was not explored. Here, we analyzed fecal samples from 
504 Fulani pastoralists, rainforest hunter-gatherers and Bantu-speaking agro-pastoralists 
from nine rural communities in Cameroon (Table 2-1). Most of these communities were 
located in forested areas in the immediate vicinity of the habitat of wild apes (Figure 2-
1A), which were previously shown to harbor both Laverania and non-Laverania infections 
(Liu et al., 2010a, 2014). Although the intensity of Plasmodium transmission in the nine 
villages was not determined, this close proximity, in addition to the fact that most villagers 
from southern field sites spent many hours every day in or adjacent to the forest (Figure 
2-1B), suggested that these communities were at risk of exposure to Anopheles spp. that 
carry ape parasites. 
Fecal DNAs were first screened with highly cross-reactive primers previously 
shown to amplify a 956 bp mitochondrial cytB fragment from both Laverania and non-
Laverania parasites (Liu et al. 2010a, 2017). Because fecal samples frequently contain 
only limited amounts of Plasmodium DNA, we intensified our PCR screening to maximise 
parasite detection (Liu et al., 2017). Performing 10 to 20 independent PCRs for each DNA 
sample (depending on sample availability), we amplified human Plasmodium sequences 
from the stool of 15 individuals (Table 2-1). For three of these subjects, more than half of 
20 PCR replicates were positive, suggesting a relatively high fecal parasite burden (Table 
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2-2). However, for most other subjects fecal Plasmodium PCR was at or near the limits of 
detection, with five samples yielding only a single positive reaction (Table 2-2). 
 
Figure 2-1. Human sampling sites in Cameroon. (A) The locations of nine rural villages 
(yellow circles) are shown in relation to field sites (red hatched circles) where wild-living 
chimpanzees and gorillas have previously been shown to harbor Plasmodium parasites 
(Liu et al., 2010a, 2014; Loy et al., 2017). Villages are denoted by a two-letter code (NT, 
Ntambang; SA, Sabga; BI, Bidou I; ND, Ndtoua; NK, Nkolbikong; MI, Missoume; NJ, 
Njibot; AV, Aviation; BO, Bosquet). Major cities, national boundaries and rivers are shown 
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in black, yellow and blue, respectively. (B) Image of a representative village with a large 
population of hunter-gatherers (photograph by Meagan A. Rubel). 
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All amplicons were sequenced directly and subjected to phylogenetic analysis. Fecal 
samples from 14 individuals contained P. falciparum, one of which (BO-6) also contained 
P. malariae, while the remaining sample (BO-3) contained P. ovale wallikeri (Figure 2-2). 
Replicate PCRs from the same samples yielded identical sequences, except for BI-2 and 
BO-2, both of which yielded one amplicon that contained two P. falciparum variants in 
approximately equal proportions, differing by one and two nucleotides, respectively 
(Figure 2-2). Analysis of available blood samples confirmed the fecal results, identifying 
additional P. malariae co-infections in three individuals that were not detected by fecal 
analysis (Table 2-2). None of the 504 fecal samples yielded sequences from ape 
Laverania parasites. 
Table 2-1. Detection of Plasmodium DNA in fecal samples of subjects from 
rural Cameroon 
Village (Code) 
Fecal 
samples 
screened 
Plasmodium speciesa  
P. 
falciparum 
P. 
malariae 
P. ovale 
wallikeri 
Ape 
Laverania 
Ape 
P. vivax 
Ape 
P. 
malariae 
Other spp. 
Aviation (AV) 19 2 0 0 0 0 0 0 
Bidou I (BI) 68 3 0 0 0 0 0 0 
Bosquet (BO) 51 6 1b 1 0 0 0 0 
Missoume (MI) 31 1 0 0 0 0 0 0 
Ndtoua (ND) 65 2 0 0 0 0 0 1c 
Njibot (NJ) 20 0 0 0 0 0 0 0 
Nkolbikong (NK) 24 0 0 0 0 0 0 0 
Ntambang (NT) 174 0 0 0 0 0 0 0 
Sabga (SA) 52 0 0 0 0 0 0 0 
Total 504 14 1 1 0 0 0 1 
aPlasmodium species were identified by direct amplicon sequencing and phylogenetic analysis. 
bSample BO-6 contained both P. falciparum (956 bp cytB fragment) and P. malariae (956 bp and 600 cytB 
fragments) sequences. 
cSample ND-1 yielded a rodent Plasmodium sequence (295 bp cox1 fragment; see Figure 2-4). 
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Table 2-2. Relative parasite burden in Plasmodium positive human fecal 
samples  
Subject  Age Ethnicity 
Fraction of 
PCR positives 
using pan-
Plasmodium 
primersa 
Fraction of 
PCR positives 
using P. 
malariae 
primersa 
Fraction of 
PCR positives 
using P. vivax 
primersa 
Plasmodium 
species in 
fecal sampleb 
Plasmodium 
species in 
matching 
bloodb 
AV-1 32 Baka 1/20 0/4 0/4 Pf Pf 
AV-2 7 Maka 3/20 0/4 0/4 Pf n/a 
BI-1 44 Fang 1/20 0/4 0/4 Pf Pf 
BI-2 50 Fang 4/20 0/4 0/4 Pf Pf, Pm 
BI-3 11 Bagyeli 8/20 0/4 0/4 Pf Pf, Pm 
BO-1 20 Baka 1/20 0/4 0/4 Pf Pf 
BO-2 15 Baka 1/20 0/4 0/4 Pf Pf 
BO-3 7 Baka 4/20c 0/4 0/4 Powc n/a 
BO-4 5 Baka 16/20 0/4 0/4 Pf n/a 
BO-5 28 Baka 7/20 0/4 0/4 Pf Pf 
BO-6 7 Baka 3/20d 3/4 0/4 Pf, Pm n/a 
BO-7 8 Baka 20/20 0/4 0/4 Pf n/a 
MI-1 17 Maka 1/20 0/4 0/4 Pf Pf, Pm 
ND-1 30 Bagyeli 0/20 0/4 1/4e rodent spp. neg 
ND-2 6 Bagyeli 14/20 0/4 0/4 Pf n/a 
ND-3 60 Fang 4/20 0/4 0/4 Pf Pf 
aNumber of positive reactions per total number of PCR replicates of the same DNA sample. 
bPf, P. falciparum, Pow, P. ovale wallikeri, Pm, P. malariae, n/a, blood sample not available; neg, negative 
for Plasmodium sequences. 
cAll four positive PCR reactions yielded P. ovale wallikeri sequences due to primer cross-reactivity. 
dTwo of three positive PCR reactions yielded P. falciparum sequences, while the third yielded P. malariae 
sequences. 
eOne positive PCR reaction yielded a P. atheruri-like sequence (see Figure 2-4A). 
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Figure 2-2. Plasmodium spp. detected in the stool and blood samples of rural 
Cameroonians. The phylogenetic positions of Plasmodium sequences (956 bp cytB 
fragment) derived from fecal (blue) and blood (red) samples of rural Cameroonians are 
shown in relation to ape and human Plasmodium reference sequences (green and black, 
respectively). Samples are labeled according to their village of origin (see Figure 2-1 
legend for details), followed by a randomly assigned number. For each fecal and blood 
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sample, only distinct haplotypes are shown (two haplotypes from the same fecal sample 
are indicated as v1 and v2, respectively). Fecal samples for which matching blood 
samples were not available are indicated by stars. Brackets indicate Plasmodium spp. (Pf, 
Plasmodium falciparum; Po-related, Plasmodium ovale-related, Poc, Plasmodium ovale 
curtisi, Pow, Plasmodium ovale wallikeri, Pm-related, Plasmodium malariae-related, Pm, 
P. malariae; Pv, Plasmodium vivax). The tree was constructed using PhyML (Guindon et 
al., 2010) with TIM2+I as the evolutionary model. Bootstrap values ≥ 80% are shown (the 
scale bar represents 0.01 nucleotide substitutions per site). GenBank accession numbers 
for individual sequences are listed in Table S3-1.  
 
Fecal samples from rural Cameroonians contain P. malariae but not P. vivax 
sequences. To specifically search for non-Laverania parasites, all 504 human fecal 
samples were rescreened using P. vivax and P. malariae-specific primer pairs. Again, 
each fecal sample was subjected to repeat PCR testing, this time using four DNA aliquots 
per primer set. This analysis confirmed the presence of P. malariae in the fecal sample of 
subject BO-6, but failed to identify additional positive samples (Table 2-2). 
Plasmodium vivax-specific primers identified one positive sample, but sequence 
analysis of the respective amplicon identified a porcupine rather than a human parasite 
(see Section 3.3 below). Thus, despite the wide distribution of P. vivax among 
chimpanzees and gorillas in southern Cameroon (Liu et al., 2010a), and the recent finding 
of P. vivax infection in both Duffy-positive and -negative humans in the same region (Fru-
Cho et al., 2014; Mbenda and Das, 2014; Russo et al., 2017; Zimmerman, 2017), P. vivax 
sequences were not amplified from the fecal samples of any of these individuals. 
To investigate the possible host origin of the newly identified P. malariae and P. 
ovale wallikeri parasites, we constructed a phylogenetic tree from available cytB 
sequences (Figure 2-2). This analysis showed that both P. malariae and P. ovale wallikeri 
sequences failed to form host-specific lineages, most likely because existing genetic 
information is too limited to differentiate ape and human parasites (Figure 2-2). We thus 
performed additional PCR amplifications to increase the number (and in some cases the 
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length) of ape- and human-derived P. malariae sequences (this was not possible for P. 
ovale wallikeri due to a lack of positive samples). Using limiting dilution PCR, we amplified 
mitochondrial fragments (3.4kb, 2.5kb, 956 bp) from stored ape (n=9) and human (n=16) 
samples previously shown to contain this parasite (Liu et al., 2010a, 2014; Sundararaman 
et al., 2013). An alignment of this expanded sequence set revealed two SNVs spaced 
1,906 bp apart that distinguished human from most ape-derived P. malariae strains 
(Figure 2-3). All human-derived P. malariae parasites contained a T at position 276 in the 
cox1 gene (SNV1), and a T or A at position 690 in the cytB gene (SNV2), while nearly all 
P. malariae parasites from wild apes contained a C at these two positions (Figure 2-3); 
the single exception was a parasite from a habituated chimpanzee (Leo) sampled in the 
Tai Forest, which contained an A in cytB (SNV1 was not sequenced).  
Since two bonobos and three chimpanzees living in sanctuaries also harbored P. 
malariae strains with human-specific SNVs, it appears that captive apes are susceptible 
to infection with human P. malariae parasites, a finding consistent with experimental 
infections of chimpanzees (Rodhain, 1948). Whether humans can become infected with 
ape P. malariae under natural conditions remains unknown; however, the fact that the P. 
malariae strain in the BO-6 fecal sample was identical to all other human parasites, 
including P. malariae sequences amplified from matching blood samples, suggests that it 
is of human origin (Figure 2-3). 
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Figure 2-3. Single nucleotide variants distinguishing human and ape Plasmodium 
malariae parasites. A schematic representation of a portion of the P. malariae 
mitochondrial genome is shown (black line), with yellow boxes denoting cox1 and cytB 
coding regions. Blue lines indicate the locations of two single nucleotide variants (SNV1 
and SNV2) spaced 1,906 bp apart, which differentiate human (black) from most ape-
derived (green) P. malariae sequences. Newly derived P. malariae reference sequences 
from humans (Hu), bonobos (Pp), chimpanzees (ptv; Pan troglodytes verus; ptt; Pan 
troglodytes troglodytes; pte, Pan troglodytes ellioti) and gorillas (ggg, Gorilla gorilla gorilla) 
are shown, with newly derived sequences in bold and sequences from captive apes 
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indicated with a yellow triangle (see Table S3-1 for a more detailed description of each 
sequence). P. malariae sequences amplified from the fecal (blue) and blood (red) samples 
of rural Cameroonians are shown at the bottom. 
 
 
Detection of a porcupine Plasmodium parasite in the fecal sample of a hunter-
gatherer. Although the P. vivax-specific primers failed to uncover P. vivax infection, they 
amplified a 295 bp cox1 sequence (Figure 2-4A) which was very similar to the 
corresponding sequence of Plasmodium atheruri, a parasite that infects African brush-
tailed porcupines (Atherurus africanus) (Van Den Berghe et al., 1958; Pacheco et al., 
2011). Since this parasite was detected in the fecal sample of a hunter-gatherer (ND-1), 
we investigated whether the subject was productively infected with the rodent parasite 
(Table 2-2). Screening a blood sample collected on the same day, we failed to amplify P. 
atheruri or any other Plasmodium sequences from this individual. To exclude sample mix-
up, we subjected the ND-1 fecal sample to host mitochondrial analysis (Gao et al., 1999). 
Amplifying a hypervariable D-loop fragment, we confirmed that this and 26 other fecal 
samples from hunter-gatherers of the same ethnic group sampled at the same village 
contained human mitochondrial sequences (Figure 2-4B). Reasoning that the detected 
parasite may have infected consumed bushmeat, we designed porcupine-specific 
mitochondrial primers and used these to probe the same fecal samples. Interestingly, this 
analysis revealed porcupine mitochondrial DNA in the feces of eight hunter-gatherers, 
including subject ND-1 (Figure 2-4C). Since two different mitochondrial DNA haplotypes 
were identified, it is likely that these individuals consumed at least two porcupines in the 
days prior to fecal testing. This is not surprising given that porcupines are frequently 
hunted for food in this and other regions in western central Africa (Jori et al., 1998; Gaubert 
et al., 2015). Thus, the P. atheruri-like parasite, which was detected in the stool, but not in 
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the blood, of subject ND-1, most likely infected a prey animal whose sequences survived 
passage through the human digestive tract (De Nys et al., 2015). Since great apes are 
also hunted for bushmeat, a similar scenario would have to be excluded if ape parasite 
sequences were detected in human fecal samples.   
Figure 2-4. Detection of a porcupine parasite in human stool. (A) The phylogenetic 
position of a Plasmodium sequence (295 bp cox1 fragment) amplified from the fecal 
sample of a human hunter-gatherer (blue) is shown in relation to rodent and human 
Plasmodium reference sequences (black). (B) Confirmation that fecal samples from 27 
hunter-gatherers (blue) are of human origin. Newly derived mitochondrial sequences (500 
bp D-loop fragment) are shown in relation to published human and chimpanzee reference 
sequences (black). (C) Fecal samples of nine hunter-gatherers (blue) contained porcupine 
mitochondrial DNA. Amplified sequences (219 bp cytB fragment) are shown in relation to 
reference sequences for African brush-tailed (Atherurus africanus) and crested (Hystrix 
cristata) porcupines (black). All trees were constructed using PhyML (Guindon et al., 2010) 
with TIM1+I (A), TPM3uf+I+G (B) and HKY+G (C) as the evolutionary models. Bootstrap 
values ≥ 80% are shown (the scale bars represents 0.05 nucleotides substitutions per 
site). GenBank accession numbers for individual sequences are listed in Table S3-1. 
 
Fecal detection of Plasmodium DNA is indicative of concurrent parasitemia. To 
determine whether any of the other individuals who were fecal Plasmodium-positive 
lacked a corresponding blood infection, we screened all subjects for whom blood samples 
were available (blood was not collected from six fecal-positive children). Using pan-
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Laverania-, P. malariae- and P. vivax-specific primers, we identified P. falciparum in all 
paired blood samples (Figure 2-2), three of which (MI-1, BI-2, and BI-3) also contained P. 
malariae parasites (Table 2-2). None of the blood samples was P. vivax-positive. All blood-
derived P. falciparum sequences were identical to the corresponding fecal parasite 
sequences (Figure 2-2). Thus, for all subjects for whom matching fecal and blood samples 
could be tested, we found that the detection of Plasmodium DNA in the fecal sample was 
indicative of a concurrent blood stage infection. 
 
Fecal Plasmodium testing underestimates blood stage infections. The fact that all 
fecal PCR-positive individuals (except for subject ND-1) were also blood stage-infected 
suggested that fecal Plasmodium DNA derived from blood parasites. However, it remained 
unclear to what extent fecal-negative individuals had blood stage infections. To address 
this question, we screened blood samples from a representative subset of fecal-negative 
individuals (n=70) from the five villages where fecal-positive individuals were identified 
(AV, BI, BO, MI, ND). Using all three Plasmodium primer sets, we identified parasite 
sequences in a large fraction (53%) of these individuals. The most common infection was 
P. falciparum, which was detected in the blood of 28 of the 70 fecal-negative individuals 
(Table 2-3). Plasmodium malariae, P. ovale wallikeri and P. ovale curtisi were also 
detected, many as coinfections with P. falciparum (Table 2-3). Of note, all blood-derived 
P. malariae sequences contained the human-specific SNVs, and none of the 70 blood 
samples was P. vivax-positive. These results show that the great majority of blood stage-
infected individuals do not have detectable parasite DNA in their stool, suggesting that 
PCR-based fecal screening is of limited utility for malaria epidemiological studies.  
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Table 2-3. Plasmodium species in the blood of fecal Plasmodium negative 
individuals 
Village Samples screened 
Plasmodium speciesa 
Pf Pm Poc Pow Pv Pf/Pmb Pf/Pocb Pf/Powb 
AV 10 3 0 0 0 0 1 0 0 
BI 25 6 3 1 0 0 4 2 1 
BO 25 3 5 0 0 0 4 0 0 
MI 5 0 0 0 0 0 0 0 0 
ND 5 3 0 0 0 0 1 0 0 
Total 70 15 8 1 0 0 10 2 1 
aPlasmodium species were identified by direct amplicon sequencing and phylogenetic analysis. Pf, P. 
falciparum; Pm, P. malariae; Pow, P. ovale wallikeri; Poc, P. ovale curtisi; Pv, P. vivax. 
bDual infections 
 
Fecal Plasmodium detection is not secondary to gastrointestinal bleeding. The 
finding that most blood-positive individuals were fecal Plasmodium-negative raised the 
possibility that fecal parasite DNA was secondary to intestinal bleeding. Gastrointestinal 
parasites are known to cause bloody stools and are frequently detected in humans from 
Cameroon (Tchuem-Tchuente et al., 2012; Karagiannis-Voules et al., 2015). To examine 
whether bleeding caused by intestinal parasites was a primary reason for fecal 
Plasmodium positivity, we compared the percentage of Plasmodium-positive and -
negative stool samples that were also positive for gastrointestinal parasites for individuals 
from five villages (AV, BI, BO, MI, ND). Although fecal Plasmodium-positive individuals 
tended to have higher rates of whipworm (Trichuris trichiura), hookworm (Ancylostoma 
duodenale or Necator americanus), and giant roundworm (Ascaris lumbricoides) 
infections than fecal Plasmodium-negative individuals, these differences were not 
statistically significant (Table 2-4). Separate analyses of adults and children yielded the 
same result (not shown). Thus, the presence of Plasmodium DNA in fecal samples was 
not secondary to infection with gastrointestinal parasites.  
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Table 2-4. Prevalence of gastrointestinal parasites in Plasmodium fecal 
positive and negative subjects 
 Fecal Plasmodium positive  Fecal Plasmodium negative  
Intestinal 
Parasite 
Number of 
samples 
Number 
positive % positive  
Number 
of 
samples 
Number 
positive 
% 
positive p value
a 
Whipworm 15 6 40  218 56 26 0.90 
Giant roundworm 15 8 53  218 59 27 0.17 
Amebiasis 15 0 0  218 9 4 1.0 
Hookworm 15 3 20  218 13 6 0.36 
Any parasite 15 10 67  218 88 40 0.22 
ap values were calculated using a one-tailed Fisher’s exact test with Bonferroni correction. 
 
 
To examine whether intestinal bleeding due to any cause was associated with fecal 
Plasmodium detection, we examined the 15 Plasmodium-positive stool samples as well 
as 69 Plasmodium-negative stool samples from 37 blood-positive and 32 blood-negative 
individuals for occult blood. Two of the Plasmodium-positive and two of the Plasmodium-
negative fecal samples were Hemosure positive; however, these differences were not 
statistically significant regardless of whether all (2/15 versus 2/69; Fisher’s exact test, P = 
0.14) or only the parasitemic individuals (2/15 versus 0/37; Fisher’s exact test, P = 0.08) 
were included in the analysis. Thus, while gastrointestinal bleeding may in some instances 
increase the likelihood of fecal Plasmodium detection, occult blood does not explain the 
presence of parasite sequences in most stool samples. 
 
Fecal Plasmodium detection is associated with parasitemia. Comparing the age 
distribution of fecal PCR-positive individuals, we noted that parasite detection was 
disproportionately higher in fecal samples of children (6/15, 40%) than in the stool of adults 
(9/204, 4%) (Fisher’s exact test, P < 0.0001). Since even among asymptomatic individuals 
parasitemia tends to decrease with age (Baird, 1998; Bousema et al., 2004; Balaraine et 
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al., 2009; Zhou et al., 2016), we hypothesized that fecal Plasmodium positivity may be 
associated with higher parasite titers in the blood. To examine this possibility, we 
developed a qPCR assay and used it to determine the copy number of P. falciparum in 
dried blood spot samples available for eight fecal-positive and 20 fecal-negative 
individuals. Testing all samples in triplicate, we found 26-fold more parasite DNA in the 
blood of fecal-positive than fecal-negative subjects (Figure 2-5). Thus, individuals with 
high Plasmodium blood titers were more likely to have detectable parasite DNA in their 
stool than individuals with low parasitemia.   
 
Figure 2-5. Fecal Plasmodium-positive individuals have higher blood parasitemia than 
fecal Plasmodium-negative individuals. Blood parasite loads were determined for fecal 
Plasmodium-positive (n = 8) and -negative (n = 20) individuals by Taqman quantitative 
PCR. Values are expressed as copies of P. falciparum per ng of whole blood DNA derived 
from dried blood spots (DBS). Each sample was tested in triplicate. Two samples that 
were below the limit of detection were set to background DNA levels (0.05).  Error bars 
shows standard deviation from the mean and the P value was calculated using a one sided 
Mann-Whitney test.  
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2.5 Discussion 
To examine the zoonotic potential of ape Plasmodium parasites, we screened fecal 
samples from humans living in close proximity of wild chimpanzees and gorillas for 
evidence of abortive liver infection. We reasoned that while receptor/ligand 
incompatibilities at the erythrocyte invasion stage may protect humans from blood stage 
infection, similar barriers may not exist to prevent invasion of hepatocytes. Despite using 
a highly sensitive PCR approach, we found no evidence for such a scenario. Although we 
amplified P. falciparum, P. malariae, and P. ovale wallikeri from human stool, none of the 
504 samples tested was positive for ape Plasmodium DNA. This finding is unlikely the 
result of insensitive detection methods. Assuming that ape Plasmodium sporozoites 
delivered by a mosquito bite would infect at least five hepatocytes, liver stage schizonts 
should produce at least 150,000 merozoites (Shortt et al., 1951). Assuming further that at 
least 5% of these merozoites are cleared into the biliary system, this would yield ~75 
parasites per gram of fecal material (the average adult excretes ~250 g of feces per day; 
Rose et al., 2015). Since we extracted ~0.22 g of fecal material and screened over 45 l 
of the resulting DNA, ~45 mitochondrial genomes (assuming 20 copies per parasite) 
should have been present and readily amplified. Indeed, we detected a porcupine parasite 
after passage through the human gastrointestinal tract, indicating sufficient PCR sensitivity 
to find even rare sequences. However, the likelihood of amplifying exo-erythrocytic 
parasite DNA from human fecal samples depends primarily on the local transmission 
intensity, especially since abortive liver infections would only be detectable for a couple of 
days following an infective mosquito bite. In the absence of such information, we cannot 
exclude that our failure to detect ape parasites reflects a lack of human exposure to 
infective mosquitoes. Alternatively, ape parasites may be unable to replicate in the human 
liver and/or pre-erythrocytic parasite DNA may not be shed into the human stool. Until 
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entomological inoculation rates (EIRs) for Anopheles spp. that transmit ape Plasmodium 
parasites are determined for these communities, it is impossible to differentiate between 
these possibilities.   
Previous studies of human communities in rural Cameroon reported P. falciparum 
EIRs to range between 17 and >500 infected bites per person per year (Njan Nloga et al., 
1993; Meunier et al., 1999; Antonio-Nikidjio et al., 2005; Atangana et al., 2010). We thus 
expected a sizable fraction of our study population to have been exposed to mosquitoes 
carrying this parasite in the days prior to the fecal collection. Since only 15 of 504 
individuals contained human Plasmodium sequences in their stool, we examined parasite 
titers in matching blood samples. This analysis revealed that all individuals with parasite 
DNA in their fecal samples were also blood stage-infected. While this alone does not argue 
against the shedding of pre-erythrocytic parasite DNA, the fact that fecal-positive 
individuals also had higher parasite titers in their blood strongly suggests that most fecal 
parasite DNA derives from infected erythrocytes. This is consistent with the observations 
that fecal and blood Plasmodium copy numbers rose concurrently in experimentally 
infected mice (Abkallo et al., 2014) and that a monkey solely infected with parasitized 
erythrocytes also had detectable Plasmodium DNA in its stool (Kawai et al., 2014). 
Moreover, Laverania parasites, which replicate to high blood titers, are more readily 
amplified from fecal material than non-Laverania parasites such as P. vivax, which exhibit 
only low levels of parasitemia (Liu et al., 2014). Although P. yoelli DNA was detected in 
the liver, gall bladder and stool of experimentally-infected mice several days before the 
onset of parasitemia, the sporozoite dose used in these studies (1,500 - 25,000 per 
mouse; Abkallo et al., 2014) was much higher than what would be delivered by a typical 
infective mosquito, which injects on average fewer than 100 sporozoites per bite (Medica 
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and Sinnis, 2005). Thus, it is possible that most, if not all, of the parasite DNA detected in 
fecal samples of naturally infected primates is derived from blood stage infection. 
The routes by which Plasmodium DNA is shed into the human stool are not 
understood. One possibility is gastrointestinal bleeding, but the detection of occult blood 
in the stool of fecal Plasmodium-positive individuals was not significantly higher than that 
of fecal Plasmodium-negative individuals. Thus, while potentially contributing to parasite 
detection in some individuals, gastrointestinal bleeding is unlikely to be the primary cause 
for fecal Plasmodium DNA positivity. A more plausible scenario is excretion into the biliary 
system, as has been proposed for P. yoelli-infected mice (Abkallo et al., 2014). Given the 
central role of the liver in removing damaged erythrocytes from the circulation (Theurl et 
al., 2016), it is likely that parasitized red blood cells are cleared into the bile proportional 
to their numbers in the blood. This scenario is consistent with the fact that higher 
parasitemia levels are associated with higher Plasmodium detection rates in fecal 
samples.  
Most indigenous people in central Africa are protected from P. vivax malaria 
because their erythrocytes lack the Duffy antigen receptor for chemokines (DARC), which 
is used by P. vivax merozoites to invade red blood cells (Miller et al., 1976). However, 
since ape P. vivax has been identified in a Duffy-positive European forest worker 
(Prugnolle et al., 2013), we reasoned that rural Cameroonians might acquire ape P. vivax 
liver infections, even if their Duffy-negative phenotype protected them from blood stage 
infection. This hypothesis was further supported by the recent finding of P. vivax in some 
Duffy-negative individuals in Cameroon, which could have, at least theoretically, been 
derived from the introduction of an ape parasite (Fru-Cho et al., 2014; Mbenda and Das, 
2014; Russo et al., 2017; Zimmerman, 2017). To examine this possibility, we used 
species-specific primers to screen all 504 human fecal samples for P. vivax sequences. 
58 
 
Despite the wide distribution of ape P. vivax among chimpanzees and gorillas in 
Cameroon (Liu et al., 2014) as well as previous reports of P. vivax-specific seroreactivity 
in Duffy-negative individuals from the Republic of Congo (Culleton et al., 2009), we failed 
to amplify ape or human P. vivax sequences from any of the specimens tested, including 
80 matched blood samples. Since the Duffy-negative phenotype is unlikely to protect 
humans against liver stage infection (Herrera et al., 2005; Culleton et al., 2009), our 
findings indicate that Cameroonian forest dwellers are either not exposed to ape P. vivax, 
which seems unlikely, or that abortive liver infection does occur, but is not detectable by 
fecal analyses. The resolution of this question may require development of new methods 
such as serological assays capable of detecting immune responses that are specific for 
ape P. vivax antigens. 
We also examined the host species origin of P. malariae parasites that were 
detected in one fecal and 18 blood samples from our study cohort. Amplifying a 956 bp 
cytB fragment, we realized that this sequence was not sufficiently diverse to differentiate 
ape- and human-specific P. malariae lineages (Figure 2-2). We thus generated longer 
mitochondrial fragments from additional P. malariae-containing samples, identifying two 
single nucleotide variants that differentiated human from most ape P. malariae parasites. 
Both fecal- and blood-derived P. malariae sequences from humans contained a T at 
position 276 in the cox1 gene (SNV1), and a T or A at position 690 in the cytB gene 
(SNV2), while P. malariae sequences from all but one wild ape contained Cs at these two 
positions (Figure 2-3). These data suggest that most wild apes harbor P. malariae strains 
that are distinct from those infecting humans and that the rural Cameroonians were 
infected with human, and not ape, parasites. However, it remains unknown whether 
human and ape P. malariae parasites represent two distinct Plasmodium spp., and if so, 
whether ape P. malariae strains would infect humans in natural settings. The same is true 
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for ape- and human-derived P. ovale parasites, which are even less well characterized 
due to the paucity of naturally occurring infections. 
Non-invasive fecal-based methods have been instrumental in characterizing the 
molecular epidemiology of ape malaria parasites, identifying numerous new Plasmodium 
spp. that were not previously known to exist (Kaiser et al., 2010; Liu et al., 2010a, 2014, 
2017; Prugnolle et al., 2010). Ape Laverania parasites, in particular, are readily detected 
in endemic areas such as Cameroon, with 18% to 25% of fecal samples from both 
chimpanzees and gorillas yielding parasite sequences when screened by diagnostic PCR 
(Liu et al., 2010a; Prugnolle et al., 2010). In light of these data, the fact that we detected 
Plasmodium DNA in only 3% of human fecal samples was surprising. Although we 
extracted DNA from a smaller fecal aliquot than is usually used for wild apes, this 
difference cannot account for the nearly 10-fold difference in detection frequency. The 
reason(s) for the much higher fecal parasite detection rates in wild apes is not known, but 
may be due to higher overall prevalence rates similar to what has been observed in wild 
macaques (Zhang et al., 2016), higher blood titers, more frequent gastrointestinal 
bleeding, or a combination of these factors. It is also possible that apes are much more 
frequently bitten by infective mosquitoes, which might result in the fecal shedding of larger 
quantities of pre-erythrocytic parasite DNA.  
In summary, we report here the absence of ape Plasmodium sequences in fecal 
samples of rural Cameroonians at risk of exposure to such parasites. While our results 
failed to provide evidence for abortive liver infections, they do not rule out that such 
infections are, in fact, occurring. This is particularly true for ape P. vivax, which is prevalent 
in wild apes and has been shown to productively infect humans. One fundamental 
question, therefore, is whether liver-derived merozoites, which lack the ability to parasitize 
erythrocytes, are cleared through excretion into the biliary tract or through other pathways 
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such as phagocytic cells in the liver or other organs. A second fundamental question is 
how often and under what circumstance humans are bitten by mosquitoes that carry ape 
Plasmodium sporozoites. Given the critical role of non-invasive testing in identifying ape 
malaria parasites and its potential to probe barriers of cross-species infection, further 
experimentation, including longitudinal studies in macaques, will be required to determine 
the sources, kinetics and mechanisms of fecal parasite shedding. Ultimately, the utility of 
fecal testing in detecting exo-erythrocytic parasite DNA will have to be addressed in 
humans, possibly in the context of P. falciparum and P. vivax vaccination studies that use 
mosquito bites to challenge immunised individuals (Roestenberg et al., 2009; Herrera et 
al., 2011; Bijker et al., 2013; Spring et al., 2014; Dunachie et al., 2015; Arevalo-Herrera et 
al., 2016). Such studies, in combination with investigations of the distribution, ecology, 
and biting behavior of the mosquito vectors that transmit ape Plasmodium parasites, will 
greatly aid in determining the zoonotic potential of these parasites and the associated 
human infection risk. 
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3.1 Abstract 
Whole genome sequencing (WGS) of microbial pathogens from clinical samples is a highly 
sensitive tool used to gain a deeper understanding of the biology, epidemiology, and drug 
resistance mechanisms of many infections.  However, WGS of organisms which exhibit 
low densities in their host is challenging due to high levels host genomic DNA (gDNA), 
which leads to very low coverage of the microbial genome.  WGS of Plasmodium vivax, 
the most widely distributed form of malaria, is especially difficult because of low parasite 
densities and the lack of an ex-vivo culture system.  Current techniques used to enrich P. 
vivax DNA from clinical samples require significant resources or are not consistently 
effective.  Here, we demonstrate that selective whole genome amplification (SWGA) can 
enrich P. vivax gDNA from unprocessed human blood samples and dried blood spots for 
high quality WGS, allowing genetic characterization of isolates that would have otherwise 
been prohibitively expensive or impossible to sequence.  We achieved an average 
genome coverage of 24x with up to 95% of the P. vivax core genome covered by ≥5 reads.  
Single nucleotide polymorphism (SNP) characteristics and drug resistance mutations 
seen were consistent with other P. vivax sequences from a similar region in Peru, 
demonstrating that SWGA produces high quality sequences for downstream analysis.  
SWGA is a robust tool that will enable efficient, cost-effective WGS of P. vivax isolates 
from clinical samples that can be applied to other neglected microbial pathogens. 
 
3.2 Introduction 
Malaria is a mosquito-borne infection caused by protozoan parasites of the Plasmodium 
genus.  Of the six Plasmodium species known to infect humans (Calderaro et al., 2013; 
Singh et al., 2004; Sutherland et al., 2010), P. vivax is the most widely distributed, causing 
approximately half of all clinical cases of malaria outside of Africa (World Health 
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Organisation, 2017).  Whole genome sequencing (WGS) of Plasmodium parasites from 
clinical samples has revealed important insights into the biology, epidemiology, and 
mechanisms of drug resistance of malaria (Borrmann et al., 2013; Chan et al., 2012; 
Flannery et al., 2016; Hester et al., 2013; Manske et al., 2012; Miotto et al., 2013; Pearson 
et al., 2016; Winter et al., 2015).  For P. vivax, WGS of clinical isolates has the potential 
to uncover mechanisms underlying some of the unique aspects of this parasite’s biology, 
such as distinguishing between reinfection and relapse due to activation of dormant liver 
parasites.  However, WGS of P. vivax from clinical samples is challenging, mainly due to 
low parasite densities in clinical samples compared to P. falciparum and the lack of a 
robust ex-vivo culture system.   
Multiple techniques have been developed to enrich Plasmodium genomic DNA 
(gDNA) from clinical samples, including leukocyte depletion (Auburn et al., 2012; Pearson 
et al., 2016; Venkatesan et al., 2012), hybrid selection with RNA baits (Bright et al., 2012; 
Hupalo et al., 2016) short-term ex-vivo culture (Auburn et al., 2013), adaptation to growth 
in splenectomized monkeys (Carlton et al., 2008; Neafsey et al., 2012) and single cell 
sequencing (Nair et al., 2014).  The majority of these techniques require significant labor 
and resources.  While leukocyte depletion is the most cost-effective, it requires sample 
processing within 6 hours of sample collection, which is not feasible at many field sites, 
and is not always effective.  Two recent studies that performed WGS on over 400 clinical 
isolates of P. vivax (Hupalo et al., 2016; Pearson et al., 2016) employed hybrid selection 
and leukocyte depletion to enrich P. vivax gDNA from clinical samples.  Pearson et al. 
(2016) used leukocyte depletion on 292 clinical samples and had to eliminate 144 (49%) 
of their samples from further population genetics analysis due to low quality, which often 
occurs due to contaminating human DNA.  Hupalo et al. (2016) used hybrid selection to 
enrich their samples, with 31 out of 170 sequences (21%) removed from further analysis 
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due to low quality.  Although more frequently successful, the hybrid selection technique 
requires either expensive synthetic RNA baits or a large amount of pure P. vivax DNA to 
create the RNA baits, which is difficult to obtain.  In addition, hybrid selection can introduce 
bias, since is approximately half as efficient at capturing regions with GC content >50% 
(Bright et al., 2012). 
An alternative method is selective whole genome amplification (SWGA).  SWGA 
has been used to enrich DNA of the ape Plasmodium parasites P. reichenowi and P. 
gaboni, from whole blood samples with submicroscopic DNA levels (Larremore et al., 
2015; Sundararaman et al., 2016) as well as P. falciparum genomes from dried blood 
spots (Guggisberg et al., 2016) for WGS.  SWGA preferentially amplifies the genomes of 
pathogens from complex mixtures of target and host DNA (Leichty and Brisson, 2014) 
(Figure 3-1).  SWGA does not require separation of target DNA from background DNA, 
making it an attractive option for pathogens that cannot be amplified in culture.  DNA 
amplification is carried out by the highly processive, strand displacing phi29 DNA 
polymerase and a set of pathogen specific primers that target short (6-12 nucleotide) 
motifs that are common in the pathogen genome and uncommon in the host genome.  The 
strand displacement function of phi29 results in the amplification of genomic regions where 
primers bind frequently, leading to the preferential amplification of genomes with frequent 
primer-binding sites.  Here, we show that SWGA efficiently enriches P. vivax gDNA from 
unprocessed human blood samples and dried blood spots for cost-effective, high-quality 
whole genome sequencing.    
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Figure 3-1. Selective whole genome amplification (SWGA) of Plasmodium vivax 
genomic DNA (gDNA) from human blood samples.  (A) SWGA primers bind frequently 
to Plasmodium vivax gDNA and infrequently to human gDNA.  (B) When phi29 encounters 
double stranded gDNA, it displaces the newly synthesized strand, opening new primer 
binding sites on the synthesized gDNA, leading to selective amplification of templates with 
frequent primer binding sites. (C) Post-SWGA, the percentage of P. vivax DNA has 
increased relative to host DNA. 
 
3.3 Results 
Primer design and optimization using P. vivax infected whole blood samples. To 
perform SWGA on P. vivax gDNA from unprocessed human blood samples, we designed 
primers that specifically amplified this parasite’s DNA using a previously published 
approach for P. falciparum (Sundararaman et al., 2016).  Briefly, we identified the most 
frequently occurring motifs of 6-12 nucleotides in length in the P. vivax Salvador-1 (Sal-1) 
reference genome.  We selected the top 10,000 primers of each length, yielding a total of 
70,000 primers for further analysis.  We filtered these primers based on characteristics 
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such as melting temperature (18–32°C), ability to homodimerize (no greater than 3 
consecutive matches), binding frequency on the human genome and Sal-1 genome (less 
frequent than once every 500,000 bp and more frequent than once every 50,000 bp, 
respectively), and infrequent binding of the human mitochondrial genome (less than 4 
binding sites).  Next, we removed primers predicted to bind the Sal-1 subtelomeres.  These 
filters resulted in a pool of 222 primers.  We separated these primers into 6 sets that were 
predicted not to form heterodimers, and identified the top set (pvset1) of 10 primers using 
a selection algorithm described previously (Sundararaman et al., 2016).  gDNA from an 
unprocessed P. vivax infected whole blood sample (MRL2) was subjected to SWGA with 
primer set pvset1 prior to shotgun sequencing (Figure S3-1).  SWGA significantly 
increased the percent of reads that mapped to the P. vivax Sal-1 reference genome from 
0.7% to 73.5% (Figure S3-1A) and improved the genome coverage obtained from ~80 
million base pairs of sequencing from 1.5% to 58% (Figure S3-1B). 
We observed that genome coverage obtained per base pair sequenced was lower 
than that achieved with SWGA of P. falciparum gDNA using the same primer set design 
methods (Sundararaman et al., 2016). Visual inspection of the P. vivax genome coverage 
from samples subjected to SWGA revealed that coverage gaps were typically in regions 
with comparatively higher GC content (Figure 3-2A).  The P. falciparum genome is 
extremely AT-rich with only 19.4% of bases consisting of Gs or Cs, while the GC content 
for the P. vivax genome is 42.3% (Carlton et al., 2008).  The P. vivax genome also has an 
isochore structure: internal chromosomal areas have a high GC-content and subtelomeres 
and centromeres have a lower GC-content (McCutchan et al., 1984).  Since phi29 DNA 
polymerase pauses more frequently during strand displacement and primer extension in 
regions with high GC content of DNA (Morin et al., 2012), we hypothesized that differences 
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in base composition could explain the more uneven amplification of the P. vivax genome 
compared to that of P. falciparum.  
Figure 3-2. Plasmodium vivax chromosomal coverage following SWGA using 
primer set pvset1 (A) or pvset1920 (B).  The base compositions of chromosomes 2 and 
6 were visualized in Geneious (version 9.1) using the P. vivax Sal-1 reference genome; 
green and blue lines represent percent AT and GC content, respectively, plotted for 25 bp 
windows across the chromosome (scale shown above the graph).  Shown in blue and red 
below is the corresponding MiSeq read coverage depth using primer sets pvset1 and 
pvset1920, respectively.  Coverage plots were generated using IGVTools (version 2.3.40) 
and are shown on a log scale with maximum read depth indicated in the upper left corner 
of the plot. 
 
We thus designed primer sets specifically targeting regions of the P. vivax Sal-1 
reference genome with high GC content and poor coverage using the swga program 
(Clarke et al., 2017), a program that identifies and scores SWGA primer sets (Figure S3-
2).  Primers were designed to bind regions of the P. vivax Sal-1 genome that had even 
AT/GC composition, were longer than 195,000 bp, and had low sequence coverage when 
amplified with pvset1.  We identified 1,939 primer sets (consisting of up to 15 primers) with 
minimal human genome binding and maximal P. vivax genome binding and scored them 
based on evenness of binding as well as mean distance between primer binding sites in 
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the foreground and background genomes.  The primer set with the best score, pvset1920, 
was chosen for subsequent testing. SWGA of an unprocessed human blood sample with 
pvset1920 yielded an overall superior P. vivax genome coverage compared to SWGA with 
pvset1 (Figure 3-3).  Visual inspection of these post-SWGA P. vivax sequences revealed 
that pvset1920 achieved improved coverage particularly in regions with high GC content 
(Figure 3-2B), with troughs in coverage in genomic regions of lower GC content, which 
include the centromeres and subtelomeres. 
 
Figure 3-3. Testing of SWGA primer sets on DNA from an unprocessed, P. vivax-
infected blood sample. (A) Unamplified DNA (black) and DNA amplified with SWGA 
primer set pvset1 (blue) or pvset1920 (red) was sequenced on a MiSeq (Illumina).  The 
percent of MiSeq reads that mapped to the P. vivax Sal-1 reference genome in Geneious 
(39) (version 9.1) was plotted for both unamplified and SWGA-amplified samples.  (B) The 
1x P. vivax genome coverage is shown relative to the total sequencing depth (in millions 
of base pairs sequenced) for samples subjected to SWGA with pvset1920 or pvset1, and 
for unamplified DNA. 
 
76 
 
Having developed a method that worked well for SWGA of P. vivax gDNA from 
whole blood, we tested whether the method could also be applied to gDNA extracted from 
dried blood spot samples.  Dried blood spots are a common method of storing patient and 
parasite DNA that utilizes a smaller volume of blood and does not require immediate cold 
storage.  DNA extracted from dried blood spots can have variable quality depending on 
the method of collection and storage (Schwartz et al., 2015).  SWGA has been used to 
enrich P. falciparum DNA from dried blood spots for WGS (Guggisberg et al., 2016), with 
an average of 48.1% +/- 3.5% of the genome covered at ≥5x for samples with an average 
parasite density of 73,601 parasites/µl +/- 19,399 (1.5% parasitemia).  Since P. vivax 
clinical samples generally have lower parasite densities, we wondered if it would be 
feasible to obtain significant genome coverage on P. vivax from dried blood spots with 
SWGA.  We extracted DNA from blood spots obtained from symptomatic patients in Peru 
and performed SWGA with pvset1920, achieving 73% and 42% of genome coverage at 
1x on initial testing for samples with high (Sample C, 56,790 parasites/µl; 1.1%) and low 
(Sample L, 2572 parasites/µl; 0.05%) parasitemia, respectively (Figure S3-3). 
We finally tested whether an enzymatic digest to remove contaminating human 
DNA could further improve P. vivax genome coverage.  Modification-dependent restriction 
endonucleases (MDREs), such as MspJI and FspEI, which specifically recognize cytosine 
C5 methylation or hydroxymethylation (Cohen-Karni et al., 2011), have been used to 
selectively degrade human DNA in P. falciparum clinical samples.  Enzyme digest of DNA 
extracted from clinical samples with >80% human contamination has previously been 
shown to enrich P. falciparum DNA ~9-fold for more efficient WGS (Oyola et al., 2013).  
However, when we performed a digest with MspJI and FspEI enzymes on gDNA extracted 
from whole blood obtained from patients with P. vivax infection, we observed either no 
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change, or markedly decreased genome coverage in the 5 enzyme-digested samples 
(Figure S3-4).   
 
SWGA and WGS of P. vivax from patient samples. To test the utility of SWGA for 
variant calling and population genetics analysis of P. vivax from unprocessed clinical blood 
samples, we used primer set pvset1920 to perform SWGA on P. vivax gDNA from 18 
whole blood and 4 dried blood spot samples collected from symptomatic patients with P. 
vivax infection in Peru.  Since the whole blood samples had not been leukocyte-filtered, 
they had significant contamination with human DNA, with less than 1.5% of reads mapping 
to the Sal-1 reference genome in unamplified samples (not shown).  For all samples, 
SWGA significantly increased the proportion of reads that mapped to the P. vivax Sal-1 
reference genome, resulting in a higher genome coverage and a higher percent of callable 
total and core genome regions (covered by ≥5 reads) (Table 3-1).  Comparison of the 
SWGA-amplified samples to 10 leukocyte-filtered samples from a field study in Peru which 
were sequenced to a similar depth (1.5 billion bp +/- 0.2 sequenced for SWGA samples 
vs. 1.5 +/- 0.5 billion bp for leukocyte-filtered samples) showed that SWGA yields a 2-fold 
increase in the percent of sequencing reads that map to the P. vivax genome and an 
average 5x P. vivax core genome coverage of 60.1% +/- 26.0 compared to 43.7% +/- 41.4 
for leukocyte-filtered samples (Flannery et al., 2016).  For the 4 dried blood spot samples, 
we achieved an average 5x core genome coverage of 54.0 +/- 34.6%. 
There was a trend towards improved mean coverage and percent of the genome 
callable in samples with higher parasite densities (Figure S3-5).  This is consistent with 
previous SWGA results for P. falciparum  (Sundararaman et al., 2016), and results from 
other P. vivax enriching methods, such as hybrid selection (Bright et al., 2012).  Samples 
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subjected to SWGA yielded similar ≥5x genome coverage per sequenced base pair when 
compared to direct sequencing of a leukocyte-filtered patient sample (Figure 3-4A).  The 
percent of the 14 large chromosomes of P. vivax considered callable for samples that 
underwent SWGA fell within the range of that obtained by direct sequencing of leukocyte-
filtered samples (Figure 3-4B).  Additionally, post-SWGA sequences yielded similar mean 
base quality when normalized across 100 base pair windows of varying percent GC-
content in the reference genome compared to leukocyte-filtered samples (Figure 3-5).  
  
79 
 
Table 3-1. Sequencing statistics for P. vivax sequences from clinical samples that 
underwent selective whole genome amplification (SWGA).   
18 blood samples (SWGA) 
Sample Parasite density a 
Total bp 
sequenced 
(billions) 
Percent 
aligned 
readsb 
Mean 
coverage (x)b 
Percent  
genome 
callableb.c  
Percent core 
genome 
callableb,d 
1 45680 (0.9%) 1.42 89.5 37.1 71.7 83.6 
2 34268 (0.7%) 1.68 80.9 37.9 72.9 85.1 
3 28474 (0.6%) 1.41 88.3 30.4 66.6 76.3 
4 25680 (0.5%) 1.50 65.1 13.8 40.2 42.1 
5 19241 (0.4%) 2.00 71.9 44.1 79.9 95.4 
6 13064 (0.3%) 1.84 83.7 43.8 76.1 90.4 
7 11438 (0.2%) 1.52 79.5 20.3 32.7 34.5 
8 9961 (0.2%) 1.36 75.4 31.0 74.6 87.3 
9 8842 (0.2%) 1.84 74.2 29.6 72.9 84.7 
10 7382 (0.1%) 1.23 72.6 23.7 65.6 73.6 
11 6258 (0.1%) 1.41 82.8 25.1 59.5 67.7 
12 5135 (0.1%) 1.82 54.9 18.0 34.8 37.0 
13 2942 (0.06%) 1.16 40.7 12.9 52.1 57.9 
14 1873 (0.04%) 1.44 17.0 5.7 13.7 14.1 
15 1652 (0.03%) 1.52 53.2 23.5 52.0 57.3 
16 1471 (0.03%) 1.26 44.0 12.9 21.5 22.9 
17 537 (0.01%) 1.92 22.5 11.1 38.1 40.7 
18 495 (0.01%) 1.44 28.6 10.0 30.0 30.5 
Averagee 12466 +/- 13107.2 1.5 +/- 0.2 62.7 +/- 23.2 23.9 +/- 11.8 53.1 +/- 20.9 60.1 +/- 26.0 
4 dried blood spot samples (SWGA) 
DBS-4 50330 (1.0%) 1.97 79.4 34.8 74.4 87.4 
DBS-3 35730 (0.7%) 1.91 46.8 20.9 69.5 80.3 
DBS-2 5932 (0.1%) 0.93 11.0 3.0 25.8 24.2 
DBS-1 3885 (0.08%) 1.57 17.7 4.2 23.2 24.1 
Averagee 23962 +/- 22826.4 1.6 +/- 0.5 38.7 +/- 27.1 15.7 +/- 13.1 48.2 +/- 27.5 54.0 +/- 34.6 
10 blood samples (Leukocyte filtration) f 
Mdio01 N/A 2.43 25.7 6.35 8.2 5.5 
Mdio02 N/A 0.80 16.2 1.65 1.3 0.6 
Mdio03 N/A 2.04 19.9 8.23 57.2 61.2 
Mdio04 N/A 1.52 14.2 1.97 18.7 9.6 
Mdio05 N/A 1.56 49 22.3 78.1 91.7 
Mdio06 N/A 1.62 55.4 28.1 79.6 93.4 
Mdio07 N/A 1.46 20.7 4.23 15.8 11.3 
Mdio08 N/A 1.50 30.3 10.6 67.3 74.9 
Mdio09 N/A 0.74 18.3 1.74 1.6 0.8 
Mdio10 N/A 1.26 43.5 16.1 76 88.1 
Averagee N/A 1.5 +/- 0.5 31.4 +/- 14.8 10.1 +/- 9.2 40.4 +/- 34.0 43.7 +/- 41.4 
a Parasites per microliter (parasitemia) as determined by microscopy. 
bSequencing statistics were determined using the Genome Analysis Toolkit’s 
(GATK) DepthofCoverage tool.   
cCovered by ≥5 reads 
dThe core genome was defined by coordinates determined in the large scale P. 
vivax sequencing study by Pearson et al. (2016) 
eThe standard deviation from the mean is shown.  
fLeukocyte-filtered sequencing statistics presented here were from P. vivax 
clinical samples obtained from a previously published study in Peru (Flannery et 
al, 2015). 
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Figure 3-4. Comparision of P. vivax genome coverage generated from samples 
treated with SWGA versus leukocyte filtration.  (A) 5x P. vivax genome coverage is 
shown relative to total sequencing depth (in millions of base pairs sequenced) for a sample 
amplified with pvset1920 (Sample 5) and for a leukocyte-filtered sample (Mdio6).  Both 
samples were sequenced on an Illumina HiSeq. (B) The percent of the 14 chromosomes 
callable (covered by ≥5 reads) for samples that underwent SWGA (colored lines) or 
leukocyte filtration (black dashed lines) was compared between multiple samples. 
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Figure 3-5. GC-bias plots for P. vivax genomes generated following leukocyte 
filtration (A) or SWGA (B). 
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Variant analysis. To examine the utility of post-SWGA sequences for variant analysis, 
we called 45,821 single nucleotide polymorphisms (SNPs) from the whole blood and dried 
blood spot samples that were subjected to SWGA.  For the whole blood samples, an 
average of 14,463 SNPs was identified per sample, which is consistent with prior studies 
of P. vivax field isolates (Flannery et al., 2016). Compared to leukocyte-filtered samples, 
SNP characteristics such as SNP rate, transition to transversion (Ti/Tv) ratio, and 
nonsynonymous to synonymous ratio were near identical in the samples that underwent 
SWGA (Table 3-2). 
 
Table 3-2. SNPs in SWGA versus leukocyte filtered whole genome sequences   
Sample 
preparation 
method 
SNP characteristics SNP effects 
Transition/ 
transversio
n ratio 
Exonic Intronic Intergenic 
SNP 
per 
base 
Nonsynonymous 
to Synonymous 
Ratio 
SWGAa 1.41 20,865 (40%) 3,714 (7%) 
25,178 
(49%) 0.002 1.63 
Leukocyte 
filtration  1.36 
18,365 
(40%) 3,029 (7%) 
23,157 
(50%) 0.002 1.74 
aSamples for SWGA were obtained from Iquitos, Peru and samples for leukocyte 
filtration were from a previously published study in Madre de dios, Peru (10). 
 
In addition, the proportion of SNPs that were exonic, intronic, intergenic, or at 5’ 
and 3’ untranslated regions were similar between the two methods of P. vivax enrichment.  
We also detected SNPs in several known drug resistance genes previously detected in 
samples from Peru (Flannery et al., 2016) and Colombia (Winter et al., 2015) in the whole 
blood and dried blood spot samples (Table 3-3, Table S3-1), further validating the utility 
of sequences derived from SWGA for variant calling.  This includes several intronic 
mutations around a putative chloroquine resistance transporter (pvcrt), in addition to 
coding mutations in dihydrofolate reductase (pvdhfr), multidrug resistance protein 1 
83 
 
(pvmdr1), multidrug resistance protein 2 (pvmrp2), and dihydropteroate synthetase 
(dhps). 
 
Table 3-3. Nonsynonymous SNPs in known drug resistance genes  
Locus Chr Position Ref Alt Amino Acid Samples
a  
pvcrt-0 
(PVX_087980) 1 
331151 T C Intron 17 (18) 
331819 G A Intron 11 (18) 
332453 T C Intron 18 (18) 
332874 A C Intron 18 (18) 
pvdhfr 
(PVX_089950) 5 
964763 C G,A Ser58Arg 12 (12) 
964939 G A Ser117Asn 16 (16) 
pvmdr1 
(PVX_080100) 10 
363223 A G Thr958Met 12 (12) 
363374 T G Met908Leu 11 (11) 
365435 C A Val221Leu 1 (12) 
pvmrp2 
(PVX_124085) 14 
2043859 G C Gln1407Glu 11 (13) 
2045050 C T Val1010Met 14 (15) 
2047090 G A Pro330Ser 1(15) 
2047233 C A Arg282Met 13 (14) 
2047816 C G Glu88Gln 3 (18) 
dhps 
(PVX_123230) 14 
1257856 G C Ala383Gly 9 (15) 
1258389 C T Met205Ile 10 (12) 
aSamples shows the number of samples confidently genotyped (in parentheses) 
and the number bearing the indicated allele. 
 
We also compared sample clonality estimates of post-SWGA sequences to microsatellite 
analyses on the same unamplified samples.  We estimated the clonality of the 6 post-
SWGA sequences with the highest coverage using the Fws statistic, a measure of within-
host diversity previously used to characterize multiplicity of infection in Plasmodium 
falciparum patient samples (Auburn et al., 2012; Manske et al., 2012) (Table 3-4).  An Fws 
score of ≥ 0.95 indicates low within-host diversity and infection with a single parasite, while 
Fws ≤ 0.70 is suggestive of a multiclonal infection.  Microsatellite analysis on these same 
6 unamplified samples indicated that all were clonal, except for sample 9, where the 
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presence of 2 microsatellite markers at more than one position suggested that it could be 
a multiclonal sample.  However, for all 6 post-SWGA sequences, Fws ≥0.95 suggesting 
that all were clonal infections.  Thus, while SWGA does not introduce errors that lead to a 
falsely low Fws, it may lead to underestimations of clonality in multiclonal samples. 
 
Table 3-4. Clonality estimates post-SWGA 
Sample Fws Heterozygous SNPs 
Microsatellite markers before SWGA 
v23 v24 v25 v28 v30 v33 
1 0.98 377 266 170 102 85 149 153 
2 0.97 446 266 170 102 85 149 163 
5 0.97 372 266 171 102 86 150 153 
6 0.98 326 266 170 102 86 149 153 
8 0.98 300 282 167 102 94 136 134 
9 0.97 354 282 163 99,94 86,118 143,150 151 
 
Finally, we constructed a neighbor-joining tree using core genome SNPs to 
determine the relatedness of our samples to one another and to other P. vivax isolates 
from Peru and around the world (Figure 3-6).  In this tree, our samples, which were from 
the Iquitos region of Peru, clustered with one another, and were most closely related to 
leukocyte-filtered samples from another region of Peru (Flannery et al., 2016).  They also 
exhibited the expected degree of relatedness to previously published P. vivax sequences 
derived from other leukocyte-filtered (Pearson et al., 2016), hybrid-selected (Hupalo et al., 
2016), and monkey-adapted (Neafsey et al., 2012) clinical samples from diverse areas of 
the world, further validating the use of post-SWGA sequences from downstream analyses. 
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Figure 3-6. Neighbor joining tree of Plasmodium vivax clinical samples from 
different regions of the world.  The tree was constructed with core genome-wide SNP 
data from P. vivax samples that underwent selective whole genome amplification (Peru-
SWGA-1 through Peru-SWGA-18) and P. vivax clinical samples from previously published 
studies that underwent leukocyte filtration (Pearson et al., 2016) (Thailand-PD0169, 
Thailand-PD0168, Thailand-PD0166, Thailand-PD-0167, PNG-0050, PNG-0065, PNG-
0068, Vietnam-PV0025, Vietnam-PV0053, Vietnam-PV0056, Vietnam-PV0061), hybrid 
selection (Hupalo et al., 2016) (Colombia-30102100437, Colombia-490, Colombia-438-A, 
Colombia-30101099036, Thailand-VKTS-36, Thailand-VKBT-73, Thailand-VKBT-58, 
Thailand VKBT-71, Thailand-VKBT-100, PNG-73, PNG-58, PNG-012, PNG-014, PNG-
025), or adaption to growth in splenectomized monkeys (Neafsey et al., 2012) (BrazilI, 
IndiaVII) prior to sequencing.  Bootstrap values are shown on each corresponding branch.   
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3.4 Discussion 
In this study, we validate SWGA as a cost-effective, robust method to enrich P. vivax 
gDNA from unprocessed whole blood and dried blood spot clinical samples to improve the 
efficiency and decrease the cost of subsequent WGS.  This is a method that can be 
applied to clinical samples infected with other malaria species, such as P. malariae, P. 
ovale curtisi, and P. ovale wallikeri, where parasite densities are low, and where there is 
no routine ex-vivo culture (Ansari et al., 2016), though species-specific primer sets would 
likely be required.  SWGA utilizes readily available reagents, does not require processing 
at the time of sample collection, and can be performed in a simple, overnight reaction.  
While several methods have been used successfully to enrich P. vivax gDNA for WGS 
from infected whole blood samples, most are resource and labor intensive.  Short-term 
ex-vivo culture of P. vivax isolates or adaptation to growth in monkeys produce a large 
amount of P. vivax DNA, but require significant resources.  Single cell sequencing allows 
for highly sensitive dissection of multiclonal samples, however this approach requires 
cryopreserved samples and specialized laboratory equipment (Nair et al., 2014). While 
leukocyte filtration is cost-effective and efficient, it is not always possible to perform at field 
sites with limited infrastructure, because samples require refrigeration within 6 hours to 
minimize white blood cell lysis and reduce irreversible contamination from human DNA. 
Hybrid selection is less labor intensive, but the production of the RNA baits used for 
capture requires either large amounts of P. vivax Sal-1 DNA or costly commercially-
synthesized RNA bait.  
Using SWGA, we achieved a higher than average callable P. vivax genome 
compared to leukocyte-depleted clinical samples sequenced at a similar depth.  SWGA 
generally yielded the highest genome coverage for clinical samples with the highest 
parasite densities, consistent with our experience with P. falciparum (Sundararaman et 
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al., 2016). For the 12 samples with parasite density >5,000 parasite/µl (0.1% parasitemia), 
we were able to call on average 71.5% of the core genome, compared to 37% for the 6 
samples with parasite densities <5,000 parasite/µl.  Increased sequencing effort is needed 
to obtain maximal genome coverage for samples with lower parasite densities (Figure S3-
8).  In these cases, the low genome coverage is likely the result of stochastic amplification 
of a small number of starting P. vivax genomes, which leads to very deep coverage of 
some genomic regions and little or no coverage of others (Sundararaman et al., 2016). If 
maximal genome coverage is desired, sequential SWGA reactions with pvset1920 
followed by pvset1 increases coverage slightly (3-5% 1x genome coverage) (Figure S3-
6).  Additionally, performing multiple independent SWGA reactions on a sample and 
combining the sequencing reads can improve genome coverage (4-12% 1x genome 
coverage) (Figure S3-7).  Since multiple rounds of SWGA or pooling the products from 
multiple reactions increases workload and expenses for a small improvement in genome 
coverage, we opted for a single amplification reaction with pvset1920 for our samples.  
However, these protocol modifications may be useful if high genome coverage is needed 
from samples with low parasitemia. 
One potential limitation of SWGA of P. vivax from clinical samples is the ability to 
amplify all clones in a multiclonal sample.  One of our samples appeared to be multiclonal 
by microsatellite analysis of the unamplified gDNA; yet, Fws analysis of the post-SWGA 
sequence suggested that the sample was comprised of a single clone.  It is possible that 
in this case a majority clone was amplified preferentially over minority clones.  Another 
possibility is that the microsatellite markers assessment may overestimate clonality.  
Analyses of additional multiclonal samples will be necessary to address this question.  
Another important limitation of SWGA is that copy number variant (CNV) detection is not 
possible on post-SWGA sequences.  The uneven distribution of primer-targeted motifs in 
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the target genome results in peaks and troughs in mean genome coverage that can 
confound CNV detection methods. Finally, SWGA requires long strands of gDNA for 
efficient amplification of the target genome and is unlikely to work well on degraded or 
ancient DNA samples. 
Whole genome analysis has the potential to reveal much about the biology and 
epidemiology of P. vivax infections.  For example, comparison of recurrent infections using 
WGS can help distinguish relapse due to reactivation of hypnozoites from reinfection or 
drug resistance, an epidemiological distinction of public health importance. SWGA 
enables high quality and cost-effective WGS of P. vivax from unprocessed blood samples 
that would otherwise be impossible or prohibitively expensive to sequence.  Advanced 
technologies such as SWGA will greatly facilitate future P. vivax whole genome 
sequencing projects, thereby improving our ability to understand and combat the most 
widespread form of malaria.  
 
3.5 Materials and methods 
Patient Sample Collection and Preparation. The P. vivax infected DNA sample used 
for initial testing of selective amplification primer sets (MRL2) was provided by the Malaria 
Reference Laboratory of the London School of Hygiene and Tropical Medicine, London, 
UK.  The six dried blood spot samples used in this study were collected from patients with 
symptomatic P. vivax infection in Peru.  Parasitemia was quantified with real time PCR 
and gDNA was extracted using a QIAamp DNA Blood Mini Kit (Qiagen).   
Eighteen whole blood samples used for additional testing and further sequencing 
analysis were derived from whole blood samples collected from patients with symptomatic 
P. vivax infections from two sites around Iquitos, Peru during a study conducted by the US 
Naval Medical Research Unit No. 6 (Durand et al., 2014). Thick blood smears were 
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examined to identify the parasite species and to determine the level of parasitemia.  
Parasite density was calculated by counting the number of asexual parasites per 200 white 
blood cells in the thick smear (Assuming an average of 6,000 white blood cells per µl).  
Each blood smear was examined by two microscopists independently and was examined 
by a third microscopist in the event of a discrepancy.  The final parasite density was 
calculated as the average of density readings from the two concordant microscopists.  
Whole blood samples were collected in the field using EDTA-containing vacutainer tubes.  
Samples were frozen and transported to the central lab until further processing.  DNA was 
isolated from thawed whole blood using QIAamp DNA Blood Mini Kit (Qiagen) following 
the manufacturer’s recommendation and as described elsewhere (Baldeviano et al., 
2015).  Samples were subsequently resuspended in TE buffer and gDNA was quantified 
using a Qubit 2.0 fluorometer.   
 
Primer design. The initial set of pvset1 primers was designed as described 
(Sundararaman et al., 2016).  Primer set pvset1920 was designed using the swga 
program, which scores primer sets based on selectivity and evenness of binding 
(measured using the Gini index), and thus automates and improves primer selection.  The 
source code of swga, along with download links and documentation are available at 
https://www.github.com/eclarke/swga. pvset1920 was designed to specifically amplify 
longer regions (>195,000 bp) of the P. vivax reference genome (Sal-1) that were GC rich 
(48.5-50.6%) and yielded low genome coverage following SWGA with pvset1.  A total of 
1,939 primer sets were identified that exhibited a minimum background binding distance 
of 25,000 bp and a maximum foreground binding distance of 37,000 bp.  These were 
scored using swga’s composite primer scoring algorithm (Gini score*foreground 
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mean/background mean) and the set with the lowest score (pvset1920) was chosen for 
testing. 
pvset1 consists of 10 primers: 5’- CGTTG*C*G-3’ 5’-TTTTTTC*G*C-3’, 5’-
TCGTG*C*G-3’, 5’-CGTTTTTT*T*T-3’, 5’-TTTTTTTC*G*T-3’, 5’-CCGTT*C*G-3’, 
CGTTTC*G*T-3’, 5’-CGTTTC*G*C-3’, 5’-CGTTTT*C*G-3’, 5’-TCGTTC*G*T-3’, with 
asterisks indicating phosphorothioate bonds that are necessary to prevent degradation by 
phi29. pvset1920 set consists of 12 primers: 5’-AACGAAGC*G*A-3’, 5’-ACGAAGCG*A*A-
3’, 5’-ACGACGA*A*G-3’, 5’-ACGCGCA*A*C-3’, 5’-CAACGCG*G*T-3’, 5’-
GACGAAA*C*G-3’, 5’-GCGAAAAA*G*G-3’, 5’-GCGAAGC*G*A-3’, 5’-GCGGAAC*G*A-
3’, 5’-GCGTCGA*A*G-3’, 5’-GGTTAGCG*G*C-3’, and 5’-AACGAAT*C*G-3’. 
 
Selective Whole Genome Amplification. 30-70 ng of input DNA was added to a 50 µl 
reaction containing 3.5 uM SWGA primers, 30 U phi29 DNA polymerase enzyme (New 
England Biolabs), phi29 DNA buffer (New England Biolabs), 1% bovine serum albumin, 
and water.  The reaction was carried out on a thermocycler consisting of a ramp down 
from 35°C to 30°C (10 minutes per degree), 16 hours at 30°C, 10 minutes at 65°C, and 
hold at 4°C.  The samples were diluted 1:1 with DNAse-free, RNAse-free water and 
purified with Ampure XP beads (Beckman-Coulter) at a 1:1 ratio per the manufacturer’s 
protocol.  When performed, a second round of selective amplification contained 100-200 
ng of the Ampure XP purified product from the first reaction. 
 
Methylation digest. 125-500 ng of gDNA extracted from P. vivax infected whole blood 
samples was digested with 5 units of FspEI (New England Biolabs) and 5 units of MspJI 
(New England Biolabs) enzymes in a 30 µl reaction.  A mock digest with an identical 
amount of gDNA and no enzymes was run in parallel.  Samples were digested for 2 hours 
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at 37°C then were heat inactivated at 80°C for 15 minutes.  For coverage analysis, 
rarefaction analysis was performed on Illumina MiSeq sequencing reads derived from 
samples digested with MspJI or FspEI (digest and SWGA) or mock digested with no 
enzyme prior to SWGA with primer set pvset1920.  Coverage obtained by mapping 
200,000 MiSeq sequencing reads (~25 million base pairs of sequencing depth) was 
compared between digested and mock digested damples.  P value was obtained using a 
two tailed t-test. 
 
Whole genome sequencing. SWGA products and unamplified DNA used for primer set 
testing were sequenced on an Illumina MiSeq using a modified Nextera library preparation 
method. For Hiseq runs, next generation sequencing libraries of SWGA products were 
prepared using the Nextera XT DNA preparation kit (Illumina) per the manufacturer’s 
protocol.  These samples were pooled and clustered on a Hiseq 2500 (Illumina) in Rapid 
Run mode with 100 base pair paired end reads. For the coverage analysis of leukocyte-
filtered samples, fastq files from a prior study of P. vivax field samples (Flannery et al., 
2016) were used.   
Raw fastq files were aligned to the Sal-1 reference genome (PlasmoDB version 
13, http://plasmodb.org/common/downloads/release-13.0/PvivaxSal1/fasta/data/) using 
the Burroughs-Wheeler Aligner (version 0.7.8) (Li, 2013.) and samtools (version 0.1.19) 
(Li, 2011; Li et al., 2009) as previously described in the Platypus pipeline (Manary et al., 
2014). Picard (version 2.0.1) was used to remove unmapped reads and the Genome 
Analysis Toolkit (GATK) (McKenna et al., 2010) was used to realign the sequences around 
the indels.   Picard’s CollectGcBiasMetrics tool was used to generate the GC bias plots.  
GATK’s DepthOfCoverage tool was used to determine the percent of the total and core 
genome covered by ≥5 reads, mean coverage, and coverage over the core genome.  The 
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coordinates of the P. vivax core genome, which excludes subtelomeric and hypervariable 
regions with significantly higher read mapping errors, was obtained from a recent analysis 
of hundreds P. vivax sequences from clinical isolates (Pearson et al., 2016). 
For rarefaction analyses, sequences were aligned with smalt (Wellcome Trust 
Sanger Institute) and mapped with custom scripts in R (https://www.r-project.org/).  To 
visualize base compisition across chromosomes, plots were created in Geneious (version 
9.1) (Kearse et al., 2012) using the Sal-1 P. vivax reference sequences and 25 bp 
windows.  Plots of chromosome coverage were created with IGVTools (version 2.3.40) 
(Robinson et al., 2011; Thorvaldsdóttir et al., 2013). 
 
Variant Calling and Analysis. We followed the GATK’s best practices to call variants 
(Auwera et al., 2014; DePristo et al., 2011). The aligned sequences were run through 
GATK’s HaplotypeCaller in “reference confidence” mode to create genomic GVCF files for 
each sample.  This reference confidence model highlights areas of the genome that are 
likely to have variation and produces a comprehensive record of genotype likelihoods and 
annotations for each site.  The samples were joint genotyped using the GenotypeGVCFs 
tool. Variants were further filtered based on quality scores and sequencing bias statistics 
based on default parameters from GATK.  SNPs were filtered out if they met any of the 
following criteria: Quality Depth (QD) < 2.0, Mapping Quality (MQ) < 50.0, Phred-scaled 
p-value using Fisher’s exact test to detect strand bias (FS) >60.0, Symmetric Odds Ratio 
(SOR) >4.0, Z-score from Wilcoxon rank sum test of Alternative vs. Reference read 
mapping qualities (MQRankSum) < -12.5, ReadPosRankSum (RPRS) < -8.0. Variants 
were annotated using snpeff (version 4.2) (Cingolani et al., 2012). 
Fws of samples with the highest genome coverage was estimated using moimix 
(http://dx.doi.org/10.5281/zenodo.58257) a package available through R.  The package 
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calculates Fws statistic using the equation Fws = 1 - (Hw/Hs), where Hw is the within-host 
heterozygosity and Hs is the population-level heterozygosity (Auburn et al., 2012; Manske 
et al., 2012). The core P. vivax genome, as defined by Pearson et al. (2016) was used for 
core genome analysis.  For microsatellite genotyping, five neutral microsatellite loci of 
significant variability in the Peruvian Amazon were typed in a previous study (Durand et 
al., 2014).  If there was more than one marker at any given locus, the sample was 
considered multiclonal, per prior genotyping studies  (De Souza et al., 2015; Imwong et 
al., 2006; Karunaweera et al., 2008). 
A neighbor joining tree was constructed using SNPs from the core P. vivax genome 
from sequences obtained in this study, along with sequences from previously published 
studies that are available in the NCBI Short Read Archive.  The mdio samples were from 
a previous study conducted by our lab in Peru (Flannery et al., 2016) and the rest of the 
sequences were obtained from two recent large scale P. vivax sequencing studies (Hupalo 
et al., 2016; Pearson et al., 2016). In order to assess the phylogenetic relationships of 
sequenced isolates we constructed a multiple sequence alignment from filtered SNPs 
called in GATK using an in-house perl script. This alignment was used as input 
for Maximum Likelihood phylogenetic analysis in the Randomized Axelerated Maximum 
Likelihood program (Stamatakis, 2014) (RAxML) with 500 pseudoreplicates using the 
generalized time reversible model and the resulting tree was visualized in dendroscope  
(Huson and Scornavacca, 2012) 
 
Ethics approval and consent to participate. The sample from Malaria Research 
Laboratories (MRL) was an anonymized DNA sample previously collected by the MRL 
and provided under the MRL’s remit to undertake epidemiological surveillance relevant to 
imported malaria in the UK.  The protocol for the collection of field samples was approved 
94 
 
by the Institutional Review Board of the US Naval Medical Research Center (Protocol 
NMRCD.2005.0005) and the National Institutes of Health of Peru (Protocol 009-2004) in 
compliance with all applicable Federal regulation governing the protection of human 
subjects.  All adult subjects provided written informed consent and all children 8-17 years 
old provided verbal assent to participate in the study. 
 
Availability of data and materials. The P. vivax genome Illumina sequencing reads of 
the 22 samples used for variant analysis in this study will be available on the National 
Center for Biotechnology Information’s Short Read Archive with the accession number: 
PRJNA344889.    
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3.7 Supplemental figures and tables 
 
Figure S3-1. Testing of SWGA primer sets on an unprocessed, P. vivax-infected 
blood sample. (A) Unamplified DNA (black) and DNA amplified with SWGA primer set 
pvset1 (blue) was sequenced on a MiSeq (Illumina). The percentage of MiSeq reads that 
mapped to the P. vivax Sal-1 reference genome in Geneious (version 9.1) was plotted for 
both the unamplified and SWGA-amplified sample. (B) Rarefaction analysis compares the 
≥1× P. vivax genome coverage relative to total sequencing depth (in millions of base pairs 
sequenced) with and without SWGA. 
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Figure S3-2. Flowchart describing the process of SWGA primer set selection for P. 
vivax. *, selected regions are >195,000 bp in length with an average 48.5 to 50.6% GC 
composition. 
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Figure S3-3. Testing of SWGA primer set pvset1920 on DNA from P. vivax patient-
derived dried blood spots. Genomic DNA from two dried blood spots with either a 
relatively high (sample C, 56,790 parasites/µl) or low (sample L, 2,572 parasites/µl) 
parasite density was subjected to SWGA with pvset1920 and sequenced on a MiSeq 
(Illumina). The percentages of the P. vivax genome with ≥1× coverage are shown relative 
to total sequencing depth (in millions of base pairs sequenced). 
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Figure S3-4. Comparison of SWGA following either a mock digestion or 
methylation-dependent restriction digest. Genomic DNA extracted from five P. vivax-
infected patient samples was subjected to a mock digest or digest with the methylation-
dependent restriction enzymes MspJI and FspEI. The percentage of the P. vivax reference 
genome covered (1×) by mapping 200,100 MiSeq (Illumina) reads (approximately 25 
million bp of sequencing depth) from each sample with or without digest is shown. 
Statistical significance was calculated using a two-tailed t test.  
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Figure S3-5. Sequencing statistics for P. vivax clinical samples with various 
parasite densities. The percentage of reads that map to P. vivax Sal-1 (blue circles), the 
mean P. vivax genome coverage (green squares), and the percentage of the P. vivax 
genome covered by ≥5 reads (red triangles) are shown for all 18 samples amplified by 
SWGA, with sample parasitemia indicated on the x axis. Sequencing statistics were 
determined using the Genome Analysis Toolkit (GATK) DepthOfCoverage tool.  
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Figure S3-6. P. vivax genome coverage for samples with high, medium, and low 
parasite densities. The percentages of the P. vivax reference genome covered at ≥1× 
are shown relative to the total sequencing depth generated on an Illumina HiSeq (in 
millions of base pairs sequenced) for samples with high (red), medium (green), and low 
(blue) parasite densities. 
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Figure S3-7. Impact of multiple independent SWGA reactions per sample on P. vivax 
genome coverage. Each panel represents the results obtained for a single patient sample 
(samples 16, 7, and 14). The percentage of the P. vivax reference genome covered at ≥1× 
is shown relative to the total sequencing depth generated on an Illumina MiSeq (in millions 
of base pairs sequenced) for each individual SWGA reaction (red) or pooled reads from 
the two independent SWGA reactions (black).  
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Figure S3-8. Combinatorial testing of SWGA primer sets on three P. vivax-infected 
patient samples. Each panel represents the results obtained for one of the three 
individual patient samples (samples 6, 2, and 4) after one round of SWGA with primer set 
pvset1920 (red) or pvset1 (blue), after two rounds of SWGA with the same primer set (dark 
red for pvset1920 and dark blue for pvset1), or after two rounds of SWGA with different 
primer sets (yellow for pvset1920 followed by pvset1 and light blue for pvset1 followed by 
pvset1920). For all primer set combinations, the percentage of the P. vivax reference 
genome covered at ≥1× is shown relative to the total sequencing depth (in millions of base 
pairs sequenced) generated on a MiSeq (Illumina). 
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Table S3-1. Drug resistance mutations in Plasmodium vivax sequences from dried 
blood spot DNA subjected to SWGA.   
Locus Chr Position Ref Alt Amino Acid Samples*  
pvcrt-0 
(PVX_087980) 
1 331151 T C Intron 3 (4) 
331819 G A Intron 1 (4) 
332453 T C Intron 4 (4) 
332874 A C Intron 4 (4) 
pvdhfr 
(PVX_089950) 
5 964762 G A Ser58Asn 1 (4) 
964763 C G,A Ser58Arg 3 (3) 
964939 G A Ser117Asn 3 (3) 
pvmdr1 
(PVX_080100) 
10 363223 A G Thr958Met 4 (4) 
363374 T G Met908Leu 2 (3) 
pvmrp2 
(PVX_124085) 
14 2043859 G C Gln1407Glu 1 (3) 
2044327 T A Asn1251Tyr 1 (3) 
2045050 C T Val1010Met 4 (4) 
2047233 C A Arg282Met 2 (2) 
2047816 C G Glu88Gln 2 (4) 
2047893 C T Cys62Tyr 1 (4) 
dhps 
(PVX_123230) 
14 1257856 G C Ala383Gly 1 (4) 
1258389 C T Met205Ile 2 (3) 
*The number of samples confidently genotyped (in parentheses) and the number 
bearing the indicated allele. 
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4.1 Abstract 
Wild-living African apes are endemically infected with parasites that are closely related to 
human Plasmodium vivax, a leading cause of malaria outside of Africa. This finding 
suggests that the origin of P. vivax was in Africa, even though the parasite is now rare in 
humans there. To elucidate the emergence of human P. vivax and its relationship to the 
ape parasites, we analyzed genome sequence data of P. vivax strains infecting six 
chimpanzees and one gorilla from Cameroon, Gabon and Côte d’Ivoire. We found that 
ape and human parasites share near-identical core genomes, differing by only 2% of 
coding sequences. However, compared with the ape parasites, human strains of P. vivax 
exhibit about 10-fold less diversity, and have a relative excess of nonsynonymous 
nucleotide polymorphisms, with site frequency spectra suggesting they are subject to 
greatly relaxed purifying selection. These data suggest that human P. vivax has 
undergone an extreme bottleneck, followed by rapid population expansion. Investigating 
potential host specificity determinants, we found that ape P. vivax parasites encode intact 
orthologs of three reticulocyte binding protein genes (rbp2d, rbp2e, rbp3), which are 
pseudogenes in all human P. vivax strains. However, binding studies of recombinant 
RBP2e and RBP3 proteins to human, chimpanzee and gorilla erythrocytes revealed no 
evidence of host-specific barriers of red blood cell invasion. These data suggest that, from 
an ancient stock of P. vivax parasites capable of infecting both humans and apes, a 
severely bottlenecked lineage emerged out of Africa and underwent rapid population 
growth as it spread globally. 
 
4.2 Introduction 
Plasmodium vivax causes over 8 million cases of human malaria per year, with the vast 
majority occurring in Southeast Asia and South America (World Health Organisation, 
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2017). P. vivax is rare in humans in Africa due to the high prevalence of the Duffy negative 
mutation (Howes et al., 2011), which abrogates expression of the Duffy antigen receptor 
for chemokines (DARC) on erythrocytes. Since DARC serves as a receptor for P. vivax, 
its absence protects Duffy negative humans from P. vivax infection (Miller et al., 1976), 
although this protection is not absolute (Zimmerman, 2017). Until recently, P. vivax was 
thought to have emerged in Asia following the cross-species transmission of a macaque 
parasite (Cornejo and Escalante, 2006; Mu et al., 2005). However, the finding of closely 
related parasites in wild-living chimpanzees and gorillas suggested an African origin of P. 
vivax (Liu et al., 2014). Indeed, parasite sequences closely resembling P. vivax have been 
detected in western (Pan troglodytes verus), central (P. t. troglodytes) and eastern (P. t. 
schweinfurthii) chimpanzees, eastern (Gorilla beringei graueri) and western (Gorilla gorilla 
gorilla) lowland gorillas, and most recently in bonobos (Pan paniscus) (Kaiser et al., 2010; 
Liu et al., 2017, 2014, 2010; Prugnolle et al., 2013). Phylogenetic analyses of available 
sequences revealed that ape and human parasites were near-identical, with human 
P. vivax sequences forming a monophyletic lineage that usually fell within the radiation of 
the ape parasites (Liu et al., 2014). These findings suggested that P. vivax infected apes 
including humans in Africa, until the spread of the Duffy negative mutation largely 
eliminated the parasite in humans there. However, definitive conclusions could not be 
drawn since all analyses of ape P. vivax genomes to date have rested on a small number 
of gene fragments amplified almost exclusively from parasite mitochondrial DNA present 
in ape fecal samples. 
Understanding the origin of human P. vivax and its relationship to the ape parasites 
is important for several reasons. First, only six Plasmodium species, out of several 
hundred so far described to infect vertebrate hosts (Faust and Dobson, 2015), have 
successfully colonized humans (Scully et al., 2017). Thus, the circumstances that 
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surround the emergence of each of these human pathogens is of interest, especially since 
most, if not all, have non-human primate parasites as their closest relatives (Liu et al., 
2014, 2010; Rutledge et al., 2017). Second, it is currently unclear whether the ape 
parasites represent a separate species, distinct from P. vivax. Although sequences from 
human P. vivax parasites form a monophyletic clade in phylogenetic trees, this may be a 
reflection of their geographic separation and not the existence of host-specific infection 
barriers. Indeed, ape P. vivax has been shown to cause malaria in a Duffy positive 
European traveler (Prugnolle et al., 2013), and human P. vivax has been transmitted to 
wild-living monkeys in South America, generating what has been called Plasmodium 
simium (Buery et al., 2017). If cross-species infection and recombination of ape and 
human P. vivax were possible, as appears to be the case for P. simium and P. vivax in 
South America (Brasil et al., 2017; Buery et al., 2017), this could have implications for 
malaria eradication efforts. Finally, ape and human P. vivax strains may have acquired 
adaptations that limit parasite transmission between different host species. Such findings 
could explain why the macaque parasites Plasmodium knowlesi and Plasmodium 
cynomolgi can infect and cause malaria in humans, but do not appear to be commonly 
transmitted between different human hosts (Brock et al., 2016). 
To elucidate the events that led to the emergence of human P. vivax, we sought 
to obtain genome sequences of parasites infecting chimpanzees and gorillas. A similar 
approach has recently uncovered processes that may have allowed the gorilla precursor 
of P. falciparum to cross the species barrier to infect humans (Otto et al., 2018; 
Sundararaman et al., 2016). However, obtaining blood samples from Plasmodium infected 
apes is challenging due to the endangered species status of these hosts. Moreover, ape 
P. vivax, like its human-infecting counterpart, exhibits only low levels of parasitemia (Liu 
et al., 2014) and has not been cultured. Although removal of host leukocytes from whole 
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blood samples (Pearson et al., 2016) and parasite nucleic acid capture (Hupalo et al., 
2016) have improved the recovery of human P. vivax genomes, these approaches are not 
readily applicable to ape parasites. We thus adapted a previously developed selective 
whole genome amplification (SWGA) method (Sundararaman et al., 2016) to generate P. 
vivax genome sequences from unprocessed chimpanzee and gorilla blood samples 
obtained in different parts of Africa. Analysis of these genomes revealed that the ape 
parasites are about 10 times more diverse than global representatives of human P. vivax 
(Hupalo et al., 2016), indicating that the human parasite has undergone a severe genetic 
bottleneck. Ape P. vivax genomes were found to have intact orthologs of three reticulocyte 
binding protein genes that are pseudogenized in all human P. vivax strains, but functional 
studies of two of the encoded proteins revealed no evidence of species-specific receptor 
interactions. The P. vivax ancestor therefore likely infected both humans and apes in 
Africa, before being eliminated in humans there by the spread of the Duffy negative 
mutation. Thus, the current human-infecting parasites represent a lineage that had 
escaped out of Africa. 
. 
4.3 Results 
Genome assemblies of chimpanzee P. vivax. Leftover blood samples from routine 
health examinations of chimpanzees cared for at the Sanaga Yong (SY) Chimpanzee 
Rescue Center in Cameroon were screened for Plasmodium infection using nested PCR 
with pan-Plasmodium and P. vivax-specific primers. Two samples, SY56 and SY43, were 
positive for ape P. vivax, with limiting dilution PCR detecting one strain in SY56 and up to 
five variants in SY43, with two strains predominating. Since these two samples lacked 
other Plasmodium species, they were suitable for selective whole genome amplification 
(SWGA) without the risk of generating inter-species recombinants (Leichty and Brisson, 
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2014; Sundararaman et al., 2016). SWGA uses the highly processive phi29 DNA 
polymerase and specific primers to preferentially amplify pathogen sequences from 
complex mixtures of target and host DNA, and has been used successfully in the past to 
generate Plasmodium sequences from blood smear negative, unprocessed blood 
samples (Sundararaman et al., 2016). Since SWGA can result in stochastic amplification 
when target templates are rare (Cowell et al., 2017; Sundararaman et al., 2016), each 
sample was amplified on more than one occasion using different primer sets, with and 
without digestion of sample DNA with methylation-dependent restriction enzymes to 
degrade host DNA (see SI Appendix, Table S4-1). Individual SWGA reactions were pooled 
and sequenced on Illumina and PacBio platforms (see SI Appendix). 
Draft genomes of the chimpanzee P. vivax strains PvSY56 and PvSY43 were 
generated using iterative reference-guided assembly to the human PvP01 reference 
genome (Auburn et al., 2016), followed by gap filling steps. In addition, PvSY56 reads that 
did not map to the PvP01 core genome were de novo assembled to obtain subtelomeric 
contigs. The resulting assemblies yielded 21.9 Mbp and 21.2 Mbp of sequence for PvSY56 
and PvSY43, respectively (Table 4-1). Because sample SY43 contained at least five P. 
vivax strains (Liu et al., 2014), the PvSY43 genome represents a consensus of these 
variants. Annotations were transferred from PvP01, with additional genes predicted in the 
de novo contigs. Since a large number of genes contained frameshifts in homopolymer 
tracts, we manually corrected annotations spanning these presumed sequencing errors to 
maintain an open reading frame. Overall, PvSY56 and PvSY43 shared a highly conserved 
core genome with human P. vivax. More than 98% of PvP01 core genes (as defined in 
19) were identified in each chimpanzee P. vivax assembly (Table 4-1), with 88% present 
as full-length genes. Although 10 human P. vivax core genes were absent from both 
PvSY56 and PvSY43, ape P. vivax reads at least partially covered these coding regions, 
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implicating assembly difficulties rather than differences between ape and human P. vivax 
genomes for their absence. Assembly issues likely also account for the small number of 
genes in subtelomeric and internal hypervariable regions that could be annotated for 
PvSY56 and PvSY43, respectively (Table 4-1). 
 
Table 4-1. Genome features of ape P. vivax  
 PvSY56 PvSY43* PvP01† 
Host species Chimpanzee  Chimpanzee  Human 
Country  Cameroon Cameroon Indonesia 
Chromosomal assembly (bp)§ 21,928,114 21,224,756 24,177,188 
Mean depth of coverage¶ 319 240 N/A 
Chromosomal contigs 7,112 6,604 14 
G + C content (%) 44.1 44.6 43.3 
Core# protein-coding genes (% of PvP01) 4,883 (98.8) 4,908 (99.3) 4,941 (100) 
     Full length# (% of PvP01) 4,391 (88.9) 4,350 (88.0) N/A 
     Partial (% of PvP01) 492 (10.0) 558 (11.3) N/A 
Genes in hypervariable regions|| 415 276 1,702 
*The genome assembly of PvSY43 represents a consensus sequence of at least two major and 
three minor chimpanzee P. vivax variants (Fig. 2C and D; see SI Appendix, Fig. S5). 
†Chimpanzee P. vivax genomes were compared to the human P. vivax reference PvP01 (Auburn 
et al., 2016). 
§Number of unambiguous bases.  
¶Calculated by dividing the number of nucleotides in reads mapped to the assemblies by the 
expected genome size in PvP01. 
#Genes classified as full-length comprised at least 90% of the length of the corresponding PvP01 
ortholog. 
||Protein-coding genes in subtelomeric and internal hypervariable regions were defined as 
described (Pearson et al., 2016).  
 
Polymorphism in ape and human P. vivax. Comparison of coding sequences between 
the PvSY56 and PvSY43 assemblies revealed that they differ at 0.61% of sites, which 
contrasts with a difference of only 0.11% between the two human P. vivax reference 
genomes, PvSalI and PvP01 (see SI Appendix, Figure S4-1A). Since PvSY56 and 
PvSY43 were both derived from chimpanzees housed at the same sanctuary, we 
reasoned that they might not represent the full extent of ape P. vivax diversity (the two 
human reference strains were sampled on two different continents in Latin America and 
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Southeast Asia). This prompted us to obtain P. vivax genome sequences from additional 
infected apes. Using SWGA followed by IIlumina sequencing, we amplified ape P. vivax 
from blood samples of two additional SY chimpanzees (SY81 and SY90), from a wild-
living western chimpanzee (Sagu) from Cote d’Ivoire (Kaiser et al., 2010), and from a 
western lowland gorilla (Gor3157) sampled in Cameroon (see SI Appendix, Table S4-2). 
We also mined the read database from a blood sample of a P. malariae-infected sanctuary 
chimpanzee from Gabon (Rutledge et al., 2017), which we had noted contained a 
substantial number of ape P. vivax reads. Reads from each sample were mapped to the 
PvSY56 assembly and single nucleotide polymorphisms (SNPs) were identified. The 
extent of genome coverage varied considerably among the six chimpanzee samples; 
however, we were able to recover between 695 and 3,006 core genes (see SI Appendix, 
Table S4-2), with 65% of genes analyzed being covered in four or more parasite genomes 
(see SI Appendix, Figure S4-2). The gorilla P. vivax strain, which was derived from a 
partially degraded bushmeat sample, yielded only 10 genes despite repeated 
amplification, and was thus not included in the diversity analysis. For comparison, we 
included sequences from seven additional human P. vivax strains (Hupalo et al., 2016), 
each from a different country (India, Myanmar, Papua New Guinea, Thailand, Colombia, 
Mexico, Peru), and identified SNPs using the same methods. Diversity values were then 
calculated across a common set of 4,262 core genes for which we obtained sequences 
from two or more strains for both ape and human P. vivax (Table 4-2). The results revealed 
a mean pairwise nucleotide sequence diversity (π) among the six chimpanzee P. vivax 
strains of 0.694%, about eight times higher than the value (0.085%) for the global sample 
of human strains (Table 4-2, Figure 4-1A; see SI Appendix, Figure S4-1B). Removal of 
the PvSY43 sequence did not decrease this difference (see SI Appendix, Figure S4-1C), 
indicating that inclusion of this multiply infected sample did not artificially inflate the 
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diversity of the chimpanzee P. vivax parasites. Similarly, there was no evidence that 
SWGA increased chimpanzee P. vivax diversity. Analysis of transition/transversion ratios 
at 4-fold degenerate sites yielded near identical results for chimpanzee (1.08) and human 
(1.06) P. vivax, excluding a technical artifact (Cowell et al., 2017; Sundararaman et al., 
2016). Thus, the P. vivax strains currently circulating in humans appear to have undergone 
a stringent population bottleneck in the recent past. 
 
Table 4-2. Nucleotide polymorphism in ape and human P. vivax 
 
n* πall† π0‡ π4 § 
NS 
polymorphisms¶ 
S 
polymorphisms¶ NS/S 
Ape P. vivax 6 0.00694 0.00354 0.01599 31,880 47,020 0.68 
Human P. vivax 9 0.00085 0.00061 0.00143 10,479 7,657 1.37 
*n = number of strains included in the analysis (see SI Appendix, Fig. S2 for gene coverage among the 
different strains). 
†Mean pairwise diversity at coding sites from 4,262 genes (6.5 million sites)  
‡Mean pairwise diversity at 0-fold degenerate sites from 4,262 genes (4.0 million sites) 
§Mean pairwise diversity at 4-fold degenerate sites from 4,262 genes (0.7 million sites) 
¶Number of nonsynonymous (NS) and synonymous (S) polymorphisms were calculated by counting the 
number of SNPs that changed (NS) or did not change (S) the protein sequence of the respective reference. 
 
 
Figure 4-1. Nucleotide sequence diversity in ape and human P. vivax. (A) Pairwise 
nucleotide sequence diversity (π) calculated across a common set of 4,259 core genes 
for six chimpanzee and nine human P. vivax strains (as in Table 4-2, but three genes with 
fewer than 35 aligned sites were excluded). Median and mean (weighted by gene length) 
π values are indicated by solid and dashed lines, with box and whiskers indicating the 
interquartile range and 99th percentiles, respectively. Plots including outliers are shown in 
the SI Appendix, Fig. S1B. (B) Density plots of neutrality index (NI) values shown on a log2 
scale for ape (red) and human (black) P. vivax genes. Values are shown for 1,582 genes 
with non-zero values of NI in both populations. (C) Site frequency spectra of 
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polymorphisms at 4-fold degenerate (blue) and 0-fold degenerate (orange) sites extracted 
from SNP data of human P. vivax samples from Southeast Asia (20). 
 
The nature of the nucleotide polymorphisms also differed substantially between 
chimpanzee and human P. vivax strains. Among the chimpanzee parasites the majority of 
polymorphisms were synonymous, with the ratio of nonsynonymous to synonymous SNPs 
(NS/S) being 0.68. In contrast, the majority of polymorphisms among the human strains 
were nonsynonymous, with a NS/S ratio of 1.37 (Table 4-2). The ratio of NS/S among 
polymorphisms can be compared to (i.e., divided by) the NS/S ratio among interspecies 
differences to yield the neutrality index (Rand and Kann, 1996). This neutrality index, or 
NI, assumes that synonymous changes, both within and between species, are selectively 
neutral, and has an expected value of one when nonsynonymous changes are also 
neutral. We thus compiled a set of 3,912 genes that were comparable among ape and 
human P. vivax strains as well as between these parasites and the macaque parasite P. 
cynomolgi (their closest relative with an available genome sequence). The overall NI value 
for ape P. vivax strains was close to the neutral expectation (NI = 0.95; see SI Appendix, 
Table S4-3). In contrast, the overall value for human P. vivax strains was much larger (NI 
= 1.91), indicating a large excess of nonsynonymous polymorphisms among human 
strains, relative to the expectation derived from patterns of divergence between species. 
Comparison of the ratios of nonsynonymous and synonymous changes, between 
within-species polymorphisms and between-species fixed differences, forms the basis of 
the McDonald-Kreitman (MK) test for adaptive evolution of individual genes (McDonald 
and Kreitman, 1991). The discrepancy in overall NI values for ape versus human P. vivax 
strains indicates that MK tests are likely to produce different results depending on which 
P. vivax strains are used. For the chimpanzee P. vivax strains, only two genes yielded 
significant results after correction for multiple testing, both with NI<1 indicating a significant 
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excess of fixed, potentially adaptive, nonsynonymous differences: one was found to be 
orthologous to PVP01_1201800, which is an immunogenic member of the tryptophan-rich 
antigen family of P. vivax (Chuquiyauri et al., 2015; Wang et al., 2015), while the other 
(orthologous to PVP01_1406200) encodes a conserved Plasmodium protein of unknown 
function. For the human P. vivax strains, five genes yielded significant MK test results, but 
all with NI>1, indicating an excess of nonsynonymous polymorphisms (see SI Appendix, 
SI Dataset). Such results are usually interpreted as evidence of balancing selection 
maintaining polymorphism, but the large overall NI value for the human strains suggests 
that there is a more pervasive factor, such as past demography, that is influencing these 
genes. Figure 4-1B shows the distributions of NI values for 1,582 individual genes with 
non-zero values in both ape and human P. vivax. These results indicate that the difference 
between ape and human P. vivax is not due to a subset of unusual genes, but rather that 
the entire distribution is shifted from being centered around 1.0 in ape P. vivax, to being 
centered around 2.0 in human P. vivax (Figure 4-1B; see SI Appendix, SI Dataset). 
To investigate this in greater detail, we examined the frequencies of 
nonsynonymous and synonymous polymorphisms per site. We obtained different results 
depending on the methodology used, primarily because different methods use different 
approaches to estimate the numbers of sites available for synonymous changes. To avoid 
this problem, we included only 4-fold and 0-fold degenerate sites where, due to the 
structure of the genetic code, either all or none of the possible changes are synonymous. 
Among ape P. vivax strains, the nucleotide diversity at 0-fold degenerate sites (0.00354) 
was 22% of that at 4-fold degenerate sites (0.01599), whereas among human P. vivax 
strains, the value at 0-fold degenerate sites (0.0061) was 43% of that at 4-fold degenerate 
sites (0.00143) (Table 4-2; see SI Appendix, Figure S4-1D and E). Thus, while 
chimpanzee parasites were 11 times more diverse than human parasites at 4-fold 
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degenerate sites, they were only 6 times more diverse at 0-fold degenerate sites, 
indicating that nonsynonymous polymorphisms in human P. vivax strains are almost twice 
as numerous as expected. 
A large number of human P. vivax genome sequences have been characterized 
(Hupalo et al., 2016; Pearson et al., 2016), and so it is possible to investigate the 
frequencies at which SNPs are segregating within the population. Synonymous 
polymorphisms are expected to be neutral, and so their site frequency spectrum (SFS) 
should reflect past demography. By comparison, many nonsynonymous polymorphisms 
are expected to be slightly deleterious, and their SFS should thus be more skewed towards 
lower frequencies. To examine a large number of parasite sequences from a single 
geographic region, we focused on SNP data from MalariaGen samples from Southeast 
Asia (Pearson et al., 2016). Ancestral and derived alleles at each site were identified by 
comparison with two outgroups: the chimpanzee P. vivax strain PvSY56 and a P. 
cynomolgi reference strain. The unfolded site frequency spectra obtained for SNPs at 0-
fold and 4-fold degenerate sites are almost identical (Figure 4-1C). Thus, the unusually 
large fraction of nonsynonymous polymorphisms among human P. vivax sequences 
appears to reflect mutations that are segregating as effectively neutral alleles. 
  
Relationship of P. vivax strains from humans and apes. In previous analyses of a 
small number of partial gene sequences, we found that sequences from human P. vivax 
parasites always formed a monophyletic clade, which usually fell within the radiation of 
sequences from chimpanzee and gorilla samples (Liu et al., 2014). This was observed for 
mitochondrial and apicoplast sequences as well as for three nuclear genes, while for a 
fourth nuclear gene ape and human P. vivax sequences formed sister clades (Liu et al., 
2014). Here we found that, across their genome, chimpanzee parasites were much more 
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divergent from the human parasites than they were from each other. For example, across 
3,957 core genes, the chimpanzee parasite genomes (PvSY56 and PvSY43) differed from 
one another at 0.6% of sites, but from the human P. vivax reference genomes (PvSalI and 
PvP01) on average at 2.2% of sites. This relationship is summarized in a neighbor-joining 
tree constructed from a matrix of pairwise genetic distances from an alignment of 232 
nuclear genes available for all six chimpanzee parasites (Figure 4-2A). Although this tree 
may not reflect the true evolutionary history of any one particular gene (due to 
recombination), the overall relationships were confirmed by phylogenetic network analysis 
(see SI Appendix, Figure S4-3A), which showed that the four chimpanzee parasites 
sampled at the same location (SY) in Cameroon are on average a little more closely 
related to each other than they are to the strains identified in Gabon (GA02) and Cote 
d’Ivoire (Sagu). Inclusion of P. vivax sequences from the gorilla sample restricted the 
analysis to six genes and only five chimpanzee parasites. For these genes the gorilla 
P. vivax strain was quite divergent (Figure 4-2B, see SI Appendix Figure S4-3B), differing 
almost as much from the chimpanzee strains (on average 1.8%) as from the human strains 
(on average 2.4%). Whether the human P. vivax lineage falls within the radiation of the 
ape strains, or groups as a sister clade, depends on the position of the root of these trees. 
The closest available outgroup is P. cynomolgi, which is much more distant from the 
P. vivax sequences than they are from each other, and may not root the tree reliably. 
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Figure 4-2. Evolutionary relationships of ape and human P. vivax strains (A) An unrooted 
neighbor-joining tree constructed from a matrix of pairwise genetic distances from an 
alignment of 232 nuclear genes is shown for nine human (black) and six chimpanzee (red) 
P. vivax strains (the inset shows the human P. vivax strains in greater detail). (B) As in 
(A), but based on 6 nuclear genes with coverage in one gorilla P. vivax strain (green). The 
same human and chimpanzee P. vivax strains were included, except for PvSY81, which 
did not cover these genes. (C and D) Maximum likelihood trees for fragments of nuclear 
genes PVP01_1418300 (C) and PVP01_1418500 (D) with P. cynomolgi and P. knowlesi 
included as outgroups. Sequences of P. carteri parasites are shown in blue. ‘Pv’ denotes 
sequences from genome-wide analyses, shown in bold if generated by SWGA or derived 
from published data (see SI Appendix, Table S4-2); all other sequences except for P. 
cynomolgi and P. knowlesi were generated by SGA and include a code identifying their 
geographic origin (see SI Appendix, Fig. S5), ape subspecies (P.t.t., P. t. troglodytes; 
P.t.e., P. t. ellioti; G.g.g., Gorilla gorilla gorilla), and sample number. Bootstrap values ≥70 
are shown for clades with two or more non-identical tips. Fragment lengths in PvP01 are 
indicated above the trees. The scale bars indicate substitutions per site (also see SI 
Appendix, Figure S4-3 for phylogenetic network analysis). 
 
To investigate further the relationships among ape and human P. vivax strains, we 
focused on the 10 genes that could be recovered from the single gorilla sample (see SI 
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Appendix, Table S2). Including both P. cynomolgi and P. knowlesi as outgroups, we found 
that four genes yielded a tree topology in which the human strains fell within the radiation 
of ape strains, while the six other genes yielded tree topologies in which human and ape 
parasites represented sister clades (see SI Appendix, Figure S4-4). To increase the 
number of geographically diverse ape P. vivax sequences, we used single genome 
amplification (SGA) to screen an existing collection of P. vivax positive ape blood and fecal 
samples for five of these genes (see SI Appendix, Figure S4-5). Each DNA preparation 
was diluted such that only single DNA templates were amplified, which precludes in vitro 
recombination. For three of these genes, this analysis also yielded sequences from 
Plasmodium carteri, a rare parasite species thus far only found in two wild chimpanzees, 
which is distinct from, but most closely related to, the P. vivax clade (Liu et al., 2014; Loy 
et al., 2017). When these additional sequences were included in the phylogenetic 
analyses, four of the five trees showed the human strains within the radiation of ape 
strains, including two where the previous topology depicted ape and human strains as 
sister clades, with three of these four trees including gene sequences for P. carteri (Figure 
4-2C; see SI Appendix, Figure S4-6). Thus, inclusion of gorilla P. vivax and/or P. carteri 
changed the topology from sister clades to a nested relationship. For the remaining gene, 
human and ape parasite sequences remained as sister clades, but only a single gorilla 
parasite sequence was available for analysis and P. carteri sequences could not be 
amplified (Figure 4-2D). These results indicate that the inferred relationships among 
P. vivax strains from apes and humans depend in large part on the number of available 
sequences, especially from gorilla parasites, as well as on the presence of a closely 
related outgroup. 
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Ape P. vivax strains maintain open reading frames for reticulocyte binding protein 
genes that are pseudogenized in human P. vivax. Adaptation of Plasmodium parasites 
to new host species has been associated with gains and losses of genes encoding 
proteins involved in red blood cell invasion (Scully et al., 2017). We therefore compared 
the repertoire of P. vivax invasion genes in the genomes of human and chimpanzee 
parasites. Like human P. vivax, the chimpanzee parasite genomes contained genes 
encoding the Duffy binding protein (DBP) and a related erythrocyte binding protein (DBP2, 
or EBP) (Hester et al., 2013), but no additional DBP-like genes were identified.  
Variation in the complement of reticulocyte binding proteins (RBPs) is thought to 
influence the ability of Plasmodium parasites to invade erythrocytes (Cowman et al., 2017; 
Scully et al., 2017). Human P. vivax, which exclusively invades reticulocytes, has full-
length open reading frames for five rbp genes (rbp1a, rbp1b, rbp2a, rbp2b, rbp2c), all of 
which were conserved in the two chimpanzee P. vivax genomes PvSY56 and PvSY43. 
Two shorter rbp genes annotated in human P. vivax (rbp2p1 and rbp2p2) are believed to 
encode proteins that lack a C-terminal transmembrane domain; one of these (rbp2p1) 
appears to be present in all human P. vivax strains and also in P. cynomolgi, while rbp2p2 
has been found only in a subset of human P. vivax strains (Hietanen et al., 2016). We 
identified orthologs of both of these partial genes in the chimpanzee P. vivax genomes 
(Figure 4-3A), indicating that variation in the presence of rbp2p2 among human P. vivax 
strains is the result of a deletion after the divergence of human and ape parasites, rather 
than a recent gene duplication. The finding of partial rbp2p1 and rbp2p2 genes in both 
ape and human P. vivax, and of rbp2p1 in P. cynomolgi, suggests that their encoded 
proteins have a conserved function. However, looking for positive selection (Yang, 2007) 
in invasion genes (dbp, ebp, rbp1a, rbp1b, rbp2a, rbp2b) on the branch leading to human 
P. vivax failed to yield evidence of human specific adaptation. 
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The human P. vivax genome also contains three rbp pseudogenes, termed rbp2d, 
rbp2e and rbp3. Seemingly functional orthologs of rbp2e and rbp3 are present in the 
genomes of the monkey parasites P. cynomolgi, P. knowlesi and P. inui, while P. fragile 
has an intact rbp2e gene but a rbp3 pseudogene (Figure 4-3A). So far, rbp2d has only 
been identified in P. vivax. The two chimpanzee P. vivax genomes PvSY56 and PvSY43 
contained full length intact open reading frames corresponding to each of these three 
human P. vivax pseudogenes, indicating that the loss of function occurred after the 
divergence of human and ape parasites (Figure 4-3A). 
Since the pseudogenization of rbp2d, rbp2e, and rbp3 seems to be unique to the 
human lineage of P. vivax, we considered the possibility that these genes may be intact 
in some human strains. We mapped sequencing reads from 374 published human P. vivax 
strains (Hupalo et al., 2016; Pearson et al., 2016) to the rbp2d, rbp2e and rbp3 reference 
genes and analyzed those that yielded greater than a three-fold read coverage of the 
entire coding sequences. In each gene, we found at least one inactivating mutation that 
was present in all human parasite samples, as well as numerous additional mutations that 
likely occurred subsequent to the initial pseudogenization event (Figure 4-3B). The 
accumulation of additional frameshifts and stop mutations, some of which occur very close 
to the 5’ end of the coding sequence, suggests that these genes do not encode truncated 
proteins.  
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Figure 4-3. The rbp gene family in ape and human P. vivax. (A) A midpoint-rooted 
maximum likelihood phylogenetic tree is shown depicting the relationships of human 
(black) and chimpanzee (PvSY56 and PvSY43, red) P. vivax rbp genes with their 
orthologs in P. knowlesi, P. cynomolgi, P. inui, P. fragile and human P. malariae (purple). 
P. vivax, P. cynomolgi and P. knowlesi genes are labeled according to their published 
names; genes from P. inui, P. fragile and P. malariae are labeled according to the clade 
in which they are placed. Pseudogenes are indicated with yellow stars. The inset shows 
the relationship of rbp1a sequences among representative human and three sequenced 
chimpanzee P. vivax strains, rooted using P. cynomolgi (see SI Appendix for details). (B) 
Locations of frameshift (purple) and premature stop (black) mutations in rbp2d, rbp2e, and 
rbp3 sequences assembled from published human P. vivax strains (20, 21), relative to the 
full length coding sequence from chimpanzee P. vivax (light green). Each bar represents 
a set of mutations that occurred in two or more human P. vivax strains for which a full 
length sequence was assembled (128, 162, and 227 sequences for rbp2d, rbp2e, rbp3, 
respectively); the percentage of sequences containing the respective mutations is shown 
on the right, with “other” summarizing all mutations that occurred only once. 
 
To examine whether the other chimpanzee P. vivax strains (PvSY81, PvSY90, 
PvSagu and PvGA02) contained any of the rbp2d, rbp2e, and rbp3 inactivating mutations, 
we mapped available sequencing reads to their respective genes. We also used SGA to 
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amplify the same regions from P. vivax positive gorilla samples. Although in most 
instances the coverage of the rbp2d, rbp2e, and rbp3 genes was incomplete, none of the 
recovered sequences contained the frameshift and stop codon mutations found in all 
human P. vivax strains (see SI Appendix, Figure S4-7). This was also true for SGA-derived 
gorilla parasite sequences from the multiply infected bushmeat sample SAggg3157, which 
contained a number of polymorphism, none of which disrupted the respective reading 
frame. Thus, both chimpanzee and gorilla P. vivax parasites appear to maintain three 
genes encoding RBPs that have been lost in all human P. vivax strains, which could 
influence their ability to infect different host species. 
 
Recombinant RBP2e and RBP3 do not exhibit species-specific red blood cell 
binding. The pseudogenization of rbp2d, rbp2e and rbp3 in all human P. vivax strains 
raised the possibility that these proteins bind gorilla- and/or chimpanzee-specific 
erythrocyte receptors that are no longer used by the human parasite. Recombinant 
proteins comprising the amino-terminal domain of RBPs encoded by human P. vivax 
(RBP2a160-1000 and RBP2b161-969) have been used to characterize their erythrocyte binding 
properties (Gruszczyk et al., 2018b, 2016). These studies showed that RBP2b binds the 
reticulocyte-specific Transferrin Receptor 1 (TfR1), also termed CD71 (Gruszczyk et al., 
2018b), while RBP2a binds an unknown receptor present on both normocytes and 
reticulocytes (Gruszczyk et al., 2016). To examine the function of chimpanzee P. vivax 
RBP2d, RBP2e, and RBP3 proteins, we expressed their amino-terminal domains in 
bacteria for subsequent erythrocyte binding studies. Although RBP2d165-967 could not be 
purified due to protein aggregation, RBP2e156-957 and RBP3149-968 were efficiently 
expressed and exhibited an alpha-helical and beta-sheet content similar to human P. vivax 
RBP2b (see SI Appendix, Figure S4-8). Because some RBPs bind only reticulocytes, we 
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s to enrich these cells from blood samples obtained from four humans, four chimpanzees 
and one gorilla using a Percoll density gradient as previously described (Gruszczyk et al., 
2018b, 2016). Despite repeated attempts, this approach yielded only partial reticulocyte 
enrichment for the ape blood samples, possibly due to differences in erythrocyte density 
between the different species (see SI Appendix, SI Methods). Nonetheless, some 
enrichment of ape reticulocytes (up to 1.8%) was achieved as determined by thiazole 
orange (TO) staining. 
To examine binding to ape red blood cells, we first tested the two previously 
characterized human P. vivax RBP proteins, RBP2a160-1000 and RBP2b161-969 (Gruszczyk 
et al., 2018b, 2016). Ape and human red blood cells were incubated with each 
recombinant protein and binding was assessed using protein-specific polyclonal rabbit 
antibodies, followed by a fluorophore-labeled anti-rabbit antibody (Gruszczyk et al., 
2018b, 2016). Reticulocytes were stained with thiazole orange (TO) prior to flow cytometry 
(Figure 4-4A). Consistent with previous results, we observed robust binding of RBP2a to 
both human normocytes (10.3% of TO negative cells; Figure 4-4B) and reticulocytes 
(32.4% of TO positive cells; Figure 4-4C). Interestingly, a similar binding profile was also 
observed for gorilla and chimpanzee red blood cells (Figure 4-4; see SI Appendix, Figure 
S4-9). As expected, RBP2b exhibited a strong preference for reticulocytes, binding 19.9% 
of human reticulocytes (Figure 4-4C), but only a minor fraction (0.9%) of human 
normocytes (Figure 4-4B), likely reflecting incomplete reticulocyte staining and/or non-
specific binding. RBP2b also bound chimpanzee and gorilla reticulocytes, albeit at a 
reduced level (Figure 4-4C). Although the TfR1 proteins of chimpanzees and gorillas differ 
from their human counterpart by a few amino acids (see SI Appendix, Figure S4-10), none 
of these residues were identified to represent RBP2b contact sites (Gruszczyk et al., 
2018a). Thus, the decreased binding of RBP2b to ape reticulocytes is unlikely the result 
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of sequence differences between chimpanzee, gorilla and human TfR1 proteins and may 
instead reflect differences in TfR1 expression levels, post-translational modifications, or 
other factors. 
 
Figure 4-4. Binding of RBPs to ape and human red blood cells. (A) Dot plots are shown 
that depict the binding of human P. vivax RBP2a and RBP2b proteins and chimpanzee P. 
vivax RBP2e and RBP3 proteins to human (first row), gorilla (second row), and 
chimpanzee (third row) red blood cells, respectively, along with antibody-only controls of 
human red blood cells (fourth row). RBP binding was detected using an RBP-specific 
polyclonal rabbit antibody and an anti-rabbit (Alexa Fluor 647 labelled) secondary antibody 
(y-axis), and reticulocytes were identified by staining with thiazole orange (TO) (x-axis). 
Flow cytometry gates separating normocytes from reticulocytes, and protein binding from 
no protein binding, are shown by vertical and horizontal lines, respectively. Numbers 
indicate the percentage of total cells within the respective gate. (B) Percentage of gorilla 
(green), chimpanzee (red) and human (black) normocytes bound by the respective RBP. 
(C) Percentage of gorilla, chimpanzee and human reticulocytes bound by the respective 
RBP. Experiments were performed as three technical replicates with the background 
signal from the antibody-only control subtracted from each binding result. 
 
Having validated the experimental system, we next tested the binding of 
chimpanzee P. vivax RBP2e156-957 and RBP3149-968 to ape and human red blood cells. We 
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found that neither of these two proteins bound particularly well to ape red blood cells, 
although RBP2e consistently yielded a higher signal than RBP3 (Figure 4-4B and C). Like 
the human P. vivax RBP2a and RBP2b proteins, RBP2e and RBP3 appeared to bind 
reticulocytes more efficiently than normocytes (Figure 4-4; see SI Appendix, Figure S4-9). 
However, there was no clear evidence for host specificity. Although RBP3 bound gorilla 
reticulocytes slightly more efficiently than chimpanzee and human reticulocytes, this result 
has to be interpreted with caution since only a single gorilla sample containing very few 
reticulocytes was available for testing (Figure 4-4A). Indeed, when red blood cells from a 
macaque were tested, RBP2e and RBP3 were found to also bind to reticulocytes from this 
host species (see SI Appendix, Figure S4-9). To determine whether the low level of RBP2e 
and RBP3 binding was due to inefficient reticulocyte enrichment, we tested an additional 
chimpanzee blood sample with a particularly high reticulocyte count. Although Percoll 
gradient enrichment of this sample yielded twice as many reticulocytes (4%), this higher 
fraction did not improve RBP2e and RBP3 binding (see SI Appendix, Figure S4-11). Thus, 
the maintenance of the rbp2e and rbp3 genes in chimpanzee P. vivax cannot be readily 
explained by invoking interaction with a host-specific erythrocyte receptor.  
 
4.4 Discussion 
It has recently become apparent that wild-living African apes, including western and 
eastern gorillas as well as chimpanzees and bonobos, harbor malaria parasites that 
appear to be very closely related to P. vivax strains infecting humans in Asia and 
Central/South America (Liu et al., 2017, 2014; Prugnolle et al., 2013). Since these results 
were based on a small number of mostly mitochondrial DNA fragments, we have now 
generated two near complete and several partial genome sequences from ape-infecting 
parasites. Analyses of these sequences show that ape and human parasites are indeed 
131 
 
very closely related, with the human P. vivax sequences forming a monophyletic lineage 
either within or as a sister group to the ape parasites. The new data also reveal that ape 
and human P. vivax strains exhibit distinct patterns of genetic diversity, reflecting very 
different demographic histories. The parasites infecting humans and apes are largely 
allopatric, but there is as yet no evidence that they represent distinct Plasmodium species. 
Thus, P. vivax in African apes represents a substantial, and genetically diverse, parasite 
reservoir from which future human infections could arise, even if eradication of current 
human strains were successful. 
Recent papers have emphasized that, across the genome, the global genetic 
diversity of human P. vivax is somewhat greater than that of P. falciparum (Hupalo et al., 
2016; Neafsey et al., 2012). Here we find that the level of neutral genetic diversity among 
P. vivax parasites from chimpanzees is about 10 times higher than that of human P. vivax 
strains. P. falciparum isolates also exhibit about 10 times less genetic diversity than is 
seen in closely related Laverania species (Otto et al., 2018; Sundararaman et al., 2016). 
This is consistent with both human parasites having undergone severe genetic 
bottlenecks. In the case of P. falciparum, this most likely occurred at the point when a 
gorilla parasite made the cross-species jump into humans (Liu et al., 2010; Loy et al., 
2017). For P. vivax, it is also possible that the ancestral parasites infected only non-human 
apes, and that one of these crossed the species barrier and gave rise to the population of 
parasites currently infecting humans. Alternatively, ancient P. vivax may have infected all 
African ape species, including humans (Liu et al., 2014). In the latter case, the bottleneck 
would likely have occurred when P. vivax migrated with human out of Africa, prior to the 
spread of the Duffy negative mutation that eliminated P. vivax from humans in most (or at 
that time, perhaps all) of sub-Saharan Africa. While it is difficult to distinguish between 
these two scenarios on the basis of genetic data, we believe that the second scenario is 
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the more likely. Ape P. vivax seems to circulate freely between chimpanzees and gorillas 
in the wild (Liu et al., 2014) and has caused disease in a Duffy-positive human (Prugnolle 
et al., 2013). Consistent with this, the very high frequency of the Duffy-negative mutation 
suggests a long history of P. vivax exerting selective pressure on humans in Africa (Carter, 
2003). It is likely that the geographic areas in which this mutation is most frequent (Howes 
et al., 2011) were influenced over a long timescale by the distribution of ape P. vivax to 
which humans were exposed. 
The nature of the genetic diversity also differs markedly between the populations 
of P. vivax parasites that infect apes and humans. Among human strains, there is an 
unusually high fraction of nonsynonymous polymorphism. Moreover, these 
nonsynonymous polymorphisms exhibit site frequency spectra that are almost identical to 
those seen for synonymous mutations, implying that they are segregating as if effectively 
neutral. Similar observations have been made for polymorphism in P. falciparum (Chang 
et al., 2012), where this has been attributed, at least in part, to the fact that the parasite 
undergoes repeated bottleneck events in every life cycle at the obligate transmission 
events between host and vector, with rapid expansion in the human host (Chang et al., 
2013). Here, we find that the ratio of nonsynonymous to synonymous mutations among 
the much more numerous polymorphisms among ape P. vivax strains is similar to the ratio 
at sites of divergence between P. vivax and its macaque relative P. cynomolgi. Thus, the 
unusual pattern of polymorphism in human P. vivax cannot reflect its life cycle, but is more 
likely the consequence of the population having undergone a rapid expansion subsequent 
to the spread out of Africa. 
 Looking for possible human specific adaptive changes, we performed McDonald-
Kreitman tests on approximately 4,000 core genes, comparing polymorphisms within ape 
P. vivax with fixed differences between ape P. vivax and human P. vivax. After correcting 
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for multiple tests, we found no gene that exhibited a significant excess of non-synonymous 
fixed differences. We also looked for positive selection in invasion genes on the branch 
leading to human P. vivax, but found no evidence of human specific adaptation. Although 
this does not exclude that a small number of human adaptive changes have occurred, the 
time when human P. vivax became specialized to humans and no longer infected apes 
seems too short to expect significant differences.  
 The pseudogenization of three reticulocyte binding proteins (rbp2d, rbp2e, and 
rbp3) in all human P. vivax strains could be taken to indicate human-specific adaptation 
after the parasite migrated out of Africa and no longer encountered chimpanzees or 
gorillas. However, our erythrocyte binding results are not consistent with this scenario. We 
observed equivalent binding of RBP2e to ape and human red blood cells, and only a 
modest increase in RBP3 binding to gorilla reticulocytes compared to human reticulocytes. 
Overall, the chimpanzee P. vivax-derived RBP2e and RBP3 proteins bound red blood 
cells much less well than the human P. vivax-derived RBP2a and RBP2b proteins, which 
could be due to low affinity interactions, improper folding of the recombinant proteins, or 
the absence of other parasite proteins required for receptor engagement. We also 
considered the possibility that RBP2e and RBP3 are not involved in erythrocyte binding, 
or that the core receptor binding domains were not included in the expressed proteins. 
However, others have shown that the P. knowlesi orthologs of RBP3 and RBP2e, termed 
PkNPBXa and PkNPBXb, both bind red blood cells (Semenya et al., 2012), and that the 
binding domain of PkNPBXb maps to a region included in our RBP2e construct (Semenya 
et al., 2012). Moreover, deletion of PkNBPXa severely reduced the ability of P. knowlesi 
merozoites to invade human red blood cells in vitro (Moon et al., 2016), despite the fact 
that all human-infecting P. vivax strains have lost RBP3. It could be argued that the large 
number of RBP genes in P. vivax (eight full-length and two partial genes) compared with 
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P. knowlesi (two full-length genes and one pseudogene) provides functional redundancy 
that compensates for the loss of rbp genes in human P. vivax. However, this would also 
apply to ape P. vivax, where pseudogenes have not been found. Instead, the loss of rbp 
genes may be slightly deleterious and incur a fitness cost. In ape P. vivax, such an 
inactivating mutation would be expected to be selected against and thus not spread in the 
population. However, in human P. vivax the same mutation could be effectively neutral, 
as many nonsynonymous mutations appear to be, and so it could survive and drift to 
fixation. Whether this explains the loss of rbp2d, rbp2e, and rbp3 in human P. vivax 
remains unknown. However, we found no evidence that rbp2e and rbp3 genes are 
maintained in ape P. vivax parasites because they interact with chimpanzee- and/or 
gorilla-specific erythrocyte receptors that are absent from human red blood cells. 
Despite their common origin in Africa, ape and human P. vivax populations have 
likely had little or no geographic overlap subsequent to the escape of the human-infecting 
lineage out of Africa. Under the bottleneck scenario, the most recent common ancestor of 
human P. vivax was in the lineage that emerged from Africa. This may have been 
coincident with the emergence of modern humans from Africa, perhaps around 75,000 
years ago (Pagani et al., 2016). Molecular clock estimates have placed the P. vivax most 
recent common ancestor (MRCA) at least 50,000-70,000 years ago (McManus et al., 
2017; Mu et al., 2005), but these relied on rate assumptions that may not be accurate. We 
have argued that the MRCA of P. falciparum strains may have existed within the last 
10,000 years (Sundararaman et al., 2016), despite molecular clock estimates that place 
the origin of that species much earlier. Similarly, the MRCA of human P. vivax may have 
left Africa in a more recent wave of human migration, although its higher levels of genetic 
diversity (Hupalo et al., 2016) suggest that human P. vivax is older than P. falciparum. 
Once out of Africa, P. vivax spread through Asia and Europe, and probably from Europe 
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into the Americas (Carter, 2003; Gelabert et al., 2016). Strains of P. vivax now present in 
Madagascar and East Africa, in areas where non-human apes are absent, likely reflect 
reintroductions from Asia (Culleton et al., 2011). Given this historical isolation of ape and 
human P. vivax strains, substantial gene flow between the two populations is unlikely. The 
mixture of topologies found for different genes, where some show separation of the ape 
and human parasite lineages, while others have the human parasites nested within the 
radiation of the ape parasites, likely reflects an ongoing process of lineage sorting in the 
absence of introgression. However, this does not mean that the two populations have 
become isolated species. Both ape and human P. vivax exhibit broad natural tropism 
(Buery et al., 2017; Liu et al., 2014; Loy et al., 2017; Prugnolle et al., 2013), and it therefore 
seems very likely that ape and human strains could infect the same hosts, and undergo 
genetic exchange, if their geography overlapped. In recent years, reports of P. vivax 
infection of African humans have been increasing, including instances of infection of Duffy-
negative individuals (Zimmerman, 2017). It will be important to monitor these cases to 
determine whether any reflect zoonotic transmissions from apes, and whether there is any 
sign of introgression between ape- and human-infecting strains. 
 
4.5 Materials and methods 
Sample collection, DNA extraction, and Plasmodium screening. Blood samples were 
obtained from chimpanzees at the Sanaga-Yong Chimpanzee Rescue Center following 
routine veterinary examination. Blood was also collected from a wild-living habituated 
chimpanzee from the Tai Forest in Cote d’Ivoire during emergency surgery (Köndgen et 
al., 2011). The gorilla blood sample (Gor3157, also referred to as SAggg3157) was 
obtained from confiscated bushmeat in Cameroon. All samples were shipped in 
compliance with Convention on International Trade in Endangered Species of Wild Fauna 
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and Flora regulations and country-specific import and export permits. DNA was extracted 
from whole blood samples using the QIAmp Blood DNA Mini Kit or the Puregene Core 
Blood Kit (Qiagen), and screened for Plasmodium using both pan-Plasmodium primers 
and P. vivax-specific primers, as described (Liu et al., 2014, 2010). Amplicons were 
sequenced using Sanger or MiSeq technologies (see SI Appendix, Materials and 
Methods). 
 
Selective whole genome amplification. Near full-length and partial P. vivax genomes 
were amplified from unprocessed chimpanzee and gorilla blood as described (Cowell et 
al., 2017; Sundararaman et al., 2016) using multiple rounds of SWGA with different primer 
sets, with and without prior digestions with MspJI and FspEI to selectively degrade host 
DNA (see SI Appendix, Table S4-1). 
 
Illumina and PacBio sequencing. Short insert libraries were prepared from pooled 
SWGA products of samples SY43 and SY56 using a KAPA HyperPlus Kit and MiSeq 
sequenced. Pooled SWGA products were also linearized with S1 nuclease (Promega), 
needle sheared to reduce fragment size, and subjected to PacBio SMRT Cell sequencing 
(University of Delaware Sequencing Core). SWGA products from samples SY81, SY90, 
Sagu, and Gor3157 were Illumina sequenced to obtain partial P. vivax genomes. 
 
Assembly of chimpanzee P. vivax draft genomes. Illumina sequencing reads were 
error-corrected using SPAdes (Bankevich et al., 2012), mapped to the chimpanzee 
reference genome, and unmapped reads were mapped to the P. vivax P01 reference 
genome (Auburn et al., 2016). Regions with low coverage or poor paired-read support 
were removed and gaps closed using FGAP (Piro et al., 2014) with proovread-corrected 
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PacBio reads (Hackl et al., 2014), followed by iterations of GapFiller (Nadalin et al., 2012) 
and IMAGE (Tsai et al., 2010). The PvSY56 draft genome was further improved by de 
novo assembly of subtelomeric reads using SPAdes (Bankevich et al., 2012). Annotations 
were transferred to the final assembly using RATT (Otto et al., 2011), and predicted using 
Companion (Steinbiss et al., 2016) in the de novo assembled subtelomeres, followed by 
manual correction. Sets of orthologous genes from PvSY43, PvSY56, PvP01 and PvSalI 
were masked using segmasker (http://nebc.nox.ac.uk/bioinformatics/docs/blast+.html) to 
exclude low-complexity regions, and aligned using TranslatorX/MUSCLE (Abascal et al., 
2010). Outgroup sequences, where available, were added to these alignments using 
MUSCLE. Divergence between sequences was calculated in R using ape (Paradis et al., 
2004) with no correction for multiple substitutions (‘raw’ model). 4-fold and 0-fold 
degenerate sites were extracted if the classification was true for all sequences in the 
alignment. 
 
Single nucleotide polymorphism (SNP) calling. In addition to sequencing SWGA 
products, we also mined publicly available databases for human (Hupalo et al., 2016) and 
chimpanzee (Rutledge et al., 2017) P. vivax reads. SNPs were called following best 
practices for the Genome Analysis Toolkit with hard filtering (Auwera et al., 2014), using 
PvSY56 and PvP01 as ape and human P. vivax reference sequences, respectively. 
Regions classified as low-complexity by dustmasker, genes in subtelomeric and internal 
hypervariable regions (Pearson et al., 2016), and all vir and phist genes were excluded. 
Sites with a coverage of at least five reads were considered callable, with genes containing 
fewer than 60% of sites of the reference excluded. Only sites callable for all strains were 
analyzed. Site frequency spectra were generated from high-quality SNP calls for all high-
coverage South East Asian P. vivax strains in the MalariaGen Genome Variation project 
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(Pearson et al., 2016). 4-fold and 0-fold degenerate sites were identified in the PvSalI 
reference sequence using custom R scripts, and derived alleles at polymorphic sites were 
identified using the est-sfs unfolder (Keightley and Jackson, 2018) with PvSY56 and PcyM 
as outgroups. 
 
Single genome amplification (SGA) of geographically diverse P. vivax strains. Ape 
P. vivax and P. carteri sequences were amplified as described from stored ape blood and 
fecal samples previously shown to be positive for these parasites (Liu et al., 2014). 
Fragments of five genes were targeted using newly designed primers. 
 
Identification of reticulocyte binding protein (rbp) genes. Chimpanzee P. vivax rbp 
genes were identified during annotation of the PVSY56 and PvSY43 genomes. rbp 
orthologs from P. malariae strain PmUG01 (Rutledge et al., 2017), P. knowlesi strain H 
((Pain et al., 2008), 2015 update), P. cynomolgi strains B and Berok (Pasini et al., 2017; 
Tachibana et al., 2012), P. inui strain San Antonio 1 and P. fragile strain Nilgiri (PlasmoDB) 
were identified from annotations and using P. vivax rbp genes as query sequences. 
Human P. vivax sequencing reads (Hupalo et al., 2016; Pearson et al., 2016) were 
downloaded and mapped to rbp2e (PVP01_0700500), rbp2p1 (PVP01_0534400), rbp2p2 
(PVP01_101590), rbp3 (PVP01_1469400), and rbp2d (PVP01_1471400 and 
PVX_101585), with a consensus sequence called for all positions with ≥3-fold coverage. 
The position of frameshifts and stop codons was identified relative to the ape P. vivax 
sequence (see SI Appendix, Materials and Methods). 
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Reticulocyte binding protein (RBP) expression and red cell binding assays. 
Chimpanzee P. vivax rbp2d, rbp2e, and rbp3 sequences were codon optimized, 
synthesized, and cloned into pET-32a(+) (Novagen), yielding constructs RBP2d165-967, 
RBP2e156-957 and RBP3149-968, respectively. Proteins were expressed using E. coli SHuffle 
T7 (New England Biolabs) and purified using a HisTrap (GE Healthcare) column. After 
hexa-histidine tag cleavage and purification through a Q-Sepharose HiTrap column (GE 
Healthcare), fractions containing the respective proteins (determined by SDS PAGE) were 
concentrated and further purified by size exclusion chromatography. RBP2d165-967 could 
not be purified due to protein aggregation. Expression and purification of two human P. 
vivax RBP proteins, RBP2a160-1000 and RBP2b161-969, were performed as described 
(Gruszczyk et al., 2018b, 2016). 
Whole blood from five chimpanzees (New Iberia Research Center, Lafayette, 
Louisiana), one gorilla (Lincoln Park Zoo, Chicago, Illinois), and one rhesus macaque 
(BioIVT, Westbury, New York) was collected in ACD collection tubes (BD Biosciences). 
All ape blood samples represented left over specimens obtained during routine health 
screenings (the macaque blood was purchased). Blood was also obtained from healthy 
human volunteers at the University of Pennsylvania under IRB protocol #813699. White 
blood cells were first removed by leukocyte filtration and reticulocyte were subsequently 
enriched by spinning red blood cells (50% hematocrit) through a 65-75% (v/v) isotonic 
Percoll cushion and collecting the cell band at the interface. To assess RBP binding, 
recombinant protein was incubated with red blood cells for one hour, followed by detection 
with an RBP-specific polyclonal rabbit antibody and an anti-rabbit (Alexa Fluor 647 
labelled) secondary antibody (ThermoFisher). Between each incubation step, cells were 
washed in 180 μl PBS containing 1% BSA (Sigma). Cells were stained in the dark with BD 
Retic-Count reagent for 30 mins at room temperature, spun, and resuspended in 1.2 ml 
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of PBS prior to analysis on an Accuri flow cytometer. Experiments were performed as 
three technical replicates with the background signal from the antibody-only control 
subtracted from each binding result. 
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Accession codes. Chimpanzee P. vivax whole genome sequences and all short-read 
data have been deposited in the GenBank BioProject database under project number 
PRJNA474492, with genome annotations for PvSY43 and PvSY56 available upon 
request. Limiting dilution PCR-derived sequences have been deposited in GenBank under 
accession codes MH443154-MH443228. 
 
4.7 Supplemental Information Appendix 
Ape samples. Whole blood samples (5-10 ml) were obtained from sanctuary 
chimpanzees (Pan troglodytes) cared for at the Sanaga Yong (SY) Chimpanzee Rescue 
Center in Cameroon as previously described (Liu et al., 2010; Sundararaman et al., 2016), 
including from members of the central (P. t. troglodytes) and Nigeria-Cameroonian (P. t. 
ellioti) subspecies. These samples were obtained for veterinary purposes only or 
represented leftover specimens from yearly health examinations. None of the 
chimpanzees exhibited symptoms of malaria at the time of sampling. Blood was preserved 
in RNAlater (1:1 vol/vol) without further processing at room temperature until shipment to 
the United States and long term storage at -80°C. Blood from a wild-living habituated 
chimpanzee (“Sagu”) in the Tai Forest (P. t. verus) was obtained during an emergency 
field immobilization for treatment of a respiratory condition as described (Köndgen et al., 
2011) and immediately frozen in liquid nitrogen prior to shipment to Germany and storage 
at -80°C. A small amount of blood (frozen directly without preservation) was also available 
from a western gorilla (Gorilla gorilla) of unknown geographic origin (Gor3157), which was 
killed by hunters and confiscated by the anti-poaching program of the Cameroonian 
Ministry of Environment and Forestry (Liu et al., 2016; Sundararaman et al., 2016). Ape 
fecal samples were selected from an existing bank of chimpanzee, bonobo, and gorilla 
specimens previously shown to contain P. vivax parasite DNA (Liu et al., 2017, 2014, 
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2010). These specimens were collected non-invasively from non-habituated apes living in 
remote forest areas, with a two-letter-code indicating their field site of origin (Figure S4-
5). Additionally, dried blood spots were available from two chimpanzees and one gorilla 
housed at the Mfou National Park Wildlife Rescue Center in Cameroon, which were 
previously shown to be P. vivax positive (Liu et al., 2014). DNA was extracted from whole 
blood and dried blood spots using the QIAmp Blood DNA Mini Kit or the Puregene Core 
Blood Kit (Qiagen). Fecal DNA was extracted using the QIAamp Stool DNA mini kit 
(Qiagen). All specimens were subjected to host mitochondrial DNA analysis to confirm 
their species and subspecies origin (Liu et al., 2017, 2014, 2010). Sample collection was 
approved by the Ministry of Environment and Forestry in Cameroon and by the Ministry of 
the Environments and Forests in Cote d’Ivoire. All samples were shipped in compliance 
with Convention on International Trade in Endangered Species of Wild Fauna and Flora 
regulations and country-specific import and export permits.  
 
PCR screening for Plasmodium infection. Ape blood and fecal samples were screened 
for Plasmodium sequences by diagnostic PCR using both pan-Plasmodium and P. vivax-
specific primer sets as previously described (Liu et al., 2017, 2014, 2010). Briefly, nested 
PCR was used to amplify a 956 bp fragment of the cytochrome b gene (pan-Plasmodium 
primers) and a 295 bp fragment of the cytochrome oxidase I gene (P. vivax-specific 
primers) of the parasite mitochondrial genome. Amplicons were subjected to Sanger or 
Illumina sequencing, and phylogenetic analysis was performed to determine the species 
of the amplified Plasmodium sequences. Because the blood sample from the chimpanzee 
Sagu was previously reported to be positive for P. vivax (Kaiser et al., 2010), it was not 
rescreened for this study. 
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Selective amplification of ape P. vivax genomes. To generate P. vivax genome 
sequences from unprocessed ape blood, we used selective whole genome amplification 
(SWGA), which utilizes the highly processive phi29 DNA polymerase to preferentially 
amplify pathogen sequences from complex mixtures of target and host DNA (Leichty and 
Brisson, 2014; Sundararaman et al., 2016). Six sets of P. vivax specific primers were 
used (Table S4-1), of which pvset1 and pvset6 (also termed pvset1920) have previously 
been reported (Cowell et al., 2017). The remaining four sets (pvset2-5) were newly 
designed to increase overall P. vivax genome coverage. Using custom scripts 
(Sundararaman et al., 2016), we initially identified sequence motifs (6-12 bp in length) that 
occurred frequently in the P. vivax SalI reference genome (Carlton et al., 2008), but only 
infrequently in the human genome. These were filtered to remove primers that exhibited 
extreme melting temperatures, were predicted to form homodimers, and/or bound the SalI 
mitochondrial genome or its subtelomeric regions more than three times. The resulting 
primer sets, including pvset1 (5’-CGTTG*C*G-3’, 5’-TTTTTTC*G*C-3’, 5’-TCGTG*C*G-3’, 
5’-CGTTTTTT*T*T-3’, 5’-TTTTTTTC*G*T-3’, 5’-CCGTT*C*G-3’, 5’-CGTTTC*G*T-3’, 5’-
CGTTTC*G*C-3’, 5’-CGTTTT*C*G-3’, and 5’-TCGTTC*G*T-3’) and pvset2 (5’-
CGAAAAAA*A*A-3’, 5’-CGCAA*C*G-3’, 5’-GCGAAA*T*G-3’, 5’-CGCAC*G*A-3’, 5’-
GCGAAAA*A*A-3’, 5’-AACGAAAA*A*A-3’, 5’-AACGAA*C*G-3’, 5’-ACGAAA*C*G-3’, 5’-
CGAACG*A*A-3’, and 5’-CGAAAC*G*G-3’), exhibited high coverage of the P. vivax 
genome and low coverage of the human genome (asterisks indicate the location of 
phosphorothioate bonds necessary to prevent degradation by the phi29 polymerase). Two 
additional sets, including pvset3 (5’-CTTCGAA*C*G-3’, 5’-GCGAAAC*G*T-3’, 5’-
GGCGAAAAA*A*A-3’, 5’-TCGCGAA*A*A-3’, 5’-TTTCGCG*T*A-3’, and 5’-
TTTCGTG*C*G-3’) and pvset4 (5’-CGAAGCGG*A*G-3’, 5’-CTTCGAA*C*G-3’, 5’-
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GCGAAAC*G*T-3’, 5’-GGCGAAAAA*A*A-3’, 5’-TCGCGAA*A*A-3’, 5’-TTTCGCG*T*A-3’, 
and 5’-TTTCGTG*C*G-3’), were generated using the program swga (Clarke et al., 2017), 
which is designed to select primer sets that bind evenly across the reference genome. 
After noticing preferential amplification of AT-rich subtelomere regions in SWGA products, 
we designed two final primer sets using only GC-rich regions of the SalI reference 
sequence as the foreground genome (Cowell et al., 2017), resulting in pvset5 (5’-
AGCGAAAAAA*A*A-3’, 5’-AGCGAAC*G*T-3’, 5’-CAAACGGG*T*G-3’, 5’-
CGAACGA*A*T-3’, 5’-CGAAGCGG*A*G-3’, 5’-CGAATGGG*G*G-3’, 5’-CGAGCGA*A*C-
3’, 5’-CGTTTGG*C*G-3’, 5’-GCGGGAAAA*A*A-3’, 5’-GCGTGTA*C*G-3’, 5’-
TACGACG*A*G-3’, and 5’-TTCAGCG*C*G-3’) and pvset6 (5’-AACGAAGC*G*A-3’, 5’-
ACGAAGCG*A*A-3’, 5’-ACGACGA*A*G-3’, 5’-ACGCGCA*A*C-3’, 5’-CAACGCG*G*T-3’, 
5’-GACGAAA*C*G-3’, 5’-GCGAAAAA*G*G-3’, 5’-GCGAAGC*G*A-3’, 5’-
GCGGAAC*G*A-3’, 5’-GCGTCGA*A*G-3’, 5’-GGTTAGCG*G*C-3’, and 5’-
AACGAAT*C*G-3’). 
 SWGA was performed as described (Cowell et al., 2017; Sundararaman et al., 
2016) by amplifying whole blood DNA (100-750 ng) in a 50 μl reaction with 1x phi29 Buffer 
(New England Biolabs), 1 mM dNTPs (Roche), 3.5 μM of SWGA primers (an equimolar 
mix of primers in the set), 1% BSA and 30 units of phi29 polymerase (New England 
Biolabs). SWGA conditions included a 1 h ramp-down step (35oC to 30oC), followed by an 
amplification step for 16 h at 30oC, followed by a phi29 denaturation step for 10 min at 
65oC. SWGA products were diluted 1:1 in water, purified using AMPure Beads (Beckman 
Coulter), and stored at 4oC. To mitigate the stochastic nature of SWGA at low template 
concentrations (Sundararaman et al., 2016), genomic DNA from each ape-derived sample 
was amplified on multiple independent occasions with different primer sets (Table S4-1). 
Because pretreatment with restriction enzymes that selectively degrade host DNA can 
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improve SWGA efficiency (Sundararaman et al., 2016), some DNA aliquots were digested 
with the methylation sensitive enzymes MspJI and FspEI (5 units each) for 2 hours at 37°C 
prior to SWGA amplification (Table S4-1). To obtain sufficient quantities of parasite 
genomic DNA for sequencing, ape-derived DNA samples were subjected to multiple 
rounds (up to 4) of successive SWGA amplification, some of which were performed with 
alternating primer sets to improve genome coverage (Cowell et al., 2017).  
 
Illumina and PacBio sequencing. To generate chimpanzee P. vivax draft genomes, we 
used SWGA amplicons from samples SY43 and SY56 for Illumina and PacBio 
sequencing. These chimpanzee blood samples were selected because they were PCR 
positive for P. vivax cytb and cox1 regions, but lacked Laverania sequences. For Illumina 
sequencing, we pooled second and fourth round SWGA products to prepare short insert 
libraries using the KAPA HyperPlus kit (Roche) with an enzyme fragmentation time of 3 
minutes. Fragmentation products were purified with AMPure Beads (Beckman Coulter), 
followed by dual-sided solid phase reversible immobilization (SPRI) to select for fragments 
550 bp in length. The resulting libraries were sequenced on an Illumina MiSeq platform 
using V2 chemistry. For PacBio sequencing, second and third round SWGA products were 
pooled for library preparation. Briefly, amplification products (7.5-40 μg) were incubated 
with S1 nuclease (15 units) for 30 min at 37°C for DNA linearization, purified using AMPure 
beads, and passed through a 26 gauge blunt end needle to reduce DNA fragment size 
from >60,000 bp to ~15,000 bp. DNA was purified, eluted in 40 μl of water, and sent to the 
University of Delaware Sequencing Core where fragments of 7,000-18,000 bp length were 
size-selected using BluePippin (Sage Biosciences) prior to SMRT Bell library preparation 
and PacBio SMRT Cell sequencing. 
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Assembly of PvSY43 and PvSY56 draft genomes. Illumina MiSeq reads from 
chimpanzee blood samples SY43 and SY56 were error corrected using SPAdes 
(Bankevich et al., 2012) and then mapped to the chimpanzee reference genome using 
smalt (http://www.sanger.ac.uk/science/tools/smalt-0). Unmapped reads were extracted 
and converted to fastq files using SAMtools (Li et al., 2009) and BEDtools (Quinlan and 
Hall, 2010), respectively. PacBio reads from samples SY43 and SY56 that were longer 
than 1,500 bp and 1,000 bp, respectively, were filtered to remove chimpanzee reads using 
BLASR (Chaisson and Tesler, 2012). The resulting non-chimpanzee reads were corrected 
using proovread (Hackl et al., 2014).  
The non-chimpanzee MiSeq reads were iteratively mapped (10 times) with 
correction to the human P. vivax PvP01 reference sequence in Geneious (version 9) to 
generate a preliminary chimpanzee P. vivax consensus sequence (Kearse et al., 2012). 
Errors were identified based on low read support as described (Sundararaman et al., 
2016), the assembly was separated into contigs by splitting at assembly gaps, and contigs 
<100 bp were removed using Geneious (Kearse et al., 2012), SAMtools (Li et al., 2009), 
BEDtools (Quinlan and Hall, 2010) and custom scripts. The resulting contigs were then 
mapped to the PvP01 reference genome using ABACAS (Assefa et al., 2009). Gaps were 
closed using FGAP (Piro et al., 2014) with proovread-corrected, non-chimpanzee PacBio 
reads. After initial gap closure, regions with low read support were again removed. Finally, 
gaps were filled using IMAGE (Tsai et al., 2010) and GapFiller (Nadalin et al., 2012), 
followed by removal of likely duplications and inversions at the edges of gaps and a final 
error correction with iCORN (Otto et al., 2010).  
 The PvSY56 genome assembly was improved by de novo assembly of 
subtelomere and internal hypervariable regions. Orthologs of genes that bounded the 
subtelomeres and internal hypervariable regions in PvSalI (Pearson et al., 2016) were 
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identified in PvP01 and PvSY56, and the subtelomeres and internal hypervariable regions 
of these genomes were then defined as the sequence between the boundary gene and 
the nearest chromosome end, or the sequence between and including the two internal 
boundary genes, respectively. For de novo assembly, corrected Illumina reads from 
sample SY56 were mapped using smalt (http://www.sanger.ac.uk/science/tools/smalt-0) 
to a version of PvP01 in which the subtelomeres and internal hypervariable regions were 
masked. Reads that did not map to the masked genome were extracted using SAMtools 
(Li et al., 2009) and BEDtools (Quinlan and Hall, 2010). Since these contained a large 
number of Pseudomonas reads, we removed these by mapping to the Pseudomonas 
yamanorum genome (GenBank accession number: LT629793). The resulting reads were 
assembled using SPAdes (Bankevich et al., 2012). De novo contigs were retained if they 
were at least 2 kb in length and either could be mapped to PvP01 subtelomeres by 
ABACAS or had a blastn hit (e-value <10-4) to any of four human P. vivax genome 
assemblies (PvSalI, PvP01, PvC01, PvT01) (Auburn et al., 2016). These were ordered to 
the PvP01 genome using Companion (Steinbiss et al., 2016). Ordered de novo contigs 
that provided a better assembly of the subtelomeres or internal hypervariable regions than 
the initial PvSY56 assembly were exchanged. 
 
Genome annotation. Annotations were transferred from the human P. vivax PvP01 
reference sequence to the PvSY56 and PvSY43 genome assemblies using RATT (Otto 
et al., 2011), with additional genes in PvSY56 subtelomeres predicted using Companion 
(Steinbiss et al., 2016). All annotations on the chromosomes were visually inspected, and 
manually corrected where necessary. In roughly 10% of genes, we noted one or two base 
pair insertions or deletions in homopolymer tracts. Since these small indels were restricted 
to homopolymer regions but found throughout the genome, we reasoned that they 
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represented sequencing errors. We thus manually corrected the annotation to maintain 
the reading frame. Additional ad hoc manual corrections were performed when alignments 
indicated an error and mapped reads supported either sequence correction or removal. 
 
Partial ape P. vivax genome sequences. To generate genome sequences from 
additional ape P. vivax strains, we subjected diagnostic PCR positive chimpanzee (SY81, 
SY90, Sagu) and gorilla (Gor3157) blood DNA to SWGA analysis (Table S4-1). The 
resulting amplification products were prepared for sequencing using Nextera protocols 
and sequenced using the IIlumina MiSeq and/or MiniSeq platforms. Reads were mapped 
to the respective host reference genome (chimpanzee or gorilla) using smalt 
(http://www.sanger.ac.uk/science/tools/smalt-0) and unmapped reads were extracted 
using SAMtools (Li et al., 2009) and BEDtools (Quinlan and Hall, 2010).  
 We also mined a publicly available read database from a blood sample of a 
P. malariae-infected sanctuary chimpanzee from Gabon (GA02), which we noted 
contained a substantial number of ape P. vivax reads (Rutledge et al., 2017). Sequencing 
reads (ERS434565) were mapped to concatenated reference sequences of the 
chimpanzee P. reichenowi strain CDC (Otto et al., 2014), the human P. vivax strain P01 
(Auburn et al., 2016), and the human P. malariae strain UG01 (Rutledge et al., 2017) using 
smalt (http://www.sanger.ac.uk/science/tools/smalt-0). Reads that mapped to P. vivax 
were used for this study. 
 
Variant calling. For human P. vivax, we included genome data from previously 
sequenced field isolates from different geographic regions (SRA accession numbers 
SRP046091, SRS805942, SRP046182, SRP046094, SRP045997, SRP046126, 
SRP046031) that were not monkey adapted and classified as high-quality single infections 
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by the authors (Hupalo et al., 2016). For ape P. vivax, we analyzed genome data from four 
chimpanzee-derived samples (PvSY81, PvSY90, PvSagu, PvGA02) and one gorilla-
derived sample (PvGor3157), with uncorrected Illumina sequencing reads from PvSY43 
and PvSY56 also included to aid validation of variants. Variants were called using the 
Genome Analysis Toolkit (GATK) version 4.0 (Auwera et al., 2014). Sequencing reads 
were mapped to either PvSY56 (ape P. vivax samples) or PvP01 (human P. vivax 
samples) using bwa (http://bio-bwa.sourceforge.net), with duplicate reads removed and 
base quality scores recalibrated. ‘Known variants’ for base quality score recalibration 
(BQSR) were generated for each reference genome by a bootstrap procedure of variant 
calling, hard filtering with GATK suggested generic filters, and BQSR using the filtered 
variants, which was repeated until variants called in subsequent iterations showed little 
difference. The de-duplicated, recalibrated bam files were used to generate genomic 
variant call format files for each sample using HaplotypeCaller, with the 
OverClippedReadFilter applied. Variants were called jointly in human P. vivax and ape P. 
vivax samples, excluding insertion-deletion polymorphisms. Single nucleotide 
polymorphisms (SNPs) were hard-filtered using a set of annotations and values selected 
to minimize the number of SNPs removed at 4-fold degenerate sites, while minimizing the 
number of subtelomeric SNPs retained (QualByDepth <2.0, FisherStrand >50.0, 
RMSMappingQuality <45.0, StrandOddsRatio >2.5, GenotypeQuality_Mean <35.0, 
Quality <30.0, MappingQualityRankSumTest <-2.0 or >2.0, ReadPosRankSumTest <-6.0 
or >10.0, BaseQualityRankSumTest <-6.0 or >10.0). Dustmasker (BLAST+ suite) 
(Camacho et al., 2009) was used with default settings to identify low-complexity regions 
within each reference, which were then excluded in all samples. Since the reference 
genome for ape P. vivax was PvSY56, sites that were called as SNPs with PvSY56 reads 
were assumed to be errors in the PvSY56 assembly and excluded. The ability to call sites 
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was assessed using CallableLoci (minimum mapping quality 20, minimum depth 5, 
OverClippedReadFilter applied). Uncallable sites and sites with heterozygous SNP calls 
in a given sample were excluded from that sample. 
 
Orthologous gene alignments. Gene coding sequences were extracted from the 
chimpanzee PvSY43 and PvSY56 genome assemblies, the human P. vivax reference 
strains PvP01 and PvSalI, the P. cynomolgi reference strain PcyM (Pasini et al., 2017) 
and the P. knowlesi reference strain PknH (Pain et al., 2008). Low-complexity regions 
were masked using segmasker (BLAST+ suite) (Camacho et al., 2009). Groups of 1:1 
orthologs were identified from the RATT annotation transfer for PvP01, PvSY43 and 
PvSY56, and from PlasmoDB ortholog groups. Genes in subtelomeric or internal 
hypervariable regions, genes that were annotated as pseudogenes or had internal stop 
codons, and all vir and phist genes were excluded from the analysis. Orthologous gene 
sequences were aligned from the P. vivax genome assemblies using 
TranslatorX/MUSCLE (Abascal et al., 2010) and genes with unusually high divergence 
were inspected and manually corrected when necessary. Orthologs from P. cynomolgi 
and P. knowlesi were added to these alignments where available, excluding the 2% and 
3% of genes with the highest divergence, respectively. To add additional ape and human 
P. vivax strains to the alignment, gene sequences were generated from SNP calls by 
changing the reference sequence to the alternative allele at variant sites. Sites that were 
excluded from SNP calling were masked. Sequences of genes with >60% of sites callable 
and no internal stop codons were added to the alignments, following the alignment of the 
appropriate reference sequence. Ambiguous and masked sites as well as assembly gaps 
in any sequence were masked in all sequences. 
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Polymorphism analysis. Nucleotide diversity and divergence were calculated from gene 
alignments using the dist.dna function with the ‘raw’ model in the ape R package (Paradis 
et al., 2004) and custom scripts. Synonymous (Ps) and nonsynonymous (Pn) 
polymorphisms were counted by determining the effect of each variant allele on the codon 
in the reference genome (PvSY56 or PvP01). If a site had multiple alternative alleles, each 
of these was counted as a separate SNP. Synonymous and nonsynonymous fixed 
differences were counted by comparing codons between P. cynomolgi strain M and 
PvSY56 or PvP01, after exclusion of sites that were polymorphic in ape P. vivax or human 
P. vivax, respectively, and assuming the mutation path with the smallest number of 
nonsynonymous changes. The neutrality index [NI = (Pn/Ps)/(Dn/Ds)] of each gene was 
calculated from the number of polymorphisms within ape and human P. vivax and the 
number of fixed differences (Ds and Dn) from the P. cynomolgi strain PcyM. Density 
distributions of log2(NI) were generated in R for genes that had a defined log2(NI) value in 
both ape and human P. vivax. McDonald-Kreitman tests were performed in R, using a two-
tailed Fisher exact test (fisher.test), followed by correction of the p-values for multiple 
testing (p.adjust, method=fdr). 
Site frequency spectra were generated from SNP calls from the MalariaGen P. 
vivax Genome Variation project, using a subset of Southeast Asian field isolates 
(Cambodia, Indonesia, Laos, Myanmar, Malaysia, Papua New Guinea, Thailand and 
Vietnam) for which ≥ 80% of variant loci had been called. 173 samples met this inclusion 
criterion. Heterozygous calls were counted as one occurrence of the reference and one of 
the alternative allele. The number of allele calls varied between sites because of missing 
data and heterozygous SNPs. To standardize the number of calls per site without losing 
large amounts of data, we down-sampled to 168 calls per site, excluding sites with fewer 
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calls (this threshold was chosen such that 95% of sites were retained). 4-fold and 0-fold 
degenerate sites were identified in the SalI reference sequence, as this was the reference 
utilized in the MalariaGen SNP data set (Pearson et al., 2016). Alignments of orthologous 
genes from PvSalI, PvSY56 and PcyM were generated with TranslatorX/MUSCLE and 
used with the est-sfs (Keightley and Jackson, 2018) unfolder to identify the derived allele 
at each site and calculate the frequency spectrum. 
 
Single genome amplification. To increase the number of geographically diverse ape 
parasite sequences, we subjected P. vivax positive ape blood and fecal samples to single 
genome amplification (SGA), which utilizes end-point-diluted template DNA and thus 
generates Plasmodium sequences devoid of PCR-induced sequence artifacts (Liu et al., 
2014, 2010). Five nuclear gene regions were targeted to complement existing genome 
data, including PVP01_1216000 (610bp), PVP01_1418300 (476 or 491bp), 
PVP01_1418500 (809 or 815bp), PVP01_1418600 (351bp), and PVP01_1418800 
(576bp). These regions were amplified using first round primers Pv6000F1 (5'-
ATGGAAAGGCAGGGCGACGC-3' and Pv6000R1 (5'- 
GCTGCACAGGTAGGAGATGTACT-3'), Pv8300F1 (5'-
AACGTGGAGATGTAATTCCTGCC-3' and Pv8300R1 (5'-
TTGTGTGCATTTTCGAGCAGGCTG-3'), Pv8500F1p (5'-
ATGGAGGACGAGACGGAGAAC-3') and Pv8500R1 (5'-
CTGAAATAGATGTAGTTGTAGAAGG -3'), Pv8600F1 (5'-
AAGAMAAACATTTTGGAAAACGCAG-3') and Pv8600R1 (5'-TCAAAACTCC 
ATGGGGATGTTCTGC-3'), as well as Pv8800F1 (5'-
TGTACGACTCGATGAGTTACTTCC-3') and Pv8800R1 (5'-
TCACAGGAAGACCGTCGAAAACG-3'), respectively. Samples were multiplexed using 
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2.5 μl of end-point diluted DNA in a 25 μl reaction volume containing 0.5 μl dNTPs (10mM 
of each dNTP), 2.5 μmol of each first round primer, 2.5 μl PCR buffer, 0.1 μl BSA solution 
(50μg/ml), and 0.25 μl expand long template enzyme mix (Expand Long Template PCR 
System, Sigma). Cycling conditions included an initial denaturing step of 2 min at 94°C, 
followed by 15 cycles of denaturation (94°C, 10 sec), annealing (45°C, 30 sec), and 
elongation (68°C, 1 min), followed by 35 cycles of denaturation (94°C, 10 sec), annealing 
(48°C, 30 sec), and elongation (68 °C, 1 min; with 10-sec increments for each successive 
cycle), followed by a final elongation step of 10 minutes at 68°C. For second round PCR, 
2 µl of the first round product were amplified using second round primers Pv6000F2 (5'- 
TAGAGGAGCAAGAGCGAGTGC-3') and Pv6000R2 (5'-
TTCGACTCCTGCATTTGCCACTTG-3'), Pv8300F2 (5'-TTAACACGGAGGA 
GGCCACAGAATG-3') and Pv8300R2 (5'-CTCTCTCGTTTGTCTGCCTTCTTCC-3'), 
Pv8500F2p (5'-CAGAACTTGAAATGTCCAGGGAG-3') and Pv8500R2 (5'-
AGCTGCCAGTTGTGCTTGTCT 
GCG-3'), Pv8600F2 (5'-GCAAAGGACATGACGCAAAGTG-3') and Pv8600R2 (5'-
TTTCATCAAACGTGCATCTCTTGG-3'), as well as Pv8800F2 (5'-
CTTATTTTGCTACGAAGATTTGGG-3') and Pv8800R2 (5'-
GCAATATATCCGCCTCTCTCCTC-3'), respectively. Cycling conditions included an initial 
denaturation step of 2 min at 94°C, followed by 60 cycles of denaturation (94°C, 10 sec), 
annealing (52°C, 30 sec), and elongation (68°C, 1 min), followed by a final elongation step 
of 10 minutes at 68°C. Amplification products were sequenced directly without interim 
cloning.  
 We also used SGA to amplify regions of ape P. vivax rbp genes, which in human 
P. vivax contained inactivating mutations. Four fragments were targeted, including rbp2d_ 
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frameshift (81bp), rbp2e_frameshift (120bp), rbp2e_stop (61bp), and rbp3_stop (52bp). 
These regions were amplified using first round primers anfsRBP2d_1F (5'-
AATGATGCAAAGAATTTTATTTCGGAT-3' and anfsRBP2d_1R (5'-
ACGCTTTCCTTTTCACTATCAATT-3'), anfsRBP2e_1F (5'- 
TGCAAGAAAACCATCTCGCT-3' and anfsRBP2e_1R (5'-
TGCTCTCTTCATTTCTTCGTCA-3'), anstopRBP2e_1F (5'-
ACAAAGCAAAAGGGCGAAGT-3') and anstopRBP2e_1R (5'- 
AGCGGATTCTTTGTGACTCCT-3'), as well as anstopRBP3_1F (5'- 
AATGAAGGGGAACTGAAAGGT-3') and anstopRBP3_1R (5'-
TTTCTTTCGCCGCACTATGG-3'), respectively. PCRs were multiplexed using 2.5 μl of 
end-point diluted sample DNA in a 25 μl reaction volume, containing 0.5 μl dNTPs (10mM 
of each dNTP), 2.5 μmol of each first round primer (4 pairs), 2.5μl PCR buffer, 0.1 μl BSA 
solution (50μg/ml), and 0.25 μl expand long template enzyme mix (Expand Long Template 
PCR System, Sigma). Cycling conditions included an initial denaturing step of 2 minutes 
at 94°C, followed by 50 cycles of denaturation (94°C, 10 sec), annealing (48°C, 30 sec), 
and elongation (68°C, 30 sec), followed by a final elongation step of 10 minutes at 68°C. 
For second round PCR, 2 l of the first round product were amplified using second round 
primers anfsRBP2d_2F (5’-AGATGATCTGAATAAACGTTTCACA-3’) and 
anfsRBP2d_2R (5’-ACAAATTCGTCAACGTTAAGTGT-3’), anfsRBP2e_2F (5’-
AGGACAACACATATGCAGTTACT-3’) and anfsRBP2e_2R (5’-
ACTTTTATGGTCACCGTAGATACA-3’), anstopRBP2e_2F (5’- 
ACACATGATATTGATGCACTCAAAGA-3’) and anstopRBP2e_2R (5’-
TCTTGATTTGTCTCACTATTCTCTGT-3’), as well as anstopRBP3_2F (5’- 
ACAATGTGTGTAAGAATATTGAGACCA-3’) and anstopRBP3_2R (5’- 
TGGGACACATTTTCTATACAGGCT-3’), respectively. Cycling conditions included an 
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initial denaturation step of 2 minutes at 94°C, followed by 50 cycles of denaturation (94°C, 
10 sec), annealing (52°C, 30 sec), and elongation (68°C, 30 sec), followed by a final 
elongation step of 10 minutes at 68°C. Amplification products were sequenced directly 
without interim cloning. 
 
Phylogenetic analyses and rbp gene comparisons. To examine the evolutionary 
relationships of ape and human P. vivax strains, phylogenetic trees were constructed from 
(i) nuclear gene sequences generated by SGA from infected ape blood or fecal DNA, (ii) 
PvP01, PvSalI, PvSY56, PvSY43, P. cynomolgi and P. knowlesi genome assemblies, and 
(iii) SNP data by changing the reference sequence to the alternative allele at variant sites. 
Sequences were aligned with TranslatorX/MUSCLE and the alignments manually 
corrected, including truncation to the SGA amplicon where appropriate and removal of 
ambiguously aligned regions. Trees were generated using PhyML with a GTR+G model 
of nucleotide evolution, 10 random starts and best of NNI/SPR trees, and bootstrap values 
calculated from 100 replicates. For neighbor-joining trees, matrices of pairwise genetic 
distances were calculated from alignments of genes that were covered in all strains, and 
unrooted trees were generated from these matrices in R with ape ‘nj’. Phylogenetic 
networks were generated from the same alignments in SplitsTree4 (Huson and Bryant, 
2006) using SplitDecomposition with uncorrected p-distances. 
Ape and human P. vivax rbp genes were identified from genome annotations. For 
rbp1a, sequences generated from SNP data were also included. For other Plasmodium 
species, rbp genes were identified from annotations in the P. malariae strain PmUG01 
(PmUG01_07014300, PmUG01_07014200, PmUG01_08058500, PmUG01_12081700, 
PmUG01_14085600) (Rutledge et al., 2017), the P. knowlesi strain H (PKNH_0700200, 
PKNH_1472300) (Pain et al., 2008), the P. cynomolgi strains B and Berok 
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(PCYB_071060, PCYB_081060, PCYB_053840, PCYB_071010, PCYB_053850, 
PCYB_147650, JQ422038) (Tachibana et al., 2012), the P. inui strain San Antonio 1 
(C922_04999, C922_01465) (PlasmoDB) and the P. fragile strain Nilgiri (AK88_00929, 
AK88_00936) (PlasmoDB). Blastn search using P. vivax rbp genes also identified two non-
annotated pseudogenes (an ortholog of rbp2a in the P. cynomolgi strain B, and nbp1 in P. 
knowlesi) as well as pseudogenes annotated as multiple gene fragments (rbp1a, rbp2a 
and rbp2e orthologs in P. inui; rbp1b and rbp3 orthologs in P. fragile). Sequences were 
aligned with TranslatorX/MUSCLE, and alignments manually corrected. A tree was 
constructed for the most conserved region of this alignment (corresponding to nucleotides 
478-7938 in PvP01 rbp1a) using PhyML with a GTR+G model of nucleotide evolution, 10 
random starts and best of NNI/SPR trees, and bootstrap values calculated from 100 
replicates. For tests of selection, branch-site models were fitted to the data using codeml 
in the PAML package (Yang, 2007), using alignments excluding P. ovale spp. and P. 
malariae, which were considered too divergent. The fit of the null model (no selection) was 
compared with the fit of the model with selection along the branch of the PhyML maximum-
likelihood phylogenetic tree leading to human P. vivax (foreground branch), by comparing 
twice the difference in log-likelihood (2∆lnL) with a Χ2 distribution with one degree of 
freedom. 
 Published human P. vivax reads (Hupalo et al., 2016; Pearson et al., 2016) were 
downloaded from the SRA database and mapped to rbp2d (PVP01_1471400 and 
PVX_101585), rbp2e (PVP01_0700500), rbp3 (PVP01_1469400), rbp2p1 
(PVP01_0534400), and rbp2p2 (PVX_101590) sequences using smalt 
(http://www.sanger.ac.uk/science/tools/smalt-0). Mapped reads were extracted, 
converted to fastq files using SAMtools (Li et al., 2009) and BEDtools (Quinlan and Hall, 
2010), and then imported into Geneious (version 9) (Kearse et al., 2012) to again be 
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mapped to the references. Because a truncation of rbp2d has been identified in some 
human P. vivax field isolates (Hietanen et al., 2016), including PvP01, reads were mapped 
to both the SalI and PvP01 alleles of rbp2d, and the correct allele for each human P. vivax 
sample was chosen by visual inspection of read mapping. A majority consensus sequence 
was called for all positions with ≥3-fold coverage. Alignments of genes with complete 
coding sequences were made to chimpanzee P. vivax rbp genes and the positions of 
frameshifts and pseudogenes were noted. After identification of the ancestral stop or 
frameshift mutation, consensus sequences from samples with fewer than 3-fold coverage 
in some regions of the genes were inspected to verify that the ancestral mutation was 
indeed in all sequenced human P. vivax strains.  
 
Recombinant RBP expression and polyclonal rabbit antibody production. 
Chimpanzee P. vivax rbp2d, rbp2e and rbp3 gene sequences were generated by aligning 
PvSY43 and PvSY56 sequencing reads to human P. vivax reference sequences. Deduced 
amino acid sequences spanning positions 100 to 1,000 of RBP2d (from PvSY43), RBP2e 
(from PvSY56), and RBP3 (from PvSY56) were codon optimized for expression in 
Escherichia coli, and the synthesized genes were purchased from Eurofins Genomics 
(RBP2d and RBP3) and GenScript (RBP2e). These were then used to generate shorter 
gene fragments (RBP2d165-967, RBP2e156-957, RBP3149-968) predicted to express stable 
recombinant proteins, which included the respective binding domain based on homology 
to human P. vivax RBP2a and RBP2b (van den Ent and Löwe, 2006). RBP2d165-967, 
RBP2e156-957 and RBP3149-968 were cloned into the pET-32a(+) vector (Novagen), which 
expresses proteins with a hexa-histidine tag (C-terminus) but also contains a tobacco etch 
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virus (TEV) protease cleavage site to allow removal of this tag. All clones were sequence 
confirmed.  
Proteins were expressed using E. coli strain SHuffle T7 (New England Biolabs) and 
Terrific Broth (TB) supplemented with 100 μg/ml of carbenicillin. Flasks containing 1 liter 
of medium were incubated in a Multitron shaker (Infors HT) at 37°C at 200 rpm. At OD600 
of ~1.0, isopropyl-(β)-D-thiogalactopyranoside (IPTG, Astral) was added to a final 
concentration of 1.0 mM and protein expression was allowed to continue for 20 hours at 
16°C. Cells were harvested by centrifugation at 6,000 x g, resuspended in freezing buffer 
containing 50 mM TrisHCl pH 7.5, 500 mM NaCl and 10% (v/v) glycerol supplemented with 
cOmplete EDTA-free protease inhibitor cocktail (Roche), flash-frozen in liquid nitrogen and 
stored at -80°C until further processing.  
For protein purification, bacterial cell pellets were thawed on ice and resuspended 
in freezing buffer supplemented with 0.5 mg/ml of DNase and 1.0 mg/ml of lysozyme 
(Sigma-Aldrich). Cells were sonicated and centrifuged at 30,000 x g for 45 minutes at 4°C, 
and the resulting supernatant was added to a 5 ml HisTrap column (GE Healthcare). All 
unbound material was washed off using at least 10 column volumes of washing buffer (50 
mM TrisHCl pH 7.5, 500 mM NaCl, 10% (v/v) glycerol, 20 mM imidazole). Bound protein 
was eluted from the column using the same buffer, but with the imidazole concentration 
increased to 300 mM. The eluted fractions were pooled and dialyzed in the presence of 
TEV protease in a buffer containing (i) 20 mM CAPS pH 10.0 and 100 mM NaCl for 
RBP2d165-967, (ii) 20 mM TrisHCl pH 8.5 and 100 mM NaCl for RBP2e156-957, and (iii) 20 
mM TrisHCl pH 8.0 and 100 mM NaCl for RBP3149-968. The resulting sample was added to 
a 5 ml Q-Sepharose HiTrap column (GE Healthcare), with unbound material washed off 
using at least 10 column volumes of the buffer. The protein was eluted using a gradient 
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(0-50%) of (i) 20 mM CAPS pH 10.0 and 1.0 M NaCl for RBP2d165-967, (ii) 20 mM TrisHCl 
pH 8.5 and 1.0 M NaCl for RBP2e156-957, and (iii) 20 mM TrisHCl pH 8.0 and 1.0 M NaCl 
for RBP3149-968. Collected fractions (2.5 ml) were analyzed on SDS PAGE and those 
containing protein were concentrated using Vivaspin 15 Turbo centrifugal concentrators 
with a molecular weight cut-off 5 kDa (Sartorius) and injected onto S200 Superdex 16/600 
size exclusion column (GE Healthcare) preequilibrated with (i) 20 mM NaHEPES pH 7.5, 
500 mM NaCl, 5 mM β-mercaptoethanol and 5% (v/v) glycerol for RBP2d165-967, (ii) 20 mM 
TrisHCl pH 8.5, 300 mM NaCl and 10% (v/v) glycerol for RBP2e156-957, and (iii) 20 mM 
TrisHCl pH 8.5, 300 mM NaCl and 10% (v/v) glycerol for RBP3149-968. Fractions containing 
pure proteins (2 ml) were pooled, concentrated and flash-frozen in liquid nitrogen. 
RBP2e156-957 and RBP3149-968 yielded monodisperse peaks; however, RBP2d165-967 was 
heavily aggregated despite using high salt and a reducing agent in the buffer. To examine 
protein folding, circular dichroism (CD) data (Figure S4-8) were collected using a CD 
spectrometer Model 410 (Aviv Biomedical) and analyzed as described (Gruszczyk et al., 
2016). Expression and purification of RBP2a160-1000 and RBP2b161-969 has been described 
previously (Gruszczyk et al., 2018b, 2016). 
Polyclonal rabbit antibodies were generated by the Walter and Eliza Hall Institute 
(WEHI) Antibody Facility. Rabbits were immunized 5 times with 150 μg of the respective 
recombinant protein. The first immunization was administered in Complete Freund’s 
adjuvant and the remainder in Incomplete Freund’s Adjuvant. Rabbit IgG fractions were 
purified from serum using Protein G sepharose. These studies were approved by the WEHI 
Institutional Animal Care and Use Committee. 
 
RBP binding assays. 30-100 ml of whole blood was collected in 10 ml ACD blood 
collection tubes (BD Biosciences) from five chimpanzees (New Iberia Research Center, 
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Lafayette, Louisiana), one gorilla (Lincoln Park Zoo, Chicago, Illinois), and one rhesus 
macaque (BioIVT, Westbury, New York). All ape blood samples represented left over 
specimens obtained during routine health screenings and were approved by the 
respective Institutional Animal Care and Use Committees. The macaque blood was 
purchased. Blood was also obtained from healthy human volunteers at the University of 
Pennsylvania under IRB protocol #813699 with informed consent (kindly provided by R. 
Collman). Whole blood was centrifuged at 1,500 x g for 20 minutes (maximum acceleration 
and low brake speed). Buffy coats containing leukocytes were removed and red blood 
cells were resuspended in their respective plasma or in PBS. Resuspended red blood 
cells were passed through a SepaCell R-500 II filter (Fenwal) or an Acrodisc filter with 
leukosorb media (PALL) to remove remaining leukocytes. Reticulocytes were enriched by 
carefully layering 5.5 ml of red blood cells diluted in plasma (50% hematocrit) over 6 ml of 
a 65-75% (v/v) isotonic Percoll cushion. The percent Percoll was varied to achieve 
maximum reticulocyte enrichment for each sample after testing a small aliquot on a 70% 
(v/v) isotonic Percoll cushion. Blood layered over Percoll was centrifuged at 1,650 x g for 
20 min (maximum acceleration and low brake speed) and the resulting cell band at the 
Percoll interface was removed, pooled, washed three times in PBS, and stored in RPMI 
(Gibco). Although this protocol achieved reticulocyte enrichment for human blood samples 
(up to 60%), this was not the case for ape and monkey blood samples. Although different 
centrifugation speeds (1,200 – 2,100 x g), Percoll densities (65-75%), and PBS 
formulations (Gibco 1x and 10x DBPS, Ambion 10x PBS pH 7.4, and human tonicity 
(HT)PBS) were tested, we were unable to achieve reticulocyte enrichment of more than 
2% for the great majority of ape and monkey samples, as measured by thiazole orange 
staining by flow cytometry (BD Retic-Count; BD Biosciences). The exception was a blood 
sample from an anemic chimpanzee, which yielded 4.0% reticulocyte enrichment. For 
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each chimpanzee and macaque, we selected the fraction with the highest percentage of 
reticulocytes for subsequent binding studies. The single gorilla blood sample was of limited 
quantity and thus only subjected to leukocyte filtration with no reticulocyte enrichment 
performed. Human control samples were diluted until the percentage of enriched 
reticulocytes matched those of the ape and monkey samples (0.5 – 4% by flow cytometry).  
 For binding assays, 800,000 red blood cells were incubated with 5 μg of 
recombinant protein in 100 μl of PBS with 1% (w/v) BSA at room temperature for one hour 
after gentle mixing. Cells were then washed with 180 μl PBS containing 1% BSA, spun at 
4,000 x g for 1 minute, resuspended in 180 μl PBS containing 1% BSA, and incubated 
with a polyclonal rabbit antibody (1 μg) raised against the respective protein. Following 
incubation at room temperature for one hour, cells were washed again, and then incubated 
with a secondary (Alexa Fluor 647 labeled) chicken anti-rabbit antibody (1 μg). After a final 
wash, 100 µl of room temperature thiazole orange (TO) (Retic-Count Reagent; BD 
Biosciences) was added and incubated for 30 min. Supernatant was removed and cells 
were resuspended in 1.2 ml PBS immediately prior to analysis on an Acurri flow cytometer. 
Antibody only controls were run in parallel, omitting the protein in the first incubation but 
otherwise following the same protocol. Approximately 200,000 events were captured for 
each sample. Data were analyzed using FlowJo software, gating on erythrocytes, then 
single cells, then TO-positive (reticulocyte) or TO-negative (normocyte) populations. 
Binding signal for each sample was obtained for both reticulocyte and normocyte 
populations by subtracting the florescence value of the corresponding antibody-only 
control from the sample value. RBP binding experiments were performed three times per 
sample on different days, with the average of these values reported. 
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SI Figures 
 
Figure S4-1. Sequence diversity between ape and human P. vivax. (A) Nucleotide 
sequence diversity (π) calculated for all coding sites in 3,955 genes of two chimpanzee 
(PvSY43 and PvSY56) and two human (PvSalI and PvP01) P. vivax strains. (B) Nucleotide 
sequence diversity (π) for all coding sites in 4,259 genes of six chimpanzee and nine 
human P. vivax strains (Table S4-2). (C) Nucleotide sequence diversity (π) for all coding 
sites in 3,904 genes of five chimpanzee and nine human P. vivax strains, after removal of 
the multiply infected PvSY43 sample. (D, E) Nucleotide sequence diversity calculated for 
chimpanzee and human P. vivax strains as in (B), but considering only 4-fold degenerate 
sites (D, 3,837 genes) or 0-fold degenerate sites (E, 4,259 genes). For all plots, the 
interquartile range is shown as a box, with the upper and lower 99th percentiles indicated 
by whiskers (outliers are shown as black dots). For each alignment set, genes with fewer 
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than 35 aligned sites were excluded (2 genes in A, 3 genes in B and E, 3 genes in C, 425 
genes in D) to avoid plotting spurious extreme values from very short sequences (these 
genes were retained in Table 4-2). 
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Figure S4-2. Chimpanzee P. vivax core genes used for diversity analyses. The 
number of genes (y-axis) that could be compared for two or more chimpanzee P. vivax 
strains (x-axis) is indicated. PvSY56 and PvSY43 genes were included if they covered 
90% or more of the length of the corresponding ortholog in the human PvP01 reference. 
Genes from the other chimpanzee parasites were included if the number of callable sites 
covered at least 60% of sites in the corresponding PvSY56 gene (with ≥5 reads mapped).  
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Figure S4-3. Phylogenetic network analysis of ape and human P. vivax strains. (A) 
A phylogenetic network was constructed using split decomposition from pairwise 
distances in an alignment of 232 nuclear genes. Nine human (black) and six chimpanzee 
(red) P. vivax strains are shown (the inset shows the human P. vivax strains in greater 
detail). The topology confirms the overall relationships of human and chimpanzee P. vivax 
depicted in Figure 4-2A. (B) As in (A), but based on 6 nuclear genes with coverage in a 
gorilla P. vivax strain (green). The same human and chimpanzee P. vivax strains were 
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included except for PvSY81, which did not cover these genes. The network suggests that 
some recombination has occurred between gorilla and ape parasites in these genes, but 
supports the overall topology shown in Figure 4-2B. 
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Figure S4-4. Phylogenetic relationships of ape and human P. vivax using whole 
genome and SNP data. Maximum likelihood trees, rooted with P. knowlesi, are shown 
for 10 nuclear genes (gene names and lengths for the PvP01 reference are indicated). P. 
vivax sequences from humans, chimpanzees and gorillas are shown in black, red and 
green, respectively. The monkey parasite species P. cynomolgi (strain M) and P. knowlesi 
(strain H) were included as outgroups (purple). Bootstrap values ≥70 are shown. The scale 
bar represents 0.02 substitutions per site.  
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Figure S4-5. Geographical origin of P. vivax-positive ape samples. Study sites are shown 
in relation to the natural ranges of chimpanzees (Pan troglodytes verus, black; P. t. ellioti, 
purple; P. t. troglodytes, red; P. t. schweinfurthii, blue), bonobos (Pan paniscus, orange), 
western lowland gorillas (Gorilla gorilla gorilla, dashed red) and eastern lowland gorillas (Gorilla 
beringei graueri, dashed blue) (Caldecott and Miles, 2005). Circles denote forest sites, while 
triangles indicate the location of sanctuaries, with colors denoting whether chimpanzee (red) 
or gorilla (green) P. vivax sequences were obtained (BQ, Belgique; DG, Diang; EK, E’kom; GT, 
Goualougo Triangle; KA, Kabuka; MO, Mfou National Park Wildlife Rescue Center; MT, Minta; 
NK, Ndongo; SY, Sanaga Yong Chimpanzee Rescue Center; TA, Tai Forest). The chimpanzee 
infected with PvGA02 was previously reported (Rutledge et al., 2017) to have been sampled 
in Park of La Lékédi (LL). 
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Figure S4-6. Phylogenetic relationships of ape and human P. vivax. Maximum 
likelihood trees rooted with P. knowlesi are shown for fragments of three nuclear genes 
(PVP01_1216000, PVP01_1418600, PVP01_1418800; the fragment size in PvP01 is 
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indicated). P. vivax sequences from humans, chimpanzees and gorillas are shown in 
black, red and green, respectively. Sequences generated by SWGA or derived from 
published data (see Table S4-2) are shown in bold. SGA-amplified sequences from ape 
fecal and blood samples include a two-letter code to denote the field site (Figure S4-5), 
lower case letters to indicate their species origin (ptt: P. t. troglodytes, red; pte: P. t. ellioti, 
red; pts: P. t. schweinfurthii, red; ggg: G. g. gorilla, green), a the sample number, as well 
as SGA dilution and well position (e.g., EKggg1179_SGA2.5 represents an SGA derived 
sequence amplified from a 1:2 dilution of fecal DNA from a western lowland gorilla sample 
1179 and identified at position 5 of a plate of multiple PCR reactions). Sequences of P. 
carteri, a parasite species closely related to P. vivax that has thus far only been identified 
in wild-living chimpanzees, are shown in blue. GenBank accession numbers for SGA 
sequences are listed in Table S4-4. The monkey parasite species P. cynomolgi (strain M) 
and P. knowlesi (strain H) were included as outgroups (purple). Bootstrap values ≥70 are 
shown for clades containing at least two non-identical tips. The scale bar represents 0.02 
substitutions per site.  
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Figure S4-7. Ape P. vivax encode three intact rbp genes that are pseudogenized in 
human P. vivax. Alignments are shown for chimpanzee (red), gorilla (green) and human 
(black) P. vivax rbp2d, rbp2e and rbp3 gene sequences (numbers indicate the nucleotide 
position within the respective gene). ‘Pv’ denotes sequences from genome-wide analyses 
(Table S4-2) which were generated by mapping sequencing reads to the PvSY56 
reference and calling bases covered by ≥3 reads. All gorilla P. vivax sequences were 
derived by single genome amplification (SGA) from the same multiply infected sample 
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(SAggg3157) and represent individual parasites. Nucleotides that differ from the PvSY56 
reference are highlighted, with dots indicating sequence identity. Inactivating mutations 
that cause frameshift and premature stop codons in all published human P. vivax strains 
are boxed. 
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Figure S4-8. Circular dichroism spectra of recombinant RBP proteins from 
chimpanzee P. vivax strains. Far UV circular dichroism spectra of two newly expressed 
chimpanzee P. vivax proteins PvRBP2e156-957 (red) and PvRBP3149-968 (green) are 
compared to the CD spectrum of the human P. vivax PvRBP2b161-969 protein (blue) as 
previously reported (Gruszczyk et al., 2018b). The mean residue molar ellipticity (θ, y-
axis) is plotted relative to the wavelength (nm; x-axis). The three spectra superimpose, 
suggesting proper folding of the newly expressed proteins. 
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Figure S4-9. Binding of chimpanzee and human P. vivax RBP proteins to red blood 
cells from different host species. The binding of human P. vivax RBP2a and RBP2b 
and chimpanzee P. vivax RBP2e and RBP3 proteins to normocytes (A) and reticulocytes 
(B) from one gorilla (G), four chimpanzees (C1-C4), four humans (H1-H4), and one 
macaque (M) is shown. Columns indicate the percentage of red blood cells (RBCs) that 
bound the respective RBP proteins after subtracting background binding in the absence 
of protein. Error bars represent one standard deviation. All red blood cell preparations 
were tested three times in independent technical replicates. 
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Figure S4-10. Alignment of human and ape transferrin receptor 1 (TfR1) protein 
sequences. An alignment of the deduced amino acid sequences of human (GRCh38, 
NC_000003.12), chimpanzee (Pan troglodytes verus, XM_003310191.3), bonobo (Pan 
paniscus, XM_003806407.2), gorilla (Gorilla gorilla gorilla, XM_004038250.2), and 
orangutan (Pongo abelii, NM_001131591.1) TfR1 sequences is shown. Residues that 
differ from the human sequence are highlighted, with dots indicating sequence identity. 
Alanine mutagenesis of TfR1 residues that were identified to form stacking interactions or 
salt bridges with RBP2b are boxed (Gruszczyk et al., 2018b), with border color indicating 
the degree to which the mutation abrogated invasion complex formation (no effect, green; 
moderate effect, orange; severe effect, red). 
 
176 
 
 
Figure S4-11. Binding of chimpanzee and human P. vivax RBP proteins to 
reticulocyte-enriched chimpanzee and human red blood cells. (A) Dot plots are 
shown that depict the binding of human P. vivax RBP2a and RBP2b and chimpanzee P. 
vivax RBP2e and RBP3 proteins to chimpanzee (first row) and human (third row) red blood 
cells, respectively. Both the chimpanzee and the human blood sample contained a large 
fraction of reticulocytes (the human sample was diluted so that equivalent numbers of 
reticulocytes were tested in the binding assays). The x-axis depicts thiazole orange (TO) 
staining of reticulocytes; the y-axis indicates protein binding as detected using an RBP-
specific polyclonal rabbit antibody, followed by a secondary chicken (Alexa 647 labeled) 
anti-rabbit antibody. The position of gates denoting normocytes versus reticulocytes as 
well as protein binding versus no protein binding are shown by vertical and horizontal 
lines, respectively. Numbers indicate the percentage of total cells within the respective 
gate. Antibody-only negative controls in which no protein was added are shown in the 
second (chimpanzee cells) and fourth (human cells) rows, respectively. (B, C) The 
percentage of chimpanzee (red) and human (black) normocytes (B) and reticulocytes (C) 
that bound the respective RBP proteins are shown. Three independent replicates were 
performed and background signal from the antibody-only control was subtracted (see SI 
Appendix, Materials and Methods). 
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Table S4-1. Select whole genome amplification and sequencing of ape P. vivax 
genomes  
*P. vivax genomes were amplified by SWGA from whole blood DNA of four sanctuary chimpanzees 
(SY43, SY56, SY81, SY90) housed at the Sanaga Yong (SY) Chimpanzee Rescue Center, one 
wild-living habituated chimpanzee (Sagu) from the Tai forest, and one western lowland gorilla 
bushmeat sample (Gor3157) confiscated by the Cameroonian Ministry of Environment and 
Forestry. 
#pvset, set of P. vivax-specific SWGA primers (see text for primer sequences). 
†Aliquots of whole blood DNA were digested with the methylation dependent restriction enzymes 
MspJI and FspEI prior to SWGA to selectively degrade host DNA (Sundararaman et al., 2016). 
‡Illumina sequencing was performed on MiSeq or MiniSeq platforms. 
§PacBio sequencing was performed on a PacBio RS II platform. 
 
  
Blood 
Sample* Digest
† pvset1# pvset2# pvset3# pvset4# pvset5# pvset6# Illumina‡ PacBio§ 
SY43 + +    +  + + 
SY56 + + + +  + + + + 
SY81 + +    + + +  
SY90 + +    + + +  
Sagu  +  +  + + +  
Gor3157 + +   + + + +  
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Table S4-2. Host species and geographic origin of ape and human P. vivax isolates 
 
P. vivax  
strain 
Host  
species* 
 
Country  
Genes  
analyzed 
 
Reference 
PvSY43 P.t.t. Cameroon 3,973 This study 
PvSY56 P.t.e. Cameroon 4,262 This study 
PvSY81 P.t.t. Cameroon 695 This study 
PvSY90 P.t.e. Cameroon 2,159 This study 
PvSagu P.t.v. Cote d’Ivoire 2,542 This study 
PvGor3157 G.g.g. Cameroon 10 This study 
PvGA02# P.t.t. Gabon 3,005 Rutledge et al., 2017 
PvColombia human Colombia 4,257 Hupalo et al., 2016 
PvIndia human India 4,258 Hupalo et al., 2016 
PvMexico human Mexico 4,258 Hupalo et al., 2016 
PvMyanmar human Myanmar 4,258 Hupalo et al., 2016 
PvPeru human Peru 4,259 Hupalo et al., 2016 
PvPNG human Papua New Guinea 4,260 Hupalo et al., 2016 
PvThailand human Thailand 4,254 Hupalo et al., 2016 
PvSalI human El Salvador 4,241 Carlton et al., 2008 
PvP01 human Indonesia 4,262 Auburn et al., 2016 
*P.t.t., Pan troglodytes troglodytes; P.t.e., P. t. ellioti; P.t.v., P. t. verus; G.g.g., Gorilla gorilla 
gorilla;  
#PvGA02 sequences were derived from a read database generated from the blood of a sanctuary 
chimpanzee (GA02) that was coinfected with ape P. malariae and P. vivax (Rutledge et al., 2017). 
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Table S4-3. Polymorphisms between chimpanzee and human P. vivax and P. 
cynomolgi 
 Polymorphisms  
in P. vivax 
Fixed differences from  
P. cynomolgi 
 NS* S* NS/S NS† S† NS/S NI‡ 
Chimpanzee P. vivax# 27,209 41,177 0.66 266,011 383,274 0.69 0.95 
Human P. vivax# 8,858 6,715 1.32 276,851 400,376 0.69 1.91 
*The number of nonsynonymous (NS) and synonymous (S) polymorphisms was calculated by 
counting the number of SNPs that changed (NS) or did not change (S) the amino acid sequence of 
PvSY56 (ape P. vivax) or PvP01 (human P. vivax). 
†The number of nonsynonymous (NS) and synonymous (S) differences was calculated between P. 
cynomolgi strain M and PvSY56 (ape P. vivax) or PvP01 (human P. vivax); sites that were 
polymorphic in ape or human P. vivax were excluded. 
‡NI, neutrality index. 
#A common set of 3,912 genes was compared among six chimpanzee and nine human P. vivax 
strains as well as between these parasites and the P. cynomolgi strain M. 
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5.1 Exposure of humans to ape Laverania and P. vivax parasites 
In the past decade, characterization of ape Plasmodium species has led to the discovery 
that the two most prevalent human malaria parasites, P. falciparum and P. vivax, both 
have an African ape origin (Liu et al., 2014, 2010). Yet despite extremely high prevalence 
rates in ape communities, multiple studies have failed to detect ape Plasmodium strains 
in human blood samples obtained from individuals living or working near infected apes 
(Délicat-Loembet et al., 2015; Ngoubangoye et al., 2016; Sundararaman et al., 2013). 
However, screening blood samples for parasite DNA does not address the possibility that 
individuals may be exposed to ape parasites through bites of infected mosquitoes and 
may develop pre-erythrocytic (i.e. liver stage) infection that fails to produce a blood stage 
infection. In Chapter 2, I used a PCR-based screen of human fecal samples to attempt to 
detect pre-erythrocytic ape Plasmodium infections. Despite using an intensified PCR 
approach, I did not detect any ape Laverania species or ape P. vivax. While one 
interpretation of this result is that humans are not exposed to ape parasites or do not 
develop liver-stage infection, it is also possible that failure to amplify ape parasite 
sequences from human fecal samples is due to an inability to detect pre-erythrocytic 
parasite DNA in human stool (in contrast to results of experimental infections in mice 
(Abkallo et al., 2014)). Indeed, I found several links between blood stage parasitemia and 
fecal Plasmodium detection, suggesting that fecal parasite DNA is derived from blood 
stage infections. Going forward, it will be necessary to determine whether liver stage 
parasite DNA is detectable in fecal samples of humans, perhaps by collecting and 
analyzing fecal samples during controlled human malaria exposure in the context of 
clinical trials. 
As no screen of human fecal or blood samples has detected infection with ape 
Plasmodium species, such infections are likely extremely rare events. However, it is not 
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clear whether this is due to biological differences that impact susceptibility to ape 
Plasmodium infection or whether humans are rarely (if ever) exposed to ape parasites. 
Thus, characterization of the transmission dynamics of ape Plasmodium species is critical 
for assessing the zoonotic risk posed by these parasites. Specifically, it is necessary to 
characterize the species of Anopheles mosquitoes that transmit the ape parasites, their 
host species preferences, and the extent to which humans are exposed to infectious 
mosquitoes (Molina-Cruz and Barillas-Mury, 2016). To date, studies of ape Plasmodium 
vectors have focused on sampling mosquitoes near ape sanctuaries or in national parks 
and have identified three Anopheles species that transmit ape parasites (Makanga et al., 
2016; Paupy et al., 2013). However, a critical missing piece of data is the frequency at 
which humans are exposed to these mosquitoes. Thus, future work should characterize 
the biting times, host species preferences, and geographic distributions of the vectors of 
ape Plasmodium. Additionally, entomological surveys of villages that are geographically 
close to infected apes could determine whether humans are routinely exposed to ape 
parasites. Finally, it will be critical to assess whether the most common vectors of human 
malaria (i.e. Anopheles gambiae, Anopheles dirus, and Anopheles albumanis (Molina-
Cruz et al., 2016)) can transmit ape Plasmodium species, as this will impact the ability of 
the parasites to spread in densely populated cities should they emerge in human 
populations. 
 Human exposure to ape Plasmodium species could also be assessed by 
identifying antibody responses that are specific to the ape parasites. Interestingly, Duffy-
negative individuals have detectable antibody response to blood stage P. vivax antigens, 
despite being protected from blood stage infection (Culleton et al., 2009; Herrera et al., 
2005). Thus, humans exposed to ape Plasmodium species might have antibody 
responses to blood stage antigens in the absence of blood sage infections. Whole genome 
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sequencing of ape Laverania parasites and ape P. vivax have revealed several 
erythrocyte invasion genes that are unique to ape parasites, such as rbp2d in ape P. vivax 
(see Chapter 4) and eba165 in Laverania species (Otto et al., 2014; Sundararaman et al., 
2016). Thus, one avenue to test for exposure to ape parasites would be to ascertain 
whether antibody response to any of these proteins is sufficiently sensitive and specific to 
enable screening of humans for past exposure to ape parasites. Alternatively, it may be 
possible to utilize whole genome sequencing data to identify molecules that are both 
immunogenic in P. falciparum and P. vivax infections and also highly divergent in ape 
parasites. If a panel of such molecules could be identified and confirmed to be specific for 
ape parasite exposure, it would be possible to assess the magnitude of human exposure 
to ape Plasmodium species even if the parasites fail to result in productive blood stage 
infections.  
While studies of wild apes suggest that the host species restriction of most 
Laverania parasites is strict (Liu et al., 2016; Sundararaman et al., 2016), there is evidence 
that these parasites can cross species barriers under some circumstances. In ape 
sanctuaries housing both chimpanzees and gorillas, the gorilla parasites P. 
praefalciparum and P. adleri were detected in chimpanzees and the chimpanzee parasite 
P. reichenowi was detected in a gorilla (Ngoubangoye et al., 2016). Yet these parasites 
have never been identified in the “wrong” host species in the wild, despite screening 
hundreds of fecal samples (Liu et al., 2016). This suggests that the biological barriers to 
cross-species transmission of ape parasites can be overcome in certain environmental 
conditions. Thus, changing climate and land use patterns could increase the risk of 
spillover of ape parasites into humans. In Southeast Asia, natural transmission of 
nonhuman primate malarias have only recently been appreciated (Singh et al., 2004; Ta 
et al., 2014), and fragmentation of forests is thought to be partially responsible for the 
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rising incidence of P. knowlesi in humans (Brock et al., 2016; Fornace et al., 2016). As 
such, even though there is no evidence that ape Plasmodium parasites routinely cause 
disease in humans at the present time, it is important to continue to monitor for cross-
species transmission, especially in regions where forest fragmentation or other social, 
economic, or political factors lead to increased exposure of humans to vectors of ape 
Plasmodium.  
 
5.2 P. malariae and P. ovale-like parasite species in African great apes 
While the geographical distribution and host species association of P. vivax and the 
Laverania parasites have been well characterized (Liu et al., 2017, 2016, 2014, 2010), 
less is known about the P. malariae- and P. ovale-like parasites of African great apes. 
Partial genome sequences of chimpanzee P. malariae strains indicate that chimpanzees 
are infected with genetically diverse parasites that are distinct from those infecting humans 
(Rutledge et al., 2017). In Chapter 2 of this dissertation, I generated P. malariae 
mitochondrial sequences from apes and humans and identified two SNVs that differ in 
parasites isolated from humans versus wild apes. None of the P. malariae strains from 
human samples contained the P. malariae SNVs found in wild chimpanzees or gorillas. 
However, both sets of SNVs were found in sanctuary chimpanzees. This suggests that 
human P. malariae parasites can infect chimpanzees (at least in captivity), and is 
consistent with the relatively relaxed host tropism of this parasite species, which infects 
several species of South American monkeys in the wild (Alvarenga et al., 2017; Collins 
and Jeffery, 2007). The P. ovale-like parasites in apes are less well characterized. Short, 
mitochondrial P. ovale wallikeri sequences have been obtained from one chimpanzee 
(Duval et al., 2009) and one gorilla (Mapua et al., 2018). These short sequences are 
identical to human parasites, but given this limited data it is impossible to know whether 
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the P. ovale wallikeri parasites in apes represent a distinct population or whether there is 
ongoing zoonotic transmission (Mapua et al., 2018). In contrast, the sequences most 
closely related to P. ovale curtisi in apes differ from human sequences at multiple 
nucleotide positions over a short sequence (Duval et al., 2009; Kaiser et al., 2010), 
suggesting the existence of a distinct population in apes. Additional data is needed to 
determine whether P. malariae and P. ovale strains circulate freely between ape and 
human hosts, or whether there are distinct populations in different host species. This will 
lead to a better understanding of the origin of these malaria parasites in humans and their 
zoonotic reservoir in African great apes. 
 In addition to the P. ovale-like and P. malariae-like parasites in apes, there are 
other ape parasite species in the Plasmodium subgenus about which almost nothing is 
known. This includes P. carteri, a parasite related to P. vivax that has thus far only been 
detected in two chimpanzees (Loy et al., 2017), and a species termed P. malariae-related 
(distinct from ape P. malariae) which has been amplified from a chimpanzee and a bonobo 
(Liu et al., 2017). Both species were discovered through off-target effects of primers 
designed to amplify Laverania or P. vivax parasites from ape fecal samples. Given the 
relatively relaxed host tropism of this clade of parasites, better characterization of all 
members of the Plasmodium subgenus in apes is warranted. However, such studies are 
severely limited by the very small number of infected samples available for analysis. 
Specifically screening existing banks of ape fecal samples and nonhuman primate blood 
samples for these parasites could reveal their distribution and host-species association. 
However, high quality DNA samples are required to generate sequences longer than a 
few hundred basepairs. Thus, whole genome sequencing of these parasites will likely be 
impossible unless infected blood samples can be obtained from sanctuary animals or 
through collection of sanguinivorous insects that have fed on infected apes. 
194 
 
 
5.3 Evolutionary history of P. vivax in humans 
P. vivax-like parasites have been identified in chimpanzees, gorillas, and in bonobos 
(Kaiser et al., 2010; Liu et al., 2017, 2014). Phylogenetic analysis of short sequences 
derived from ape and human parasites suggested an African origin of P. vivax (Liu et al., 
2014), yet the precise relationship of ape and human parasites and the circumstances 
surrounding the emergence of P. vivax in humans remained unknown. Reasoning that 
comparative genomics of ape and human P. vivax could lead to insights into the origins of 
P. vivax in humans, I optimized selective whole genome amplification (SWGA) of P. vivax 
to facilitate sequencing of parasite genomes from asymptomatic apes. In Chapter 3, I 
showed that SWGA can dramatically increase the proportion of P. vivax DNA in 
unprocessed human whole blood and dried blood spot samples. While primers targeting 
the entire P. vivax genome biased amplification towards the AT-rich subtelomeres (likely 
a result of phi29’s increased replication efficiency in AT-rich genomic regions), I was able 
to overcome this issue by designing primers to target GC-rich regions of the genome.  
Application of this method to P. vivax-infected ape samples resulted in amplification of 
partial to near-complete genomes from samples with low parasitemia, without introduction 
of systemic sequencing errors. Thus, SWGA is a flexible method that is suited to a variety 
of eukaryotic genomes including those with mixed AT/GC content. 
Performing genome wide comparison of the magnitude and character of diversity 
in ape and human P. vivax strains, I found that ape parasites are approximately 10-fold 
more diverse than human parasites and that human, but not ape, P. vivax has a relative 
excess of nonsynonymous polymorphism. The latter observation suggests this unusual 
pattern of polymorphism in human P. vivax is not a byproduct of the parasite life cycle 
(which is characterized by bottlenecks during transmission between hosts followed by 
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rapid multiplication within hosts), as has been suggested (Chang et al., 2013, 2012). 
Instead, this pattern must reflect evolutionary forces unique to the human parasite 
population. The most likely explanation is that the human parasite lineage has undergone 
rapid population expansion, which has resulted in relaxed selection pressure and 
maintenance of slightly deleterious mutations. If this is indeed the explanation, it suggests 
that all human Plasmodium species studied to date have undergone the same expansion, 
as an excess of nonsynonymous polymorphism is observed in human P. falciparum, P. 
vivax, and P. malariae populations (Chang et al., 2013, 2012; Rutledge et al., 2017), yet 
not in any of the ape parasite species analyzed to date (data from ape P. vivax presented 
here; unpublished data from P. gaboni and P. reichenowi from O. A. MacLean). Future 
studies should seek to identify the timing of and circumstances surrounding the dramatic 
population expansions of human malaria parasites. 
 
5.4 No evidence of positive selection unique to the human P. vivax lineage 
Unlike ape P. vivax, which is transmitted between chimpanzees, bonobos, and gorillas, 
human P. vivax has been exclusively infecting a single species (humans) for thousands 
of years. Reasoning that the human lineage of P. vivax may therefore have accumulated 
human-specific adaptations, I tested for evidence of selection in the human lineage using 
McDonald-Kreitman tests on over 4,000 genes. However, I did not detect a signal of 
positive selection (a relative excess of fixed, nonsynonymous differences) in any of the 
genes analyzed. This result does not rule out the possibility that some genes in human P. 
vivax may have acquired mutations that improve their ability to infect human hosts, as a 
small number of nonsynonymous changes can be adaptive yet fail to meet the threshold 
required for significance in the McDonald-Kreitman test. However, it is possible there is a 
true paucity of host-specific adaptations due to the relatively short time in which human P. 
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vivax strains have been exclusively circulating in humans.  Indeed, this is consistent with 
the fact that natural and experimental transmission studies indicate that P. vivax is able to 
infect multiple host species: some chimpanzees develop parasitemia upon injection with 
human P. vivax parasites (Rodhain, 1956), splenectomized chimpanzees are readily 
infected with human P. vivax (Sullivan et al., 1996) and ape P. vivax can cause malaria in 
Duffy-positive humans (Prugnolle et al., 2013). Host species adaptation can be further 
explored in vitro if human P. vivax is adapted to long-term culture, as this would facilitate 
side-by-side comparisons of invasion efficiency and growth dynamics within ape and 
human erythrocytes.  
 
5.5 Loss of three invasion genes in human P. vivax 
While no genes exhibited signals of positive selection unique to the human P. vivax 
lineage, I did find that human P. vivax has lost three reticulocyte binding protein (RBP) 
genes (rbp2d, rbp2e, and rbp3) that are maintained in ape P. vivax parasites. 
Hypothesizing that these proteins were lost in human P. vivax because they bind poorly 
or not at all to human erythrocyte receptors, I expressed recombinant RBP2e and RBP3 
proteins and assessed their binding to red blood cells from humans and chimpanzees, as 
well a single gorilla and a macaque. Surprisingly, neither protein bound ape cells better 
than human cells. This suggests that they were not lost in human parasites because they 
bind poorly to their human receptor orthologs or because they bind receptors unique to 
chimpanzee and/or gorilla erythrocytes. 
I was also surprised to observe that the ape P. vivax-derived RBP2e and RBP3 
proteins both bound a much smaller fraction of erythrocytes compared to human P. vivax-
dervied RBP2a and RBP2b. While it’s possible that this suggests expression of a domain 
insufficient for receptor binding and/or improper protein folding, RBP2e bound very well to 
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macaque red blood cells and both proteins adopted secondary structure similar to that of 
RBP2a and RBP2b. One possible explanation is that the interaction between the proteins 
and their ape receptors is a low affinity interaction or that the receptors are expressed at 
low levels on a small number of cells. If erythrocyte receptors are identified for RBP2e and 
RBP3, the first hypothesis could be tested using surface plasmon resonance and/or more 
sensitive binding assays which utilize recombinant host protein and pentamerized 
recombinant RBPs to quantify protein interactions (Bushell et al., 2008). Identification of 
the receptors would also allow characterization of their abundance and distribution on ape 
and human erythrocytes. Alternatively, RBP2e and RBP3 may require additional proteins 
to bind host receptors, as is the case for P. falciparum Rh5 which binds only weakly to 
human erythrocytes in the absence of its essential interaction partners (Reddy et al., 2015; 
Volz et al., 2016; Wanaguru et al., 2013; W. H. Tham unpublished observation). This 
possibility could be explored by harvesting native RBP2e and RBP3 proteins from P. vivax 
(or, more feasibly, P. knowlesi or P. cynomolgi parasites) and using the RBPs to pull down 
other parasite proteins for identification through mass spectrometry.  
While analysis of recombinant RBP binding to ape and human erythrocytes 
suggests that these proteins do not impact host species specificity, in vitro adaptation of 
Plasmodium species to non-native host cells is often accompanied by gains or losses of 
invasion genes (Scully et al., 2017), including loss of rbp2e during adaptation of P. 
knowlesi to cynomolgus erythrocytes (Moon et al., 2016). Additional studies will be 
required to resolve this apparent discrepancy. The recent adaptation of P. cynomolgi to in 
vitro culture (J. Straimer, unpublished data) opens up new avenues for experimentation 
with this protein family, as P. cynomolgi has a large complement of RBPs orthologous to 
those found in P. vivax. For example, it is now possible to use gene-editing technologies 
such as CRISPR/Cas9 to delete rbp2e and rbp3 in cultured P. cynomolgi parasites to 
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determine whether this impacts invasion efficiency of monkey and/or human red blood 
cells. This would help clarify whether the loss of these RBPs in human P. vivax was 
adaptive or whether their loss was slightly deleterious but maintained due to the relaxed 
purifying selection within the human P. vivax population. 
 
5.6 P. vivax parasites in gorillas and bonobos 
One limitation of my analysis of ape P. vivax is the fact that, while ape P. vivax has been 
detected in chimpanzees, bonobos, and gorillas, most (6 out of 7) of the samples I 
analyzed were from chimpanzees. While I was able to obtain one P. vivax-infected gorilla 
sample (Gor3157), amplification of P. vivax was highly stochastic and yielded coverage of 
only 10 genes. While phylogenetic trees of short sequences from chimpanzees and 
gorillas fail to show host-species specific clades (Liu et al., 2014), in many cases I found 
that the most divergent P. vivax sequences were obtained from gorilla samples. Indeed, 
in the 10 genes analyzed, the Gor3157 strain was nearly as divergent from chimpanzee 
parasites as it was from human parasites. Additional sequences from gorilla parasites are 
required to determine whether gorillas are infected with a P. vivax population that is distinct 
from chimpanzee-infecting strains. At the present time, all P. vivax sequences from 
bonobos are very short (Liu et al., 2017), so it is not possible to determine how bonobo 
parasites compare to the strains in chimpanzees and gorillas. In addition, it will be 
important to investigate whether the rbp genes that contain open reading frames in 
chimpanzee but not human parasites are fully intact in gorilla- and bonobo-infecting 
parasites. Thus, characterization of gorilla and bonobo P. vivax strains will allow better 
estimation of the diversity of ape parasites may reveal unappreciated differences in 
transmission dynamics and host-species susceptibility of ape P. vivax.  
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5.7 P. vivax transmission in modern African humans 
P. vivax was long thought to be completely absent in African humans due to the high 
prevalence of the protective Duffy-negative phenotype, yet there are now numerous 
reports of P. vivax malaria Africa (Howes et al., 2015; Zimmerman, 2017). Sequences 
obtained from a small subset of P. vivax strains from Duffy-positive individuals suggest 
that African P. vivax represents a reintroduction of human parasite strains from outside 
Africa (Koepfli et al., 2015; Rodrigues et al., 2014). However, most of the analyzed 
samples were collected in Madagascar or from the horn of Africa, neither of which are 
populated with apes. While P. vivax has been reported in humans in countries with ape 
populations, the sequencing data available for these strains is either nonexistent or limited 
to extremely short DNA fragments. As such, it is impossible to determine what proportion, 
if any, of these cases represent ape-derived parasites. Future research should therefore 
focus on obtaining informative sequences from P. vivax strains infecting African humans, 
especially in countries with large ape populations. Diagnostic fragments need not be long: 
mitochondrial genome sequences are easily obtained from infected blood samples and 
are adequate for distinguishing ape and human P. vivax strains (Liu et al., 2014). 
Importantly, P. vivax in Africa is not confined to Duffy-positive humans. Recently it 
has become clear that human P. vivax is able to infect Duffy-negative individuals (Gunalan 
et al., 2018; Zimmerman, 2017). It is not known, however, whether the sudden appearance 
of P. vivax in Duffy-negative humans is a result of parasite adaptation to Duffy-negative 
hosts, or whether this represents better surveillance and/or more sensitive screening 
methods for P. vivax. One way to address this question would be to test the ability of P. 
vivax strains from Duffy-negative individuals to infect Duffy-negative cells in vitro, 
compared to strains obtained from Duffy-positive individuals. However, this would require 
a large number of parasites and ability to perform short term in vitro culture near collection 
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sites, and is likely not feasible at this time. On the other hand, whole genome sequencing 
of P. vivax from Duffy-negative individuals is relatively straightforward, especially as 
SWGA is an effective tool for generating genome sequences from samples with low 
parasitemia (as is often the case in these infections). Genome sequencing could reveal 
whether the P. vivax strains isolated from Duffy-negative individuals are closely related to 
each other and/or whether there are genetic features (such as genes gained or lost, 
shared polymorphisms, or locally reduced genetic diversity suggestive of recent selective 
sweep) that are found at significantly higher frequency in this P. vivax population. 
 
5.8 Conclusions 
The work presented in this dissertation clarifies the history of P. vivax in human 
populations and provides further evidence that African humans rarely (if ever) acquire 
zoonotic malaria infections from great apes. Additionally, in light of the fact that these 
parasites have not been adapted to in vitro culture, the ape P. vivax genomes presented 
here represent a vital resource for exploring P. vivax biology. Thus, this work provides a 
foundation for exploration of the mechanisms that underlie cross species transmission and 
host species adaptation of malaria parasites. 
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